BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16. [PMID: 2617184 DOI: 10.3109/00365528909091339] [Cited by in Crossref: 1341] [Cited by in F6Publishing: 1368] [Article Influence: 41.9] [Reference Citation Analysis]
Number Citing Articles
1 Perdigones N, Martín E, Robledo G, Lamas JR, Taxonera C, Díaz-rubio M, de la Concha EG, López-nevot MA, García A, Gómez-garcía M, Fernández-gutiérrez B, Martín J, Urcelay E. Study of chromosomal region 5p13.1 in Crohn's disease, ulcerative colitis, and rheumatoid arthritis. Human Immunology 2010;71:826-8. [DOI: 10.1016/j.humimm.2010.05.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
2 Garrido Gómez E, Lopez San Román A, Bermejo San José F. Idiopathic pancreatitis in inflammatory bowel disease. J Crohns Colitis 2008;2:237-40. [PMID: 21172217 DOI: 10.1016/j.crohns.2008.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
3 Steiner CA, Berinstein JA, Louissaint J, Higgins PDR, Spence JR, Shannon C, Lu C, Stidham RW, Fletcher JG, Bruining DH, Feagan BG, Jairath V, Baker ME, Bettenworth D, Rieder F; Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00593-0. [PMID: 34089850 DOI: 10.1016/j.cgh.2021.05.054] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Krupoves A, Seidman EG, Mack D, Israel D, Morgan K, Lambrette P, Costea I, Deslandres C, Grimard G, Law L, Levy E, Amre DK. Associations between ABCB1/MDR1 gene polymorphisms and Crohn's disease: a gene-wide study in a pediatric population. Inflamm Bowel Dis 2009;15:900-8. [PMID: 19107781 DOI: 10.1002/ibd.20849] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
5 Nolan DJ, Han DY, Lam WJ, Morgan AR, Fraser AG, Tapsell LC, Ferguson LR. Genetic adult lactase persistence is associated with risk of Crohn's Disease in a New Zealand population. BMC Res Notes 2010;3:339. [PMID: 21167073 DOI: 10.1186/1756-0500-3-339] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
6 Machida H, Tsukamoto K, Wen CY, Narumi Y, Shikuwa S, Isomoto H, Takeshima F, Mizuta Y, Niikawa N, Murata I, Kohno S. Association of polymorphic alleles of CTLA4 with inflammatory bowel disease in the Japanese. World J Gastroenterol 2005; 11(27): 4188-4193 [PMID: 16015687 DOI: 10.3748/wjg.v11.i27.4188] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
7 Castro-Santos P, Suarez A, Mozo L, Gutierrez C. Association of IL-10 and TNFalpha genotypes with ANCA appearance in ulcerative colitis. Clin Immunol. 2007;122:108-114. [PMID: 17070109 DOI: 10.1016/j.clim.2006.09.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
8 Lü M, Xia B, Li J, Ye M, Zhang X, Tan Q. MICB microsatellite polymorphism is associated with ulcerative colitis in Chinese population. Clin Immunol. 2006;120:199-204. [PMID: 16679067 DOI: 10.1016/j.clim.2006.03.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
9 Roggenbuck D, Reinhold D, Werner L, Schierack P, Bogdanos DP, Conrad K. Glycoprotein 2 antibodies in Crohn's disease. Adv Clin Chem. 2013;60:187-208. [PMID: 23724745 DOI: 10.1016/b978-0-12-407681-5.00006-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
10 Koutroubakis IE, Malliaraki N, Vardas E, Ganotakis E, Margioris AN, Manousos ON, Kouroumalis EA. Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis? Eur J Gastroenterol Hepatol 2001;13:1415-9. [PMID: 11742189 DOI: 10.1097/00042737-200112000-00004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
11 Boga S, Alkim H, Koksal AR, Ozagari AA, Bayram M, Tekin Neijmann S, Sen I, Alkim C. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity. J Investig Med 2016;64:1016-24. [PMID: 27001944 DOI: 10.1136/jim-2016-000062] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
12 Iwatani S, Shinzaki S, Amano T, Otake Y, Tani M, Yoshihara T, Tsujii Y, Hayashi Y, Inoue T, Okuzaki D, Mizushima T, Miyoshi E, Iijima H, Takehara T. Oligosaccharide‐dependent anti‐inflammatory role of galectin‐1 for macrophages in ulcerative colitis. Journal of Gastroenterology and Hepatology 2020;35:2158-69. [DOI: 10.1111/jgh.15097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Drobin K, Assadi G, Hong MG, Andersson E, Fredolini C, Forsström B, Reznichenko A, Akhter T, Ek WE, Bonfiglio F, Hansen MB, Sandberg K, Greco D, Repsilber D, Schwenk JM, D'Amato M, Halfvarson J. Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci. Inflamm Bowel Dis 2019;25:306-16. [PMID: 30358838 DOI: 10.1093/ibd/izy326] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
14 Bermejo F, San Román AL, Algaba A, Van Domselaar M, Carneros JA, Rivero M, Piqueras B, Paz Valer M. Eficacia de la premedicación con un esteroide y un antihistamínico en la prevención de reacciones infusionales por infliximab. Gastroenterología y Hepatología 2008;31:629-32. [DOI: 10.1016/s0210-5705(08)75809-6] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
15 Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C, O’Morain CA, Gassull M. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411:599-603. [PMID: 11385576 DOI: 10.1038/35079107] [Cited by in Crossref: 3772] [Cited by in F6Publishing: 3523] [Article Influence: 179.6] [Reference Citation Analysis]
16 Hisabe T, Hirai F, Matsui T, Watanabe M. Evaluation of diagnostic criteria for Crohn's disease in Japan. J Gastroenterol 2014;49:93-9. [PMID: 23546557 DOI: 10.1007/s00535-013-0798-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
17 Lopez RN, Evans HM, Appleton L, Bishop J, Chin S, Mouat S, Gearry RB, Day AS. Point Prevalence of Pediatric Inflammatory Bowel Disease in New Zealand in 2015: Initial Results from the PINZ Study. Inflammatory Bowel Diseases 2017;23:1418-24. [DOI: 10.1097/mib.0000000000001138] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
18 Hampe J, Lynch NJ, Daniels S, Bridger S, Macpherson AJ, Stokkers P, Forbes A, Lennard-Jones JE, Mathew CG, Curran ME. Fine mapping of the chromosome 3p susceptibility locus in inflammatory bowel disease. Gut. 2001;48:191-197. [PMID: 11156639 DOI: 10.1136/gut.48.2.191] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 2.6] [Reference Citation Analysis]
19 Pavlidis P, Romanidou O, Roggenbuck D, Mytilinaiou MG, Al-Sulttan F, Liaskos C, Smyk DS, Koutsoumpas AL, Rigopoulou EI, Conrad K, Forbes A, Bogdanos DP. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease. Clin Dev Immunol. 2012;2012:640835. [PMID: 23118780 DOI: 10.1155/2012/640835] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
20 Lapidus A, Bernell O, Hellers G, Persson PG, Löfberg R. Incidence of Crohn’s disease in Stockholm County 1955-1989. Gut. 1997;41:480-486. [PMID: 9391246 DOI: 10.1136/gut.41.4.480] [Cited by in Crossref: 99] [Cited by in F6Publishing: 99] [Article Influence: 4.0] [Reference Citation Analysis]
21 Reinisch W, Heider KH, Oberhuber G, Dejaco C, Müllner M, Adolf GR, Gasché C. Poor diagnostic value of colonic CD44v6 expression and serum concentrations of its soluble form in the differentiation of ulcerative colitis from Crohn's disease. Gut 1998;43:375-82. [PMID: 9863483 DOI: 10.1136/gut.43.3.375] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
22 Thia KT, Chan ES, Ling KL, Ng WY, Jacob E, Ooi CJ. Role of procalcitonin in infectious gastroenteritis and inflammatory bowel disease. Dig Dis Sci. 2008;53:2960-2968. [PMID: 18415679 DOI: 10.1007/s10620-008-0254-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
23 Cross RK, Cheevers N, Finkelstein J. Home telemanagement for patients with ulcerative colitis (UC HAT). Dig Dis Sci. 2009;54:2463-2472. [PMID: 19104937 DOI: 10.1007/s10620-008-0640-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
24 Glas J, Török HP, Tonenchi L, Müller-Myhsok B, Mussack T, Wetzke M, Klein W, Epplen JT, Griga T, Schiemann U, Lohse P, Seiderer J, Schnitzler F, Brand S, Ochsenkühn T, Folwaczny M, Folwaczny C. Role of the NFKB1 -94ins/delATTG promoter polymorphism in IBD and potential interactions with polymorphisms in the CARD15/NOD2, IKBL, and IL-1RN genes. Inflamm Bowel Dis 2006;12:606-11. [PMID: 16804398 DOI: 10.1097/01.ibd.0000225346.23765.6b] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
25 Higashijima J, Kono T, Shimada M, Kashihara H, Takasu C, Nishi M, Tokunaga T, Sugitani A, Yoshikawa K. Intestinal hypoperfusion in patients with Crohn's disease revealed by intraoperative indocyanine green fluorescence imaging. Ann Med Surg (Lond) 2021;66:102402. [PMID: 34136203 DOI: 10.1016/j.amsu.2021.102402] [Reference Citation Analysis]
26 Varzari A, Deyneko IV, Tudor E, Turcan S. Polymorphisms of glutathione S-transferase and methylenetetrahydrofolate reductase genes in Moldavian patients with ulcerative colitis: Genotype-phenotype correlation. Meta Gene 2016;7:76-82. [PMID: 26862484 DOI: 10.1016/j.mgene.2015.12.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
27 Kim MC, Jung YS, Song YS, Lee JI, Park JH, Sohn CI, Choi KY, Park DI. Factors Associated with Anxiety and Depression in Korean Patients with Inactive Inflammatory Bowel Disease. Gut Liver 2016;10:399-405. [PMID: 26470768 DOI: 10.5009/gnl15188] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
28 Waschke KA, Villani AC, Vermeire S, Dufresne L, Chen TC, Bitton A, Cohen A, Thomson AB, Wild GE. Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes. Am J Gastroenterol. 2005;100:1126-1133. [PMID: 15842589 DOI: 10.1111/j.1572-0241.2005.40534.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 2.9] [Reference Citation Analysis]
29 Kennedy NA, Clark A, Walkden A, Chang JC, Fascí-Spurio F, Muscat M, Gordon BW, Kingstone K, Satsangi J, Arnott ID. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years. J Crohns Colitis. 2015;9:41-49. [PMID: 25135754 DOI: 10.1016/j.crohns.2014.07.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
30 Lawrance IC, Murray K, Hall A, Sung JJ, Leong R. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol. 2004;99:2186-2194. [PMID: 15555001 DOI: 10.1111/j.1572-0241.2004.40486.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 2.8] [Reference Citation Analysis]
31 Frigstad SO, Høivik ML, Jahnsen J, Cvancarova M, Grimstad T, Berset IP, Huppertz-Hauss G, Hovde Ø, Bernklev T, Moum B, Jelsness-Jørgensen LP. Fatigue is not associated with vitamin D deficiency in inflammatory bowel disease patients. World J Gastroenterol 2018; 24(29): 3293-3301 [PMID: 30090009 DOI: 10.3748/wjg.v24.i29.3293] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
32 Nos P, Garrigues V, Bastida G, Maroto N, Ponce M, Ponce J. Outcome of patients with nonstenotic, nonfistulizing Crohn’s disease. Dig Dis Sci. 2004;49:1771-1776. [PMID: 15628701 DOI: 10.1007/s10620-004-9568-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
33 Zeng Z, Zhu Z, Yang Y, Ruan W, Peng X, Su Y, Peng L, Chen J, Yin Q, Zhao C, Zhou H, Yuan S, Hao Y, Qian J, Ng SC, Chen M, Hu P. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol. 2013;28:1148-1153. [PMID: 23432198 DOI: 10.1111/jgh.12164] [Cited by in Crossref: 89] [Cited by in F6Publishing: 89] [Article Influence: 11.1] [Reference Citation Analysis]
34 Hampe J, Shaw SH, Saiz R, Leysens N, Lantermann A, Mascheretti S, Lynch NJ, MacPherson AJ, Bridger S, van Deventer S. Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet. 1999;65:1647-1655. [PMID: 10577918 DOI: 10.1086/302677] [Cited by in Crossref: 152] [Cited by in F6Publishing: 154] [Article Influence: 6.9] [Reference Citation Analysis]
35 Kariyawasam VC, Mourad FH, Mitrev N, Paramsothy S, Selinger CP, Katelaris PH, Jones B, McDonald C, Barr G, Chapman G, Cowlishaw J, Andrews J, Leong RW. Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis. Eur J Gastroenterol Hepatol 2021;33:1524-32. [PMID: 33731581 DOI: 10.1097/MEG.0000000000002101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Regimbeau JM, Panis Y, Pocard M, Bouhnik Y, Lavergne-Slove A, Rufat P, Matuchansky C, Valleur P. Long-term results of ileal pouch-anal anastomosis for colorectal Crohn's disease. Dis Colon Rectum. 2001;44:769-778. [PMID: 11391134 DOI: 10.1007/bf02234693] [Cited by in Crossref: 127] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
37 Gustavsson A, Magnuson A, Blomberg B, Andersson M, Halfvarson J, Tysk C. Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn's disease. Aliment Pharmacol Ther. 2012;36:151-158. [PMID: 22612326 DOI: 10.1111/j.1365-2036.2012.05146.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 8.6] [Reference Citation Analysis]
38 Peter I, Mitchell AA, Ozelius L, Erazo M, Hu J, Doheny D, Abreu MT, Present DH, Ullman T, Benkov K, Korelitz BI, Mayer L, Desnick RJ; New York Crohn's Disease Working Group. Evaluation of 22 genetic variants with Crohn's disease risk in the Ashkenazi Jewish population: a case-control study. BMC Med Genet 2011;12:63. [PMID: 21548950 DOI: 10.1186/1471-2350-12-63] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
39 Park MY, Yoon YS, Lee JL, Park SH, Ye BD, Yang SK, Yu CS. Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn's disease: a retrospective observational study. Stem Cell Res Ther 2021;12:401. [PMID: 34256838 DOI: 10.1186/s13287-021-02484-6] [Reference Citation Analysis]
40 Sasaki Y, Tanaka M, Kudo H. Differentiation between ulcerative colitis and Crohn’s disease by a quantitative immunohistochemical evaluation of T lymphocytes, neutrophils, histiocytes and mast cells. Pathol Int. 2002;52:277-285. [PMID: 12031083 DOI: 10.1046/j.1440-1827.2002.01354.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
41 Wolters FL, Joling C, Russel MG, Sijbrandij J, De Bruin M, Odes S, Riis L, Munkholm P, Bodini P, Ryan B. Treatment inferred disease severity in Crohn's disease: evidence for a European gradient of disease course. Scand J Gastroenterol. 2007;42:333-344. [PMID: 17354113 DOI: 10.1080/00365520600930750] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
42 Jakobsen C, Wewer V, Urne F, Andersen J, Faerk J, Kramer I, Stagegaard B, Pilgaard B, Weile B, Paerregaard A. Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out? J Crohns Colitis. 2008;2:152-157. [PMID: 21172205 DOI: 10.1016/j.crohns.2008.01.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
43 Szamosi T, Banai J, Lakatos L, Czegledi Z, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp M. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn’s disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol. 2010;22:872-879. [PMID: 19648821 DOI: 10.1097/meg.0b013e32833036d9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
44 Fidder HH, Olschwang S, Avidan B, Zouali H, Lang A, Bardan E, Picard O, Bar-meir S, Colombel JF, Chowers Y. Association between mutations in theCARD15 (NOD2) gene and Crohn's disease in Israeli Jewish patients. Am J Med Genet 2003;121A:240-4. [DOI: 10.1002/ajmg.a.20209] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
45 Aldhous MC, Drummond HE, Anderson N, Baneshi MR, Smith LA, Arnott ID, Satsangi J. Smoking habit and load influence age at diagnosis and disease extent in ulcerative colitis. Am J Gastroenterol. 2007;102:589-597. [PMID: 17338737 DOI: 10.1111/j.1572-0241.2007.01065.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
46 Molnar T, Hofner P, Nagy F, Lakatos PL, Fischer S, Lakatos L, Kovacs A, Altorjay I, Papp M, Palatka K, Demeter P, Tulassay Z, Nyari T, Miheller P, Papp J, Mandi Y, Lonovics J; Hungarian IBD Study Group. NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease. Dig Liver Dis 2007;39:1064-70. [PMID: 17964870 DOI: 10.1016/j.dld.2007.09.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
47 Lok KH, Hung HG, Ng CH, Kwong KC, Yip WM, Lau SF, Li KK, Li KF, Szeto ML. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: experience from a single center in Hong Kong. J Gastroenterol Hepatol. 2008;23:406-410. [PMID: 17623033 DOI: 10.1111/j.1440-1746.2007.05079.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 3.8] [Reference Citation Analysis]
48 Zaid Y, Senhaji N, Bakhtaoui FZ, Serrano A, Serbati N, Karkouri M, Badre W, Oudghiri M, Martin J, Nadifi S. The PTPN22 C1858T (R620W) functional polymorphism in inflammatory bowel disease. BMC Res Notes 2018;11:783. [PMID: 30384859 DOI: 10.1186/s13104-018-3875-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y, Inohara N, Núñez G, Kishi Y, Koike Y, Shimosegawa T, Shimoyama T, Hibi T. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002;123:86-91. [DOI: 10.1053/gast.2002.34155] [Cited by in Crossref: 311] [Cited by in F6Publishing: 307] [Article Influence: 15.6] [Reference Citation Analysis]
50 Manetti N, Bagnoli S, Rogai F, Bonanomi AG, Vannozzi G, Giannotta M, Annese V. Disease Course and Colectomy Rate of Ulcerative Colitis: A Follow-up Cohort Study of a Referral Center in Tuscany. Inflamm Bowel Dis 2016;22:1945-53. [PMID: 27104823 DOI: 10.1097/MIB.0000000000000787] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
51 Bermejo F, Garrido E, Chaparro M, Gordillo J, Mañosa M, Algaba A, López-Sanromán A, Gisbert JP, García-Planella E, Guerra I, Domènech E. Efficacy of different therapeutic options for spontaneous abdominal abscesses in Crohn's disease: are antibiotics enough? Inflamm Bowel Dis 2012;18:1509-14. [PMID: 22674826 DOI: 10.1002/ibd.21865] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
52 Sura R, Colombel J, Van Kruiningen HJ. Lymphatics, tertiary lymphoid organs and the granulomas of Crohn’s disease: an immunohistochemical study: Lymphatics and Crohn’s disease. Alimentary Pharmacology & Therapeutics 2011;33:930-9. [DOI: 10.1111/j.1365-2036.2011.04605.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
53 Teruel M, Martin JE, Gómez-García M, Cardeña C, Rodrigo L, Nieto A, Alcain G, Cueto I, López-Nevot MA, Martin J. Lack of association of ACP1 gene with inflammatory bowel disease: a case-control study. Tissue Antigens 2012;80:61-4. [PMID: 22428720 DOI: 10.1111/j.1399-0039.2012.01861.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Gao X, Yang RP, Chen MH, Xiao YL, He Y, Chen BL, Hu PJ. Risk factors for surgery and postoperative recurrence: analysis of a south China cohort with Crohn's disease. Scand J Gastroenterol. 2012;47:1181-1191. [PMID: 22845663 DOI: 10.3109/00365521.2012.668931] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
55 Oostenbrug LE, Dijkstra G, Nolte IM, van Dullemen HM, Oosterom E, Faber KN, de Jong DJ, van der Linde K, te Meerman GJ, van der Steege G. Absence of association between the multidrug resistance (MDR1) gene and inflammatory bowel disease. Scand J Gastroenterol. 2006;41:1174-1182. [PMID: 16990202 DOI: 10.1080/00365520600575746] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
56 Herzog D, Fournier N, Buehr P, Rueger V, Koller R, Heyland K, Nydegger A, Braegger CP; Swiss IBD Cohort Study Group. Prevalence of intestinal complications in inflammatory bowel disease: a comparison between paediatric-onset and adult-onset patients. Eur J Gastroenterol Hepatol 2017;29:926-31. [PMID: 28471820 DOI: 10.1097/MEG.0000000000000896] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
57 Nam SY, Kim N, Kim JS, Lim SH, Jung HC, Song IS. Heat shock protein gene 70-2 polymorphism is differentially associated with the clinical phenotypes of ulcerative colitis and Crohn's disease. J Gastroenterol Hepatol 2007;22:1032-8. [PMID: 17532782 DOI: 10.1111/j.1440-1746.2007.04927.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
58 Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BM, Poen AC, van Nieuwkerk KM, Drenth JP, Witteman BJ, Tuynman HA, Naber AH, Kingma PJ, van Buuren HR, van Hoek B, Vleggaar FP, van Geloven N, Beuers U, Ponsioen CY; on behalf of the EpiPSCPBC Study Group. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis: Boonstra et al. Hepatology 2013;58:2045-55. [DOI: 10.1002/hep.26565] [Cited by in Crossref: 335] [Cited by in F6Publishing: 283] [Article Influence: 37.2] [Reference Citation Analysis]
59 Franchimont N, Reenaers C, Lambert C, Belaiche J, Bours V, Malaise M, Delvenne P, Louis E. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol 2004;138:491-8. [PMID: 15544627 DOI: 10.1111/j.1365-2249.2004.02643.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
60 Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250. [PMID: 12131607 DOI: 10.1097/00054725-200207000-00002] [Cited by in Crossref: 892] [Cited by in F6Publishing: 768] [Article Influence: 44.6] [Reference Citation Analysis]
61 Vavassori P, Borgiani P, Biancone L, D'apice MR, Blanco GDV, Vallo L, De Nigris F, Monteleone I, Monteleone G, Pallone F, Novelli G. CARD15 Mutation Analysis in an Italian Population: Leu1007fsinsC but Neither Arg702Trp nor Gly908Arg Mutations Are Associated with Crohn’s Disease. Inflammatory Bowel Diseases 2004;10:116-21. [DOI: 10.1097/00054725-200403000-00009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
62 Minderhoud IM, Steyerberg EW, van Bodegraven AA, van der Woude CJ, Hommes DW, Dijkstra G, Fidder HH, Schwartz MP, Oldenburg B. Predicting Endoscopic Disease Activity in Crohn's Disease: A New and Validated Noninvasive Disease Activity Index (The Utrecht Activity Index). Inflamm Bowel Dis 2015;21:2453-9. [PMID: 26181428 DOI: 10.1097/MIB.0000000000000507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
63 Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol 2008; 14(43): 6641-6647 [PMID: 19034966 DOI: 10.3748/wjg.14.6641] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
64 Schoepfer AM, Schaffer T, Mueller S, Flogerzi B, Vassella E, Seibold-Schmid B, Seibold F. Phenotypic associations of Crohn’s disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort. Inflamm Bowel Dis. 2009;15:1358-1367. [PMID: 19253375 DOI: 10.1002/ibd.20892] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
65 Lopes S, Figueiredo P, Portela F, Freire P, Almeida N, Lérias C, Gouveia H, Leitão MC. Capsule endoscopy in inflammatory bowel disease type unclassified and indeterminate colitis serologically negative. Inflamm Bowel Dis 2010;16:1663-8. [PMID: 20848457 DOI: 10.1002/ibd.21249] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
66 Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blankenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39:690-697. [PMID: 9014768 DOI: 10.1136/gut.39.5.690] [Cited by in Crossref: 662] [Cited by in F6Publishing: 598] [Article Influence: 26.5] [Reference Citation Analysis]
67 Jharap B, Seinen ML, de Boer NK, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJ, van Bodegraven AA. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010;16:1541-9. [PMID: 20155846 DOI: 10.1002/ibd.21221] [Cited by in Crossref: 124] [Cited by in F6Publishing: 116] [Article Influence: 10.3] [Reference Citation Analysis]
68 Pichler J, Huber WD, Aufricht C, Bidmon-Fliegenschnee B. Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody. World J Gastroenterol 2015; 21(21): 6613-6620 [PMID: 26074699 DOI: 10.3748/wjg.v21.i21.6613] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
69 Xia B, Guo HJ, Crusius J, Deng CS, Meuwissen S, Pena A. In vitro production of TNFα, IL-6 and sIL-2R in Chinese patients with ulcerative colitis. World J Gastroenterol 1998; 4(3): 252-255 [PMID: 11819289 DOI: 10.3748/wjg.v4.i3.252] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
70 Mallolas J, Esteve M, Rius E, Cabré E, Gassull MA. Antineutrophil antibodies associated with ulcerative colitis interact with the antigen(s) during the process of apoptosis. Gut. 2000;47:74-78. [PMID: 10861267 DOI: 10.1136/gut.47.1.74] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
71 Al-jarallah K, Shehab D, Al-attiyah R, Al-azmi W, Al-fadli A, Zafar Haider M, Panaccione R, Ghosh S. Antibodies to mutated citrullinated vimentin and anti-cyclic citrullinated peptide antibodies in inflammatory bowel disease and related arthritis: . Inflammatory Bowel Diseases 2012;18:1655-62. [DOI: 10.1002/ibd.21937] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
72 Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrügger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology. 2000;119:1203-1208. [PMID: 11054377 DOI: 10.1053/gast.2000.19280] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 4.5] [Reference Citation Analysis]
73 Bastida Paz G, Nos Mateu P, Aguas Peris M, Beltrán Niclós B, Rodríguez Soler M, Ponce García J. [Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease]. Gastroenterol Hepatol. 2007;30:511-516. [PMID: 17980127 DOI: 10.1157/13111681] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
74 Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43:1069-1079. [PMID: 26953251 DOI: 10.1111/apt.13585] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
75 Fiorino G, Cortes PN, Ellul P, Felice C, Karatzas P, Silva M, Lakatos PL, Bossa F, Ungar B, Sebastian S, Furfaro F, Karmiris K, Katsanos KH, Muscat M, Christodoulou DK, Maconi G, Kopylov U, Magro F, Mantzaris GJ, Armuzzi A, Boscà-watts MM, Ben-horin S, Bonovas S, Danese S. Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. Clinical Gastroenterology and Hepatology 2016;14:1426-1432.e1. [DOI: 10.1016/j.cgh.2016.05.044] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
76 Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol. 2000;35:1163-1169. [PMID: 11145287 DOI: 10.1080/003655200750056637] [Cited by in Crossref: 110] [Cited by in F6Publishing: 120] [Article Influence: 5.2] [Reference Citation Analysis]
77 Golovics PA, Lakatos L, Mandel MD, Lovasz BD, Vegh Z, Kurti Z, Szita I, Kiss LS, Pandur T, Lakatos PL. Prevalence and predictors of hospitalization in Crohn’s disease in a prospective population-based inception cohort from 2000-2012. World J Gastroenterol 2015; 21(23): 7272-7280 [PMID: 26109815 DOI: 10.3748/wjg.v21.i23.7272] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
78 Sun L, Roesler J, Rösen-wolff A, Winkler U, Koch R, Thürigen A, Henker J. CARD15 Genotype and Phenotype Analysis in 55 Pediatric Patients With Crohn Disease From Saxony, Germany: . Journal of Pediatric Gastroenterology and Nutrition 2003;37:492-7. [DOI: 10.1097/00005176-200310000-00017] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
79 Kwak MS, Kim DH, Park SJ, Kim TI, Hong SP, Kim WH, Cheon JH. Efficacy of early immunomodulator therapy on the outcomes of Crohn's disease. BMC Gastroenterol. 2014;14:85. [PMID: 24886458 DOI: 10.1186/1471-230x-14-85] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
80 de Krijger M, Visseren T, Wildenberg ME, Hooijer GKJ, Verstegen MMA, van der Laan LJW, de Jonge WJ, Verheij J, Ponsioen CY. Characterization of gut-homing molecules in non-endstage livers of patients with primary sclerosing cholangitis and inflammatory bowel disease. J Transl Autoimmun 2020;3:100054. [PMID: 32743534 DOI: 10.1016/j.jtauto.2020.100054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Yamazaki K, Umeno J, Takahashi A, Hirano A, Johnson TA, Kumasaka N, Morizono T, Hosono N, Kawaguchi T, Takazoe M, Yamada T, Suzuki Y, Tanaka H, Motoya S, Hosokawa M, Arimura Y, Shinomura Y, Matsui T, Matsumoto T, Iida M, Tsunoda T, Nakamura Y, Kamatani N, Kubo M. A genome-wide association study identifies 2 susceptibility Loci for Crohn's disease in a Japanese population. Gastroenterology 2013;144:781-8. [PMID: 23266558 DOI: 10.1053/j.gastro.2012.12.021] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 9.5] [Reference Citation Analysis]
82 Aterido A, Palau N, Domènech E, Nos Mateu P, Gutiérrez A, Gomollón F, Mendoza JL, Garcia-planella E, Barreiro-de Acosta M, Muñoz F, Vera M, Saro C, Esteve M, Andreu M, Chaparro M, Panés J, García-sánchez V, López-lasanta M, Pluma A, Codó L, García-montero A, Manyé J, Gisbert JP, Marsal S, Julià A. Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn’s disease. Pharmacogenomics J 2019;19:547-55. [DOI: 10.1038/s41397-019-0090-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
83 Odes S, Vardi H, Friger M, Wolters F, Russel MG, Riis L, Munkholm P, Politi P, Tsianos E, Clofent J, Vermeire S, Monteiro E, Mouzas I, Fornaciari G, Sijbrandij J, Limonard C, Van Zeijl G, O'morain C, Moum B, Vatn M, Stockbrugger R; European Collaborative Study on Inflammatory Bowel Disease. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131:719-728. [PMID: 16952541 DOI: 10.1053/j.gastro.2006.05.052] [Cited by in Crossref: 161] [Cited by in F6Publishing: 146] [Article Influence: 10.1] [Reference Citation Analysis]
84 Yu Q, Zhang S, Wang H, Zhang Y, Feng T, Chen B, He Y, Zeng Z, Chen M. TNFAIP6 is a potential biomarker of disease activity in inflammatory bowel disease. Biomark Med 2016;10:473-83. [PMID: 27088253 DOI: 10.2217/bmm.16.9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
85 Yamada T, Hino S, Iijima H, Genda T, Aoki R, Nagata R, Han KH, Hirota M, Kinashi Y, Oguchi H, Suda W, Furusawa Y, Fujimura Y, Kunisawa J, Hattori M, Fukushima M, Morita T, Hase K. Mucin O-glycans facilitate symbiosynthesis to maintain gut immune homeostasis. EBioMedicine 2019;48:513-25. [PMID: 31521614 DOI: 10.1016/j.ebiom.2019.09.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
86 Koutroubakis IE, Petinaki E, Anagnostopoulou E, Kritikos H, Mouzas IA, Kouroumalis EA, Manousos ON. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci. 1998;43:2507-2512. [PMID: 9824143 DOI: 10.1023/a:1026602803622] [Cited by in Crossref: 55] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
87 Lakatos PL, Fischer S, Claes K, Kovacs A, Molnar T, Altorjay I, Demeter P, Tulassay Z, Palatka K, Papp M. DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn's disease. Inflamm Bowel Dis. 2006;12:362-368. [PMID: 16670524 DOI: 10.1097/01.MIB.0000217336.38312.09] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
88 Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J. Effects of light smoking consumption on the clinical course of Crohn's disease. Inflamm Bowel Dis 2009;15:734-41. [PMID: 19067428 DOI: 10.1002/ibd.20828] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
89 Flasar MH, Quezada S, Bijpuria P, Cross RK. Racial differences in disease extent and severity in patients with ulcerative colitis: a retrospective cohort study. Dig Dis Sci. 2008;53:2754-2760. [PMID: 18273704 DOI: 10.1007/s10620-007-0190-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
90 Püspök, Oberhuber, Wyatt, Maier-dobersberger, Hammer, Pfeffel, Wrba, Pötzi, Vogelsang. Gastroduodenal permeability in Crohn's disease: Sucrose test in Crohn's disease. European Journal of Clinical Investigation 1998;28:67-71. [DOI: 10.1046/j.1365-2362.1998.00241.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
91 Peddle L, Zipperlen K, Melay B, Hefferton D, Rahman P. Association of SEEK1 polymorphisms in Crohn's disease. Hum Immunol 2004;65:706-9. [PMID: 15301859 DOI: 10.1016/j.humimm.2004.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
92 Werner H, Braegger C, Buehr P, Koller R, Nydegger A, Spalinger J, Heyland K, Schibli S, Landolt M; Swiss IBD Cohort Study Group. Shorter time since inflammatory bowel disease diagnosis in children is associated with lower mental health in parents. Acta Paediatr 2015;104:e32-8. [DOI: 10.1111/apa.12781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
93 Heliö T, Halme L, Lappalainen M, Fodstad H, Paavola-Sakki P, Turunen U, Färkkilä M, Krusius T, Kontula K. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn’s disease. Gut. 2003;52:558-562. [PMID: 12631669 DOI: 10.1136/gut.52.4.558] [Cited by in Crossref: 174] [Cited by in F6Publishing: 177] [Article Influence: 9.2] [Reference Citation Analysis]
94 Sempere GA, Martinez Sanjuan V, Medina Chulia E, Benages A, Tome Toyosato A, Canelles P, Bulto A, Quiles F, Puchades I, Cuquerella J. MRI evaluation of inflammatory activity in Crohn’s disease. AJR Am J Roentgenol. 2005;184:1829-1835. [PMID: 15908538 DOI: 10.2214/ajr.184.6.01841829] [Cited by in Crossref: 167] [Cited by in F6Publishing: 138] [Article Influence: 9.8] [Reference Citation Analysis]
95 Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006;52:171-81. [PMID: 16339302 DOI: 10.1373/clinchem.2005.058560] [Cited by in Crossref: 129] [Cited by in F6Publishing: 121] [Article Influence: 7.6] [Reference Citation Analysis]
96 Machida H, Tsukamoto K, Wen CY, Shikuwa S, Isomoto H, Mizuta Y, Takeshima F, Murase K, Matsumoto N, Murata I, Kohno S, Wen CY. Crohn’s disease in Japanese is associated with a SNP-haplotype of N-acetyltransferase 2 gene. World J Gastroenterol 2005; 11(31): 4833-4837 [PMID: 16097053 DOI: 10.3748/wjg.v11.i31.4833] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
97 McLarren KW, Cole AE, Weisser SB, Voglmaier NS, Conlin VS, Jacobson K, Popescu O, Boucher JL, Sly LM. SHIP-deficient mice develop spontaneous intestinal inflammation and arginase-dependent fibrosis. Am J Pathol 2011;179:180-8. [PMID: 21640975 DOI: 10.1016/j.ajpath.2011.03.018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
98 Buchman AL, Miller FH, Wallin A, Chowdhry AA, Ahn C. Videocapsule endoscopy versus barium contrast studies for the diagnosis of Crohn's disease recurrence involving the small intestine. Am J Gastroenterol. 2004;99:2171-2177. [PMID: 15554999 DOI: 10.1111/j.1572-0241.2004.40253.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 92] [Article Influence: 5.3] [Reference Citation Analysis]
99 Lakatos PL, Altorjay I, Szamosi T, Palatka K, Vitalis Z, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis. 2009;15:365-374. [PMID: 18972554 DOI: 10.1002/ibd.20778] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
100 Magyari L, Faragó B, Bene J, Horvatovich K, Lakner L, Varga M, Figler M, Gasztonyi B, Mózsik G, Melegh B. No association of the cytotoxic T-lymphocyte associated gene CTLA4 +49A/G polymorphisms with Crohn’s disease and ulcerative colitis in Hungarian population samples. World J Gastroenterol 2007; 13(15): 2205-2208 [PMID: 17465502 DOI: 10.3748/wjg.v13.i15.2205] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
101 Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, Groenen P, Vlietinck R, Rutgeerts P. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology. 2001;120:827-833. [PMID: 11231936 DOI: 10.1053/gast.2001.22546] [Cited by in Crossref: 98] [Cited by in F6Publishing: 98] [Article Influence: 4.7] [Reference Citation Analysis]
102 Lee HW, Chung SH, Moon CM, Che X, Kim SW, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. The Correlation of Serum IL-12B Expression With Disease Activity in Patients With Inflammatory Bowel Disease. Medicine (Baltimore) 2016;95:e3772. [PMID: 27281077 DOI: 10.1097/MD.0000000000003772] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
103 Gisbert JP, Niño P, Rodrigo L, Cara C, Guijarro LG. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol 2006;101:2769-76. [PMID: 17026564 DOI: 10.1111/j.1572-0241.2006.00843.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
104 Heikius B, Niemelä S, Lehtola J, Karttunen TJ. Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease. Am J Gastroenterol. 1999;94:1062-1069. [PMID: 10201484 DOI: 10.1111/j.1572-0241.1999.01015.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 2.1] [Reference Citation Analysis]
105 Chengxiao Y, Dongmei W, Kai Z, Hou L, Xiao H, Ding T, Liu D, Ye X, Linhardt RJ, Chen S. Challenges of pectic polysaccharides as a prebiotic from the perspective of fermentation characteristics and anti-colitis activity. Carbohydr Polym 2021;270:118377. [PMID: 34364621 DOI: 10.1016/j.carbpol.2021.118377] [Reference Citation Analysis]
106 Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm Bowel Dis. 2004;10:646-651. [PMID: 15472528 DOI: 10.1097/00054725-200409000-00022] [Cited by in Crossref: 157] [Cited by in F6Publishing: 149] [Article Influence: 8.7] [Reference Citation Analysis]
107 Morgan AR, Lam WJ, Han DY, Fraser AG, Ferguson LR. DNase1: No Association with Crohn's Disease in a New Zealand Population. ISRN Gastroenterol 2012;2012:826323. [PMID: 22701800 DOI: 10.5402/2012/826323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
108 Tremelling M, Hancock L, Bredin F, Sharpstone D, Bingham SA, Parkes M. Complex insertion/deletion polymorphism in NOD1 (CARD4) is not associated with inflammatory bowel disease susceptibility in East Anglia panel. Inflamm Bowel Dis. 2006;12:967-971. [PMID: 17012967 DOI: 10.1097/01.mib.0000234131.89971.e5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
109 Huh J, Kim KJ, Park SH, Park SH, Yang SK, Ye BD, Park SH, Han K, Kim AY. Diffusion-Weighted MR Enterography to Monitor Bowel Inflammation after Medical Therapy in Crohn's Disease: A Prospective Longitudinal Study. Korean J Radiol. 2017;18:162-172. [PMID: 28096726 DOI: 10.3348/kjr.2017.18.1.162] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
110 Sýkora J, Pomahačová R, Kreslová M, Cvalínová D, Štych P, Schwarz J. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol 2018; 24(25): 2741-2763 [PMID: 29991879 DOI: 10.3748/wjg.v24.i25.2741] [Cited by in CrossRef: 108] [Cited by in F6Publishing: 84] [Article Influence: 27.0] [Reference Citation Analysis]
111 Morohoshi Y, Matsuoka K, Chinen H, Kamada N, Sato T, Hisamatsu T, Okamoto S, Inoue N, Takaishi H, Ogata H. Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodium-induced colitis. J Gastroenterol. 2006;41:318-324. [PMID: 16741610 DOI: 10.1007/s00535-005-1768-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
112 Almer S, Granerus G, Ström M, Olaison G, Bonnet J, Lémann M, Smedh K, Franzén L, Bertheau P, Cattan P, Rain JD, Modigliani R. Leukocyte scintigraphy compared to intraoperative small bowel enteroscopy and laparotomy findings in Crohn's disease. Inflamm Bowel Dis 2007;13:164-74. [PMID: 17206712 DOI: 10.1002/ibd.20001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
113 Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth H, Schoelmerich J, Gregor M. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology. 2003;124:26-33. [PMID: 12512026 DOI: 10.1053/gast.2003.50010] [Cited by in Crossref: 231] [Cited by in F6Publishing: 199] [Article Influence: 12.2] [Reference Citation Analysis]
114 Song EM, Lee HS, Kim YJ, Oh EH, Ham NS, Kim J, Hwang SW, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK. Incidence and clinical impact of perianal disease in patients with ulcerative colitis: A nationwide population-based study. J Gastroenterol Hepatol. 2018;. [PMID: 30549125 DOI: 10.1111/jgh.14555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
115 Katsanos KH, Vermeire S, Christodoulou DK, Riis L, Wolters F, Odes S, Freitas J, Hoie O, Beltrami M, Fornaciari G, Clofent J, Bodini P, Vatn M, Nunes PB, Moum B, Munkholm P, Limonard C, Stockbrugger R, Rutgeerts P, Tsianos EV; EC-IBD Study Group. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion. 2007;75:113-121. [PMID: 17598963 DOI: 10.1159/000104731] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
116 Lee N, Radford-Smith GL, Forwood M, Wong J, Taaffe DR. Body composition and muscle strength as predictors of bone mineral density in Crohn’s disease. J Bone Miner Metab. 2009;27:456-463. [PMID: 19333683 DOI: 10.1007/s00774-009-0059-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
117 Fries W, Viola A, Manetti N, Frankovic I, Pugliese D, Monterubbianesi R, Scalisi G, Aratari A, Cantoro L, Cappello M, Samperi L, Saibeni S, Casella G, Mocci G, Rea M, Furfaro F, Contaldo A, Magarotto A, Calella F, Manguso F, Inserra G, Privitera AC, Principi M, Castiglione F, Caprioli F, Ardizzone S, Danese S, Papi C, Bossa F, Kohn A, Armuzzi A, D'Incà R, Annese V, Alibrandi A, Bonovas S, Fiorino G; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". Dig Liver Dis 2017;49:17-23. [PMID: 27717794 DOI: 10.1016/j.dld.2016.09.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
118 Romberg-Camps M, Kuiper E, Schouten L, Kester A, Hesselink-van de Kruijs M, Limonard C, Bos R, Goedhard J, Hameeteman W, Wolters F. Mortality in inflammatory bowel disease in the Netherlands 1991-2002: results of a population-based study: the IBD South-Limburg cohort. Inflamm Bowel Dis. 2010;16:1397-1410. [PMID: 20027652 DOI: 10.1002/ibd.21189] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
119 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Vaji S, Salehi Z, Aminian K. Association of p53 codon 72 genetic polymorphism with the risk of ulcerative colitis in northern Iran. Int J Colorectal Dis 2011;26:235-8. [PMID: 20669023 DOI: 10.1007/s00384-010-1021-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
121 Tan SY, Wu PB, Zhang G, Luo HS, Ye HL. Association between interleukin-10-819 promoter polymorphism and susceptibility to Crohn's disease: A meta-analysis. Shijie Huaren Xiaohua Zazhi 2012; 20(35): 3603-3608 [DOI: 10.11569/wcjd.v20.i35.3603] [Reference Citation Analysis]
122 Ossum AM, Palm Ø, Cvancarova M, Solberg IC, Vatn M, Moum B, Høivik ML; the IBSEN study group. Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study. Scandinavian Journal of Gastroenterology 2018;53:1250-6. [DOI: 10.1080/00365521.2018.1518482] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
123 H Allin K, Jess T. Editorial: do thiopurines and biologics decrease the risk of colectomy? Aliment Pharmacol Ther 2017;46:896-7. [DOI: 10.1111/apt.14292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
124 Oliver J, Rueda B, López-Nevot MA, Gómez-García M, Martín J. Replication of an association between IL23R gene polymorphism with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:977-81, 981.e1-2. [PMID: 17678845 DOI: 10.1016/j.cgh.2007.05.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
125 Su HY, Gupta V, Day AS, Gearry RB. Rising Incidence of Inflammatory Bowel Disease in Canterbury, New Zealand. Inflamm Bowel Dis. 2016;22:2238-2244. [PMID: 27482976 DOI: 10.1097/mib.0000000000000829] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
126 Arin Letamendia A, Borda Celaya F, Burusco Paternain MJ, Prieto Martínez C, Martínez Echeverría A, Elizalde Apestegui I, Laiglesia Izquierdo M, Macias Mendizábal E, Tamburri Moso P, Sánchez Valverde F. [High incidence rates of inflammatory bowel disease in Navarra (Spain). Results of a prospective, population-based study]. Gastroenterol Hepatol 2008;31:111-6. [PMID: 18341841 DOI: 10.1157/13116497] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
127 Van Limbergen J, Russell RK, Nimmo ER, Zhao Y, Liao H, Drummond HE, Davies G, Gillett PM, McGrogan P, Bisset WM, Mahdi G, Wilson DC, Brown SJ, McLean WH, Satsangi J. Filaggrin loss-of-function variants are associated with atopic comorbidity in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1492-8. [PMID: 19408338 DOI: 10.1002/ibd.20926] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
128 Oostlander AE, Everts V, Schoenmaker T, Bravenboer N, van Vliet SJ, van Bodegraven AA, Lips P, de Vries TJ. T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for Crohn's disease-associated bone loss. J Cell Biochem 2012;113:260-8. [PMID: 21898548 DOI: 10.1002/jcb.23352] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
129 Glas J, Wagner J, Seiderer J, Olszak T, Wetzke M, Beigel F, Tillack C, Stallhofer J, Friedrich M, Steib C. PTPN2 gene variants are associated with susceptibility to both Crohn’s disease and ulcerative colitis supporting a common genetic disease background. PLoS One. 2012;7:e33682. [PMID: 22457781 DOI: 10.1371/journal.pone.0033682] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
130 Aheman A, Gao F, Kuerbanjiang A, Li YX, Abuduhadeer M. Difference in DRB1* gene polymorphisms between Han and Uyghur ulcerative colitis patients in China. World J Gastroenterol 2013; 19(17): 2709-2713 [PMID: 23674880 DOI: 10.3748/wjg.v19.i17.2709] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
131 Gisbert JP, Luna M, Legido J, Hermida C, Maté J, María Pajares J. Anticuerpos anticitoplasma de los neutrófilos en el diagnóstico de la colitis ulcerosa y la enfermedad de Crohn. Medicina Clínica 2004;122:134-5. [DOI: 10.1016/s0025-7753(04)74171-8] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
132 Klausz G, Molnár T, Nagy F, Gyulai Z, Boda K, Lonovics J, Mándi Y. Polymorphism of the heat-shock protein gene Hsp70-2, but not polymorphisms of the IL-10 and CD14 genes, is associated with the outcome of Crohn's disease. Scand J Gastroenterol 2005;40:1197-204. [PMID: 16165702 DOI: 10.1080/00365520510023350] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
133 Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-678. [PMID: 17554300 DOI: 10.1038/nature05911] [Cited by in Crossref: 6756] [Cited by in F6Publishing: 6076] [Article Influence: 450.4] [Reference Citation Analysis]
134 Birkenfeld S, Zvidi I, Hazazi R, Niv Y. The Prevalence of Ulcerative Colitis in Israel: A Twenty-year Survey. Journal of Clinical Gastroenterology 2009;43:743-6. [DOI: 10.1097/mcg.0b013e31818b3a02] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
135 Noble CL, Nimmo ER, Drummond H, Ho GT, Tenesa A, Smith L, Anderson N, Arnott ID, Satsangi J. The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease. Gastroenterology. 2005;129:1854-1864. [PMID: 16344054 DOI: 10.1053/j.gastro.2005.09.025] [Cited by in Crossref: 96] [Cited by in F6Publishing: 92] [Article Influence: 6.0] [Reference Citation Analysis]
136 Ye L, Zhang YP, Yu N, Jia YX, Wan SJ, Wang FY. Serum platelet factor 4 is a reliable activity parameter in adult patients with inflammatory bowel disease: A pilot study. Medicine (Baltimore) 2017;96:e6323. [PMID: 28296751 DOI: 10.1097/MD.0000000000006323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
137 Terracciano F, Scalisi G, Bossa F, Scimeca D, Biscaglia G, Mangiacotti M, Valvano MR, Perri F, Simeone A, Andriulli A. Transperineal ultrasonography: First level exam in IBD patients with perianal disease. Digestive and Liver Disease 2016;48:874-9. [DOI: 10.1016/j.dld.2016.03.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
138 Malik S, Wong SC, Bishop J, Hassan K, McGrogan P, Ahmed SF, Russell RK. Improvement in growth of children with Crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr. 2011;52:31-37. [PMID: 21150651 DOI: 10.1097/mpg.0b013e3181edd797] [Cited by in Crossref: 49] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
139 Cosnes J, Bourrier A, Nion-Larmurier I, Sokol H, Beaugerie L, Seksik P. Factors affecting outcomes in Crohn's disease over 15 years. Gut. 2012;61:1140-1145. [PMID: 22387526 DOI: 10.1136/gutjnl-2011-301971] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 7.1] [Reference Citation Analysis]
140 Kuenzig ME, Yim J, Coward S, Eksteen B, Seow CH, Barnabe C, Barkema HW, Silverberg MS, Lakatos PL, Beck PL, Fedorak R, Dieleman LA, Madsen K, Panaccione R, Ghosh S, Kaplan GG. The NOD2-Smoking Interaction in Crohn's Disease is likely Specific to the 1007fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study. EBioMedicine 2017;21:188-96. [PMID: 28668336 DOI: 10.1016/j.ebiom.2017.06.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
141 Kwak MS, Kim KJ, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK. Elevated C-reactive protein is associated with disease progression in patients with mild Crohn's disease. Springerplus 2016;5:878. [PMID: 27386326 DOI: 10.1186/s40064-016-2606-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
142 Robinson RJ, Iqbal SJ, Al-Azzawi F, Abrams K, Mayberry JF. Sex hormone status and bone metabolism in men with Crohn's disease. Aliment Pharmacol Ther 1998;12:21-5. [PMID: 9692696 DOI: 10.1046/j.1365-2036.1998.00271.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 1.5] [Reference Citation Analysis]
143 Li YC, Li WZ, Wu CR, Feng Y, Ren L, Mi C, Li Y. Prevalence and characteristics of ophthalmological extra-intestinal manifestations in Chinese patients with inflammatory bowel disease. Int J Ophthalmol 2016;9:1476-9. [PMID: 27803867 DOI: 10.18240/ijo.2016.10.18] [Reference Citation Analysis]
144 Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45:872-877. [PMID: 20377469 DOI: 10.3109/00365521003782389] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 5.5] [Reference Citation Analysis]
145 Rönnblom A, Holmström T, Karlbom U, Tanghöj H, Thörn M, Sjöberg D. Clinical course of Crohn's disease during the first 5 years. Results from a population-based cohort in Sweden (ICURE) diagnosed 2005-2009. Scand J Gastroenterol 2017;52:81-6. [PMID: 27632773 DOI: 10.1080/00365521.2016.1230777] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
146 Riegler G, Bossa F, Caserta L, Pera A, Tonelli F, Sturniolo GC, Oliva L, Contessini Avesani E, Poggioli G; IG-IBD Group. Colorectal cancer and high grade dysplasia complicating ulcerative colitis in Italy. A retrospective co-operative IG-IBD study. Dig Liver Dis 2003;35:628-34. [PMID: 14563184 DOI: 10.1016/s1590-8658(03)00380-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
147 Romberg-Camps MJ, Bol Y, Dagnelie PC, Hesselink-van de Kruijs MA, Kester AD, Engels LG, van Deursen C, Hameeteman WH, Pierik M, Wolters F. Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort. Inflamm Bowel Dis. 2010;16:2137-2147. [PMID: 20848468 DOI: 10.1002/ibd.21285] [Cited by in Crossref: 125] [Cited by in F6Publishing: 120] [Article Influence: 11.4] [Reference Citation Analysis]
148 Stio M, Martinesi M, Bruni S, Treves C, d'Albasio G, Bagnoli S, Bonanomi AG. Interaction among vitamin D(3) analogue KH 1060, TNF-alpha, and vitamin D receptor protein in peripheral blood mononuclear cells of inflammatory bowel disease patients. Int Immunopharmacol. 2006;6:1083-1092. [PMID: 16714211 DOI: 10.1016/j.intimp.2006.01.018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
149 Guerini FR, Cagliani R, Forni D, Agliardi C, Caputo D, Cassinotti A, Galimberti D, Fenoglio C, Biasin M, Asselta R, Scarpini E, Comi GP, Bresolin N, Clerici M, Sironi M. A functional variant in ERAP1 predisposes to multiple sclerosis. PLoS One 2012;7:e29931. [PMID: 22253828 DOI: 10.1371/journal.pone.0029931] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
150 Bafford AC, Latushko A, Hansraj N, Jambaulikar G, Ghazi LJ. The Use of Temporary Fecal Diversion in Colonic and Perianal Crohn's Disease Does Not Improve Outcomes.Dig Dis Sci. 2017;62:2079-2086. [PMID: 28550490 DOI: 10.1007/s10620-017-4618-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
151 Linares PM, Algaba A, Urzainqui A, Guijarro-Rojas M, González-Tajuelo R, Garrido J, Chaparro M, Gisbert JP, Bermejo F, Guerra I, Castellano V, Fernández-Contreras ME. Ratio of Circulating Estrogen Receptors Beta and Alpha (ERβ/ERα) Indicates Endoscopic Activity in Patients with Crohn's Disease. Dig Dis Sci 2017;62:2744-54. [PMID: 28823012 DOI: 10.1007/s10620-017-4717-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
152 Meggyesi N, Kiss LS, Koszarska M, Bortlik M, Duricova D, Lakatos L, Molnar T, Leniček M, Vítek L, Altorjay I, Papp M, Tulassay Z, Miheller P, Papp J, Tordai A, Andrikovics H, Lukas M, Lakatos PL. NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients. World J Gastroenterol 2010; 16(41): 5233-5240 [PMID: 21049557 DOI: 10.3748/wjg.v16.i41.5233] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
153 Schoon EJ, Müller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrügger RW. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? Gut 2001;48:473-7. [PMID: 11247890 DOI: 10.1136/gut.48.4.473] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 3.8] [Reference Citation Analysis]
154 Li K, Wang B, Liu S, Yao S, Guo L, Mao D. The combination of polymorphisms within MCP-1 and IL-1β associated with ulcerative colitis. International Journal of Immunogenetics 2009;36:135-9. [DOI: 10.1111/j.1744-313x.2009.00836.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
155 Sura R, Gavrilov B, Flamand L, Ablashi D, Cartun R, Colombel JF, Van Kruiningen HJ. Human herpesvirus-6 in patients with Crohn's disease. APMIS 2010;118:394-400. [PMID: 20477816 DOI: 10.1111/j.1600-0463.2010.02613.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
156 Inoue T, Murano M, Abe Y, Morita E, Murano N, Toshina K, Umegaki E, Hirata I, Higuchi K. Colonoscopic differences of erosive and/or small ulcerative lesions for diagnosis of colonic inflammatory diseases. J Gastroenterol Hepatol 2010;25 Suppl 1:S149-54. [PMID: 20586858 DOI: 10.1111/j.1440-1746.2010.06233.x] [Reference Citation Analysis]
157 Alzafiri R, Holcroft CA, Malolepszy P, Cohen A, Szilagyi A. Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years. Clin Exp Gastroenterol 2011;4:9-17. [PMID: 21694867 DOI: 10.2147/CEG.S16168] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
158 Kim JW, Hwang SW, Park SH, Song TJ, Kim MH, Lee HS, Ye BD, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK. Clinical course of ulcerative colitis patients who develop acute pancreatitis. World J Gastroenterol 2017; 23(19): 3505-3512 [PMID: 28596686 DOI: 10.3748/wjg.v23.i19.3505] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
159 Ho GT, Seddon AJ, Therapondos G, Satsangi J, Hayes PC. The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. Eur J Gastroenterol Hepatol 2005;17:1379-85. [PMID: 16292093 DOI: 10.1097/00042737-200512000-00018] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
160 Vegh Z, Golovics PA, Lovasz BD, Kurti Z, Gecse KB, Szita I, Balogh M, Pandur T, Lakatos L, Lakatos PL. Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort. Scand J Gastroenterol. 2015;50:306-311. [PMID: 25471148 DOI: 10.3109/00365521.2014.985708] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
161 Jeon HH, Lee HJ, Jang HW, Yoon JY, Jung YS, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis. World J Gastroenterol 2013; 19(2): 265-273 [PMID: 23345950 DOI: 10.3748/wjg.v19.i2.265] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
162 Fernández A, Barreiro-de Acosta M, Vallejo N, Iglesias M, Carmona A, González-Portela C, Lorenzo A, Domínguez-Muñoz JE. Complementary and alternative medicine in inflammatory bowel disease patients: frequency and risk factors. Dig Liver Dis 2012;44:904-8. [PMID: 22795615 DOI: 10.1016/j.dld.2012.06.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
163 Pontes RM, Miszputen SJ, Ferreira-Filho OF, Miranda C, Ferraz MB. [Quality of life in patients with inflammatory bowel diseases: translation to Portuguese language and validation of the “Inflammatory Bowel Disease Questionnaire” (IBDQ)]. Arq Gastroenterol. 2004;41:137-143. [PMID: 15543390 DOI: 10.1590/s0004-28032004000200014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
164 Swift GL, Srivastava ED, Stone R, Pullan RD, Newcombe RG, Rhodes J, Wilkinson S, Rhodes P, Roberts G, Lawrie BW. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn’s disease. Gut. 1994;35:363-368. [PMID: 8150348 DOI: 10.1136/gut.35.3.363] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 2.0] [Reference Citation Analysis]
165 Azevedo LF, Magro F, Portela F, Lago P, Deus J, Cotter J, Cremers I, Vieira A, Peixe P, Caldeira P, Lopes H, Gonçalves R, Reis J, Cravo M, Barros L, Ministro P, Lurdes M, Duarte A, Campos M, Carvalho L, Costa-pereira A. Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach: PREVALENCE OF IBD IN PORTUGAL-A PHARMACO-EPIDEMIOLOGICAL APPROACH. Pharmacoepidem Drug Safe 2010;19:499-510. [DOI: 10.1002/pds.1930] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
166 de Vries M, van der Horst-Bruinsma I, van Hoogstraten I, van Bodegraven A, von Blomberg BM, Ratnawati H, Dijkmans B. pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease. J Rheumatol 2010;37:2340-4. [PMID: 20810508 DOI: 10.3899/jrheum.100269] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
167 Paerregaard A, Uldall Urne F. Anthropometry at the time of diagnosis in Danish children with inflammatory bowel disease. Acta Paediatr 2005;94:1682-3. [PMID: 16303711 DOI: 10.1080/08035250500254068] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
168 Patrick D, Doecke JD, Irwin J, Hanigan K, Simms LA, Howlett M, Radford-Smith GL. Short-term colectomy is avoided in over half of regional patients failing medical therapy for acute severe ulcerative colitis with co-ordinated transfer and tertiary care. Intern Med J 2020;50:823-9. [PMID: 31589361 DOI: 10.1111/imj.14649] [Reference Citation Analysis]
169 Niv Y, Abuksis G, Fraser GM. Epidemiology of ulcerative colitis in Israel: a survey of Israeli kibbutz settlements. Am J Gastroenterol. 2000;95:693-698. [PMID: 10710059 DOI: 10.1111/j.1572-0241.2000.01849.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
170 Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol. 2009;24:1252-1257. [PMID: 19220669 DOI: 10.1111/j.1440-1746.2009.05786.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
171 Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp J, Lakatos L. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn’s disease. World J Gastroenterol 2009; 15(28): 3504-3510 [PMID: 19630105 DOI: 10.3748/wjg.15.3504] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 81] [Article Influence: 5.8] [Reference Citation Analysis]
172 Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004;2:309-313. [PMID: 15067625 DOI: 10.1016/S1542-3565(04)00060-6] [Cited by in Crossref: 122] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
173 Gaetani E, Del Zompo F, Marcantoni M, Gatto I, Giarretta I, Porfidia A, Scaldaferri F, Laterza L, Lopetuso L, Gasbarrini A, Pola R. Microparticles Produced by Activated Platelets Carry a Potent and Functionally Active Angiogenic Signal in Subjects with Crohn's Disease. Int J Mol Sci 2018;19:E2921. [PMID: 30261608 DOI: 10.3390/ijms19102921] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
174 Annese V, Andreoli A, Andriulli A, D'inca' R, Gionchetti P, Latiano A, Lombardi G, Piepoli A, Poulain D, Sendid B, Colombel JF. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am J Gastroenterol 2001;96:2407-12. [DOI: 10.1111/j.1572-0241.2001.04043.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 2.4] [Reference Citation Analysis]
175 Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13. [DOI: 10.1016/s0016-5085(00)70140-5] [Cited by in Crossref: 734] [Cited by in F6Publishing: 169] [Article Influence: 33.4] [Reference Citation Analysis]
176 Li K, Wang B, Sui H, Liu S, Yao S, Guo L, Mao D. Polymorphisms of the macrophage inflammatory protein 1 alpha and ApoE genes are associated with ulcerative colitis. Int J Colorectal Dis. 2009;24:13-17. [PMID: 18762952 DOI: 10.1007/s00384-008-0575-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
177 Schulz S, Reichert S, Streetz K, Trautwein C, Reichert Y, Gläser C, Schaller H, Stein JM. Tumor Necrosis Factor-α and Oral Inflammation in Patients With Crohn Disease. Journal of Periodontology 2014;85:1424-31. [DOI: 10.1902/jop.2014.130644] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
178 Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D, Cardon L, Takazoe M, Tanaka T, Ichimori T, Saito S, Sekine A, Iida A, Takahashi A, Tsunoda T, Lathrop M, Nakamura Y. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 2005;14:3499-506. [PMID: 16221758 DOI: 10.1093/hmg/ddi379] [Cited by in Crossref: 336] [Cited by in F6Publishing: 320] [Article Influence: 19.8] [Reference Citation Analysis]
179 Aoyama Y, Inaba T, Takahashi S, Yasuhara H, Hiraoka S, Morimoto T, Colvin HS, Wato M, Ando M, Nakamura S, Mizobuchi K, Okada H. Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects disease activity and predicts the response to steroid therapy in ulcerative colitis. BMC Gastroenterol 2021;21:325. [PMID: 34425765 DOI: 10.1186/s12876-021-01903-5] [Reference Citation Analysis]
180 Fatemi A, Jazi HH, Emami MH, Kazemizadeh A, Tavakkoli H, Smiley A. Relationship between articular and nonarticular manifestations in inflammatory bowel diseases. J Res Med Sci 2016;21:48. [PMID: 27904594 DOI: 10.4103/1735-1995.183989] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
181 Martínez A, Martín MC, Mendoza JL, Taxonera C, Díaz-Rubio M, de la Concha EG, Urcelay E. Association of the organic cation transporter OCTN genes with Crohn's disease in the Spanish population. Eur J Hum Genet 2006;14:222-6. [PMID: 16333318 DOI: 10.1038/sj.ejhg.5201529] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
182 Jiang T, Ge LQ, Chen ZT, Li C, Zhou F, Luo Y, Xia B. Effect of cytotoxic T lymphocyte-associated molecule 4 1661 gene polymorphism on its expression and transcription in ulcerative colitis. J Dig Dis. 2010;11:369-375. [PMID: 21091900 DOI: 10.1111/j.1751-2980.2010.00462.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
183 Krupoves A, Mack D, Seidman E, Deslandres C, Amre D. Associations between variants in the ABCB1 (MDR1) gene and corticosteroid dependence in children with Crohn’s disease. Inflamm Bowel Dis. 2011;17:2308-2317. [PMID: 21987299 DOI: 10.1002/ibd.21608] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
184 Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, Quertinmont E, Abramowicz M, Van Gossum A, Devière J. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut. 2004;53:987-992. [PMID: 15194649 DOI: 10.1136/gut.2003.030205] [Cited by in Crossref: 422] [Cited by in F6Publishing: 408] [Article Influence: 23.4] [Reference Citation Analysis]
185 Vermeire S, Rutgeerts P, Van Steen K, Joossens S, Claessens G, Pierik M, Peeters M, Vlietinck R. Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis. Gut. 2004;53:980-986. [PMID: 15194648 DOI: 10.1136/gut.2003.034033] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 2.9] [Reference Citation Analysis]
186 Yang S, Jung Y, Hong M, Kim H, Ye BD, Lee I, Song K. No association between TNFSF15 and IL23R with ulcerative colitis in Koreans. J Hum Genet 2011;56:200-4. [DOI: 10.1038/jhg.2010.166] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
187 Geboes K, Joossens S, Prantera C, Rutgeerts P. Indeterminate colitis in clinical practice. Current Diagnostic Pathology 2003;9:179-87. [DOI: 10.1016/s0968-6053(02)00099-6] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
188 Molendijk I, Nuij VJ, van der Meulen-de Jong AE, van der Woude CJ. Disappointing durable remission rates in complex Crohn's disease fistula. Inflamm Bowel Dis. 2014;20:2022-2028. [PMID: 25159455 DOI: 10.1097/mib.0000000000000148] [Cited by in Crossref: 71] [Cited by in F6Publishing: 27] [Article Influence: 10.1] [Reference Citation Analysis]
189 Koh SJ, Choi Y, Kim BG, Lee KL, Kim DW, Kim JH, Kim JW, Kim JS. Matricellular Protein Periostin Mediates Intestinal Inflammation through the Activation of Nuclear Factor κB Signaling. PLoS One 2016;11:e0149652. [PMID: 26890265 DOI: 10.1371/journal.pone.0149652] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
190 Ellinghaus D, Folseraas T, Holm K, Ellinghaus E, Melum E, Balschun T, Laerdahl JK, Shiryaev A, Gotthardt DN, Weismüller TJ, Schramm C, Wittig M, Bergquist A, Björnsson E, Marschall HU, Vatn M, Teufel A, Rust C, Gieger C, Wichmann HE, Runz H, Sterneck M, Rupp C, Braun F, Weersma RK, Wijmenga C, Ponsioen CY, Mathew CG, Rutgeerts P, Vermeire S, Schrumpf E, Hov JR, Manns MP, Boberg KM, Schreiber S, Franke A, Karlsen TH. Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology 2013;58:1074-83. [PMID: 22821403 DOI: 10.1002/hep.25977] [Cited by in Crossref: 101] [Cited by in F6Publishing: 87] [Article Influence: 11.2] [Reference Citation Analysis]
191 Bouma G, Xia B, Crusius JB, Bioque G, Koutroubakis I, Von Blomberg BM, Meuwissen SG, Peña AS. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1996;103:391-6. [PMID: 8608636 DOI: 10.1111/j.1365-2249.1996.tb08292.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 93] [Article Influence: 3.6] [Reference Citation Analysis]
192 Morgan AR, Han DY, Lam WJ, Fraser AG, Ferguson LR. Association analysis of 3p21 with Crohn's disease in a New Zealand population. Hum Immunol 2010;71:602-9. [PMID: 20307617 DOI: 10.1016/j.humimm.2010.03.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
193 Siddique I, Alazmi W, Al-ali J, Longenecker JC, Al-fadli A, Hasan F, Memon A. Demography and clinical course of ulcerative colitis in Arabs – a study based on the Montreal classification. Scandinavian Journal of Gastroenterology 2014;49:1432-40. [DOI: 10.3109/00365521.2014.966318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
194 Cox DG, Crusius JBA, Peeters PH, Bueno-de-Mesquita HB, Peña AS, Canzian F. Haplotype of prostaglandin synthase 2/cyclooxygenase 2 is involved in the susceptibility to inflammatory bowel disease. World J Gastroenterol 2005; 11(38): 6003-6008 [PMID: 16273614 DOI: 10.3748/wjg.v11.i38.6003] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
195 Tan SY, Wu PB, Zhang G, Luo HS, Yao WM. Association between macrophage migration inhibitory factor _173G/C polymorphism and inflammatory bowel disease: A meta-analysis. Shijie Huaren Xiaohua Zazhi 2013; 21(12): 1140-1145 [DOI: 10.11569/wcjd.v21.i12.1140] [Reference Citation Analysis]
196 Papp M, Lakatos PL, Harsfalvi J, Farkas G, Palatka K, Udvardy M, Molnar T, Farkas K, Nagy F, Veres G. Mannose-binding lectin level and deficiency is not associated with inflammatory bowel diseases, disease phenotype, serology profile, and NOD2/CARD15 genotype in a large Hungarian cohort. Hum Immunol. 2010;71:407-413. [PMID: 20079790 DOI: 10.1016/j.humimm.2010.01.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
197 Glas J, Seiderer J, Czamara D, Pasciuto G, Diegelmann J, Wetzke M, Olszak T, Wolf C, Müller-Myhsok B, Balschun T, Achkar JP, Kamboh MI, Franke A, Duerr RH, Brand S. PTGER4 expression-modulating polymorphisms in the 5p13.1 region predispose to Crohn's disease and affect NF-κB and XBP1 binding sites. PLoS One 2012;7:e52873. [PMID: 23300802 DOI: 10.1371/journal.pone.0052873] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
198 Sikander A, Rana SV, Sharma SK, Sinha SK, Arora SK, Prasad KK, Singh K. Association of alpha 2A adrenergic receptor gene (ADRAlpha2A) polymorphism with irritable bowel syndrome, microscopic and ulcerative colitis. Clin Chim Acta. 2010;411:59-63. [PMID: 19833115 DOI: 10.1016/j.cca.2009.10.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
199 Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67:1298-1323. [PMID: 28802875 DOI: 10.1016/j.jhep.2017.07.022] [Cited by in Crossref: 244] [Cited by in F6Publishing: 209] [Article Influence: 48.8] [Reference Citation Analysis]
200 Iwatani S, Iijima H, Otake Y, Amano T, Tani M, Yoshihara T, Tashiro T, Tsujii Y, Inoue T, Hayashi Y, Takeda K, Hayashi A, Fujita S, Shinzaki S, Takehara T. Novel mass spectrometry‐based comprehensive lipidomic analysis of plasma from patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology 2020;35:1355-64. [DOI: 10.1111/jgh.15067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
201 Hilmi I, Singh R, Ganesananthan S, Yatim I, Radzi M, Chua AB, Tan HJ, Huang S, Chin KS, Menon J, Goh KL. Demography and clinical course of ulcerative colitis in a multiracial Asian population: a nationwide study from Malaysia. J Dig Dis 2009;10:15-20. [PMID: 19236542 DOI: 10.1111/j.1751-2980.2008.00357.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
202 Chen B, Zeng Z, Hou J, Chen M, Gao X, Hu P. Association of interleukin-17F 7488 single nucleotide polymorphism and inflammatory bowel disease in the Chinese population. Scand J Gastroenterol. 2009;44:720-726. [PMID: 19263269 DOI: 10.1080/00365520902795430] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
203 Ren J, Tao Q, Wang X, Wang Z, Li J. Efficacy of T2 in Active Crohn’s Disease: A Prospective Study Report. Dig Dis Sci 2007;52:1790-7. [DOI: 10.1007/s10620-007-9747-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
204 Seiderer J, Brand S, Herrmann KA, Schnitzler F, Hatz R, Crispin A, Pfennig S, Schoenberg SO, Göke B, Lohse P, Ochsenkühn T. Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohnʼs disease in clinical practice: Results of a Prospective Study: . Inflammatory Bowel Diseases 2006;12:1114-21. [DOI: 10.1097/01.mib.0000235836.32176.5e] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 4.4] [Reference Citation Analysis]
205 Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR. IL23R and IL12B SNPs and Haplotypes Strongly Associate with Crohn's Disease Risk in a New Zealand Population. Gastroenterol Res Pract. 2010;2010:539461. [PMID: 21253534 DOI: 10.1155/2010/539461] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
206 Lü M, Xia B, Ge L, Li Y, Zhao J, Chen F, Zhou F, Zhang X, Tan J. Role of major histocompatibility complex class I-related molecules A*A5.1 allele in ulcerative colitis in Chinese patients. Immunology. 2009;128:e230-e236. [PMID: 19016911 DOI: 10.1111/j.1365-2567.2008.02953.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
207 Salgado VCL, Luiz RR, Boéchat NLF, Leão IS, Schorr BDC, Parente JML, Lima DC, Silveira Júnior ES, Silva GOS, Almeida NP, Vieira A, de Bueno MLQ, Chebli JM, Bertges ÉR, Brugnara LMDC, Junqueira Neto C, Campbell SBG, Discacciati LL, Cézar JPS, Nunes T, Kaplan GG, Zaltman C. Risk factors associated with inflammatory bowel disease: A multicenter case-control study in Brazil. World J Gastroenterol 2020; 26(25): 3611-3624 [PMID: 32742130 DOI: 10.3748/wjg.v26.i25.3611] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
208 De Jager PL, Franchimont D, Waliszewska A, Bitton A, Cohen A, Langelier D, Belaiche J, Vermeire S, Farwell L, Goris A. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun. 2007;8:387-397. [PMID: 17538633 DOI: 10.1038/sj.gene.6364398] [Cited by in Crossref: 99] [Cited by in F6Publishing: 101] [Article Influence: 6.6] [Reference Citation Analysis]
209 Ouyang Q, Tandon R, Goh KL, Pan GZ, Fock KM, Fiocchi C, Lam SK, Xiao SD. Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol 2006;21:1772-82. [PMID: 17074013 DOI: 10.1111/j.1440-1746.2006.04674.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 4.5] [Reference Citation Analysis]
210 Vidal Á, Gómez-gil E, Sans M, Portella MJ, Salamero M, Piqué JM, Panés J. Psychometric properties of the original Inflammatory Bowel Disease Questionnaire, a Spanish version. Gastroenterología y Hepatología 2007;30:212-8. [DOI: 10.1157/13100587] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
211 Qiu Y, Chen BL, Feng R, Zhang SH, He Y, Zeng ZR, Ben-Horin S, Peyrin-Biroulet L, Mao R, Chen MH. Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease. J Gastroenterol Hepatol 2018;33:664-70. [PMID: 28940780 DOI: 10.1111/jgh.14000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
212 Shaghaghi Z, Bonyadi M, Somi MH, Khoshbaten M. Association of plasminogen activator inhibitor-1 gene polymorphism with inflammatory bowel disease in Iranian Azeri Turkish patients. Saudi J Gastroenterol 2014;20:54-8. [PMID: 24496159 DOI: 10.4103/1319-3767.126322] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
213 Bharadwaj S, Narula N, Tandon P, Yaghoobi M. Role of endoscopy in inflammatory bowel disease. Gastroenterol Rep (Oxf) 2018;6:75-82. [PMID: 29780594 DOI: 10.1093/gastro/goy006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
214 Yang S, Hong M, Oh H, Low H, Jung S, Ahn S, Kim Y, Baek J, Lee CH, Kim E, Kim KM, Ye BD, Kim K, Park SH, Lee H, Lee I, Shin HD, Han B, Mcgovern DP, Liu J, Song K. Identification of Loci at 1q21 and 16q23 That Affect Susceptibility to Inflammatory Bowel Disease in Koreans. Gastroenterology 2016;151:1096-1099.e4. [DOI: 10.1053/j.gastro.2016.08.025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
215 Fujii H, Shinzaki S, Iijima H, Wakamatsu K, Iwamoto C, Sobajima T, Kuwahara R, Hiyama S, Hayashi Y, Takamatsu S, Uozumi N, Kamada Y, Tsujii M, Taniguchi N, Takehara T, Miyoshi E. Core Fucosylation on T Cells, Required for Activation of T-Cell Receptor Signaling and Induction of Colitis in Mice, Is Increased in Patients With Inflammatory Bowel Disease. Gastroenterology 2016;150:1620-32. [DOI: 10.1053/j.gastro.2016.03.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 7.7] [Reference Citation Analysis]
216 Bouma G, Crusius JB, García-González MA, Meijer BU, Hellemans HP, Hakvoort RJ, Schreuder GM, Kostense PJ, Meuwissen SG, Peña AS. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol 1999;115:294-300. [PMID: 9933456 DOI: 10.1046/j.1365-2249.1999.00797.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 70] [Article Influence: 3.8] [Reference Citation Analysis]
217 Cross RK, Finkelstein J. Feasibility and acceptance of a home telemanagement system in patients with inflammatory bowel disease: a 6-month pilot study. Dig Dis Sci 2007;52:357-64. [PMID: 17211702 DOI: 10.1007/s10620-006-9523-4] [Cited by in Crossref: 65] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
218 Suzuki H, Kato J, Kuriyama M, Hiraoka S, Kuwaki K, Yamamoto K. Specific endoscopic features of ulcerative colitis complicated by cytomegalovirus infection. World J Gastroenterol 2010; 16(10): 1245-1251 [PMID: 20222169 DOI: 10.3748/wjg.v16.i10.1245] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
219 Lee HA, Suk JY, Choi SY, Kim ER, Kim YH, Lee CK, Huh KC, Lee KM, Park DI. Characteristics of Pediatric Inflammatory Bowel Disease in Korea: Comparison with EUROKIDS Data. Gut Liver 2015;9:756-60. [PMID: 25963086 DOI: 10.5009/gnl14338] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
220 Koutroubakis IE, Xidakis C, Karmiris K, Sfiridaki A, Kandidaki E, Kouroumalis EA. Serum Angiogenin in Inflammatory Bowel Disease. Dig Dis Sci 2004;49:1758-62. [DOI: 10.1007/s10620-004-9565-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
221 Bermejo F, López-San Román A, Algaba A, Guerra I, Valer P, García-Garzón S, Piqueras B, Villa C, Bermejo A, Rodríguez-Agulló JL. Factors that modify therapy adherence in patients with inflammatory bowel disease. J Crohns Colitis. 2010;4:422-426. [PMID: 21122538 DOI: 10.1016/j.crohns.2010.01.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
222 Leong RW, Lawrance IC, Chow DK, To KF, Lau JY, Wu J, Leung WK, Chan FK, Sung JJ. Association of intestinal granulomas with smoking, phenotype, and serology in Chinese patients with Crohn’s disease. Am J Gastroenterol. 2006;101:1024-1029. [PMID: 16573779 DOI: 10.1111/j.1572-0241.2006.00503.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
223 Chen X, Yang K, Xu Y, Li K. Top-100 highest-cited original articles in inflammatory bowel disease: A bibliometric analysis. Medicine (Baltimore) 2019;98:e15718. [PMID: 31096525 DOI: 10.1097/MD.0000000000015718] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
224 Gasche C, Alizadeh BZ, Peña AS. Genotype–phenotype correlations: how many disorders constitute inflammatory bowel disease? European Journal of Gastroenterology & Hepatology 2003;15:599-606. [DOI: 10.1097/00042737-200306000-00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
225 Lü M, Xia B. Polymorphism of HLA-DRB1 gene shows no strong association with ulcerative colitis in Chinese patients. Int J Immunogenet. 2006;33:37-40. [PMID: 16426241 DOI: 10.1111/j.1744-313x.2005.00559.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
226 Murillo LS, Morré SA, Peña AS. Role of the CARD15 gene in the pathogenesis of Crohn disease: phenotypic classification and prognostic implications. Scandinavian Journal of Gastroenterology 2009;38:1107-14. [DOI: 10.1080/00365520310005703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
227 Chaparro M, Barreiro-de Acosta M, Benítez JM, Cabriada JL, Casanova MJ, Ceballos D, Esteve M, Fernández H, Ginard D, Gomollón F, Lorente R, Nos P, Riestra S, Rivero M, Robledo P, Rodríguez C, Sicilia B, Torrella E, Garre A, García-Esquinas E, Rodríguez-Artalejo F, Gisbert JP; EpidemIBD study group of GETECCU. EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. Therap Adv Gastroenterol 2019;12:1756284819847034. [PMID: 31205485 DOI: 10.1177/1756284819847034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
228 Costa Pereira C, Durães C, Coelho R, Grácio D, Silva M, Peixoto A, Lago P, Pereira M, Catarino T, Pinho S, Teixeira JP, Macedo G, Annese V, Magro F. Association between Polymorphisms in Antioxidant Genes and Inflammatory Bowel Disease. PLoS One 2017;12:e0169102. [PMID: 28052094 DOI: 10.1371/journal.pone.0169102] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
229 Taherkhani R, Farshadpour F, Makvandi M, Hamidifard M, Esmailizadeh M, Ahmadi B, Heidari H. Determination of cytomegalovirus prevalence and glycoprotein B genotypes among ulcerative colitis patients in ahvaz, iran. Jundishapur J Microbiol 2015;8:e17458. [PMID: 25793098 DOI: 10.5812/jjm.17458] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
230 Reikvam DH, Perminow G, Lyckander LG, Gran JM, Brandtzaeg P, Vatn M, Carlsen HS. Increase of regulatory T cells in ileal mucosa of untreated pediatric Crohn's disease patients. Scandinavian Journal of Gastroenterology 2011;46:550-60. [DOI: 10.3109/00365521.2011.551887] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
231 Kiss LS, Szamosi T, Molnar T, Miheller P, Lakatos L, Vincze A, Palatka K, Barta Z, Gasztonyi B, Salamon A. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease. Aliment Pharmacol Ther. 2011;34:911-922. [PMID: 21883326 DOI: 10.1111/j.1365-2036.2011.04827.x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 107] [Article Influence: 10.9] [Reference Citation Analysis]
232 Hiyama S, Iijima H, Sakakibara Y, Yamada T, Mukai A, Otake Y, Yamaguchi T, Araki M, Kawai S, Tsujii Y, Inoue T, Hayashi Y, Shinzaki S, Takehara T. Endoscopic alterations in Peyer's patches in patients with ulcerative colitis: A prospective, multicenter study. J Gastroenterol Hepatol 2020;35:1143-9. [PMID: 31734952 DOI: 10.1111/jgh.14933] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
233 Ye X, Jiang Y, Wang H, Chen L, Yuan S, Xia B. Genetic polymorphisms of glutathione S-transferases are associated with ulcerative colitis in central China. Cell Biochem Biophys. 2011;60:323-328. [PMID: 21301992 DOI: 10.1007/s12013-011-9154-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
234 Odes S, Friger M, Vardi H, Claessens G, Bossuyt X, Riis L, Munkholm P, Wolters F, Yona H, Hoie O, Beltrami M, Tsianos E, Katsanos K, Mouzas I, Clofent J, Monteiro E, Messori A, Politi P, O'Morain C, Limonard C, Russel M, Vatn M, Moum B, Stockbrugger R, Vermeire S; European Collaborative Study Group on Inflammatory Bowel disease. Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: a project of the European Collaborative Study Group on Inflammatory Bowel Disease. Inflamm Bowel Dis 2007;13:874-81. [PMID: 17278126 DOI: 10.1002/ibd.20122] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
235 Yang SK, Hong M, Choi H, Zhao W, Jung Y, Haritunians T, Ye BD, Kim KJ, Park SH, Lee I, Kim WH, Cheon JH, Kim YH, Jang BI, Kim HS, Choi JH, Koo JS, Lee JH, Jung SA, Shin HD, Kang D, Youn HS, Taylor KD, Rotter JI, Liu J, McGovern DP, Song K. Immunochip analysis identification of 6 additional susceptibility loci for Crohn's disease in Koreans. Inflamm Bowel Dis 2015;21:1-7. [PMID: 25489960 DOI: 10.1097/MIB.0000000000000268] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 5.1] [Reference Citation Analysis]
236 Leong RW, Lee YT, Ching JY, Sung JJ. Quality of life in Chinese patients with inflammatory bowel disease: validation of the Chinese translation of the Inflammatory Bowel Disease Questionnaire. Aliment Pharmacol Ther 2003;17:711-8. [PMID: 12641521 DOI: 10.1046/j.1365-2036.2003.01489.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
237 Geerling BJ, Badart-Smook A, van Deursen C, van Houwelingen AC, Russel MG, Stockbrügger RW, Brummer RJ. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis. 2000;6:77-84. [PMID: 10833065 DOI: 10.1097/00054725-200005000-00002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 1.8] [Reference Citation Analysis]
238 Vatn MH, Sandvik AK. Inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2015;50:748-62. [DOI: 10.3109/00365521.2015.1033000] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
239 Roggenbuck D, Reinhold D, Wex T, Goihl A, von Arnim U, Malfertheiner P, Büttner T, Porstmann T, Porstmann S, Liedvogel B. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn’s disease. Clin Chim Acta. 2011;412:718-724. [PMID: 21195704 DOI: 10.1016/j.cca.2010.12.029] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
240 Hwang SW, Kwak MS, Kim WS, Lee JM, Park SH, Lee HS, Yang DH, Kim KJ, Ye BD, Byeon JS. Influence of a positive family history on the clinical course of inflammatory bowel disease. J Crohns Colitis. 2016;10:1024-1032. [PMID: 26933029 DOI: 10.1093/ecco-jcc/jjw063] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
241 Szántó K, Nyári T, Bálint A, Bor R, Milassin Á, Rutka M, Fábián A, Szepes Z, Nagy F, Molnár T, Farkas K. Biological therapy and surgery rates in inflammatory bowel diseases - Data analysis of almost 1000 patients from a Hungarian tertiary IBD center. PLoS One 2018;13:e0200824. [PMID: 30059523 DOI: 10.1371/journal.pone.0200824] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
242 Manousou P, Kolios G, Drygiannakis I, Pyrovolaki K, Bourikas L, Papadaki HA, Kouroumalis E. Expression of a splice variant of CXCR3 in Crohn's disease patients; indication for a lymphocyte--epithelial cell interaction. J Gastroenterol Hepatol 2008;23:1823-33. [PMID: 18761554 DOI: 10.1111/j.1440-1746.2008.05486.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
243 Baudet A, Colombel J, Cortot A, Dupas J, Brazier F, Savoye G, Lerebours E, Justum A, Reimund J. A fulminant colitis index greater or equal to 8 is not predictive of colectomy risk in infliximab-treated moderate-to-severe ulcerative colitis attacks. Gastroentérologie Clinique et Biologique 2010;34:612-7. [DOI: 10.1016/j.gcb.2010.07.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
244 Gisbert JP, Niño P, Cara C, Rodrigo L. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther 2008;28:228-38. [PMID: 18485129 DOI: 10.1111/j.1365-2036.2008.03732.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
245 Trbojević Akmačić I, Ventham NT, Theodoratou E, Vučković F, Kennedy NA, Krištić J, Nimmo ER, Kalla R, Drummond H, Štambuk J, Dunlop MG, Novokmet M, Aulchenko Y, Gornik O, Campbell H, Pučić Baković M, Satsangi J, Lauc G; IBD-BIOM Consortium. Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome. Inflamm Bowel Dis 2015;21:1237-47. [PMID: 25895110 DOI: 10.1097/MIB.0000000000000372] [Cited by in Crossref: 38] [Cited by in F6Publishing: 65] [Article Influence: 6.3] [Reference Citation Analysis]
246 Yang Q, Tang J, Ding N, Chao K, Li M, Huang Z, Guo H, Chen J, Zhi M, Hu P, Gao X. Twelve-week peptide-based formula therapy may be effective in inducing remission of active Crohn disease among women who are pregnant or preparing for pregnancy. Nutr Clin Pract 2021. [PMID: 34245474 DOI: 10.1002/ncp.10733] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Defendenti C, Atzeni F, Malandrin S, Ardizzone S, Almasio PL, Saibeni S, Bezzio C, Bollani S, Salerno R, Declich P, Sarno Z, Bruno S, Talotta R, Sarzi-Puttini P. Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases. Int Immunopharmacol 2018;54:329-35. [PMID: 29197269 DOI: 10.1016/j.intimp.2017.11.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
248 Ko MK, Ng SC, Mak L, Li MK, Lo FH, Ng CKM, Lao WC, Tsang S, Chan KH, Hui YT, Shan EHS, Loo CK, Hui AJ, To WP, Hung IF, Leung WK. Infection-related hospitalizations in the first year after inflammatory bowel disease diagnosis: Infection in new IBD patients. Journal of Digestive Diseases 2016;17:610-7. [DOI: 10.1111/1751-2980.12397] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
249 Moon CM, Kim SW, Ahn JB, Ma HW, Che X, Kim TI, Kim WH, Cheon JH. Deep Resequencing of Ulcerative Colitis-Associated Genes Identifies Novel Variants in Candidate Genes in the Korean Population. Inflamm Bowel Dis 2018;24:1706-17. [PMID: 29733354 DOI: 10.1093/ibd/izy122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
250 Oikonomou KA, Kapsoritakis AN, Theodoridou C, Karangelis D, Germenis A, Stefanidis I, Potamianos SP. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol. 2012;47:519-530. [PMID: 22200942 DOI: 10.1007/s00535-011-0516-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 6.4] [Reference Citation Analysis]
251 Karmiris K, Avgerinos A, Tavernaraki A, Zeglinas C, Karatzas P, Koukouratos T, Oikonomou KA, Kostas A, Zampeli E, Papadopoulos V. Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease. J Crohns Colitis. 2016;10:429-436. [PMID: 26721936 DOI: 10.1093/ecco-jcc/jjv232] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 7.9] [Reference Citation Analysis]
252 Cao Y, Dai Y, Zhang L, Wang D, Yu Q, Hu W, Wang X, Yu P, Ping Y, Sun T, Sang Y, Liu Z, Chen Y, Tao Z. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay. Clin Biochem 2021:S0009-9120(21)00310-6. [PMID: 34843732 DOI: 10.1016/j.clinbiochem.2021.11.011] [Reference Citation Analysis]
253 Bermejo F, Lopez-Sanroman A, Taxonera C, Gisbert JP, Pérez-Calle JL, Vera I, Menchén L, Martín-Arranz MD, Opio V, Carneros JA. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther. 2008;28:623-628. [PMID: 18513380 DOI: 10.1111/j.1365-2036.2008.03746.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 68] [Article Influence: 6.1] [Reference Citation Analysis]
254 Walker LJ, Aldhous MC, Drummond HE, Smith BR, Nimmo ER, Arnott ID, Satsangi J. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol. 2004;135:490-496. [PMID: 15008984 DOI: 10.1111/j.1365-2249.2003.02392.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 3.5] [Reference Citation Analysis]
255 Su H, Kang Q, Wang H, Yin H, Duan L, Liu Y, Fan R. Changes in expression of p53 and inflammatory factors in patients with ulcerative colitis. Exp Ther Med 2019;17:2451-6. [PMID: 30906432 DOI: 10.3892/etm.2019.7253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
256 Noble CL, Nimmo ER, Drummond H, Smith L, Arnott ID, Satsangi J. DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population. Gut. 2005;54:1416-1120. [PMID: 15843420 DOI: 10.1136/gut.2005.066621] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 2.9] [Reference Citation Analysis]
257 Thude H, Rebstock K, Blume J, Lutz B, Barz D. No association of the CD45 77C>G transversion with inflammatory bowel disease in German patients. International Journal of Immunogenetics 2008;35:335-7. [DOI: 10.1111/j.1744-313x.2008.00777.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
258 Oudkerk Pool M, Bouma G, Visser JJ, Kolkman JJ, Tran DD, Meuwissen SG, Peña AS. Serum nitrate levels in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1995;30:784-8. [PMID: 7481547 DOI: 10.3109/00365529509096328] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 1.8] [Reference Citation Analysis]
259 Chen Z, Zhang H, Xia B, Wang P, Jiang T, Song M, Wu J. Association of PTPN22 gene (rs2488457) polymorphism with ulcerative colitis and high levels of PTPN22 mRNA in ulcerative colitis. Int J Colorectal Dis 2013;28:1351-8. [PMID: 23456301 DOI: 10.1007/s00384-013-1671-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
260 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 297] [Article Influence: 120.3] [Reference Citation Analysis]
261 Fart F, Salihović S, McGlinchey A, Gareau MG, Orešič M, Halfvarson J, Hyötyläinen T, Schoultz I. Perfluoroalkyl substances are increased in patients with late-onset ulcerative colitis and induce intestinal barrier defects ex vivo in murine intestinal tissue. Scand J Gastroenterol 2021;:1-10. [PMID: 34383611 DOI: 10.1080/00365521.2021.1961306] [Reference Citation Analysis]
262 Guan S, Jia B, Chao K, Zhu X, Tang J, Li M, Wu L, Xing L, Liu K, Zhang L, Wang X, Gao X, Huang M. UPLC–QTOF-MS-Based Plasma Lipidomic Profiling Reveals Biomarkers for Inflammatory Bowel Disease Diagnosis. J Proteome Res 2020;19:600-9. [DOI: 10.1021/acs.jproteome.9b00440] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
263 Cloché V, Buisson A, Tréchot F, Batta B, Locatelli A, Favel C, Premy S, Collet-Fenetrier B, Fréling E, Lopez A, Massoure MP, Humbert AL, Hansmannel F, Guéant JL, Bigard MA, Peyrin-Biroulet L, Angioi K. Ocular symptoms are not predictive of ophthalmologic inflammation in inflammatory bowel disease. Dig Liver Dis 2013;45:195-9. [PMID: 23200464 DOI: 10.1016/j.dld.2012.10.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
264 Lakatos PL, Altorjay I, Mándi Y, Lakatos L, Tumpek J, Kovacs A, Molnar T, Tulassay Z, Miheller P, Palatka K, Szamosi T, Fischer S, Papp J, Papp M; the Hungarian IBD Study Group. Interaction between seroreactivity to microbial antigens and genetics in Crohn’s disease: is there a role for defensins? Tissue Antigens 2008;71:552-9. [DOI: 10.1111/j.1399-0039.2008.01049.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
265 Henderson P, Casey A, Lawrence SJ, Kennedy NA, Kingstone K, Rogers P, Gillett PM, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2012;107:941-9. [PMID: 22370604 DOI: 10.1038/ajg.2012.33] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 6.9] [Reference Citation Analysis]
266 Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2008;20:912-916. [PMID: 18794606 DOI: 10.1097/meg.0b013e3282faa759] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
267 Gómez-García M, Oliver J, Márquez A, Mendoza JL, López-Nevot MA, Fernández-Arquero M, González-Escribano MF, Díaz-Rubio M, de la Concha EG, Urcelay E. Strong protective effect of DR3 against ulcerative colitis in the Spanish population. Am J Gastroenterol. 2007;102:2762-2766. [PMID: 17714554 DOI: 10.1111/j.1572-0241.2007.01487.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
268 Zabala W, Cruz R, Barreiro-de Acosta M, Chaparro M, Panes J, Echarri A, Esteve M, Carpio D, Andreu M, García-planella E, Domenech E, Carracedo A, Gisbert JP, Barros F. New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients. Pharmacogenomics 2013;14:631-40. [DOI: 10.2217/pgs.13.38] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
269 Mizrahi MC, Reicher-Atir R, Levy S, Haramati S, Wengrower D, Israeli E, Goldin E. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychol Health. 2012;27:1463-1479. [PMID: 22646975 DOI: 10.1080/08870446.2012.691169] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
270 Filippi J, Laharie D, Michiels C, Flamand M, Bouguen G, Nancey S, Presles E, Paul S, Schneider S, Hébuterne X. Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience. J Crohns Colitis. 2015;9:252-258. [PMID: 25588386 DOI: 10.1093/ecco-jcc/jjv001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
271 Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, Geboes K, Bossuyt X, Vandewalle P, Oberhuber G, Vogelsang H, Rutgeerts P, Colombel JF. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002;122:1242-7. [PMID: 11984510 DOI: 10.1053/gast.2002.32980] [Cited by in Crossref: 212] [Cited by in F6Publishing: 174] [Article Influence: 10.6] [Reference Citation Analysis]
272 Russell RK, Drummond HE, Nimmo ER, Anderson N, Wilson DC, Gillett PM, McGrogan P, Hassan K, Weaver LT, Bisset WM. The contribution of the DLG5 113A variant in early-onset inflammatory bowel disease. J Pediatr. 2007;150:268-273. [PMID: 17307543 DOI: 10.1016/j.jpeds.2006.12.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
273 Krupoves A, Mack DR, Seidman EG, Deslandres C, Bucionis V, Amre DK. Immediate and long-term outcomes of corticosteroid therapy in pediatric Crohn's disease patients. Inflamm Bowel Dis 2011;17:954-62. [PMID: 20684012 DOI: 10.1002/ibd.21415] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
274 Lorenzo-Pouso AI, Castelo-Baz P, Rodriguez-Zorrilla S, Pérez-Sayáns M, Vega P. Association between periodontal disease and inflammatory bowel disease: a systematic review and meta-analysis. Acta Odontol Scand 2021;79:344-53. [PMID: 33370548 DOI: 10.1080/00016357.2020.1859132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
275 Lakatos PL, Lovasz BD, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Golovics PA, Vegh Z, Mandel M, Horvath A, Szathmari M, Kiss LS, Lakatos L. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe. J Crohns Colitis 2013;7:385-91. [PMID: 22766526 DOI: 10.1016/j.crohns.2012.06.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
276 Lakatos PL, Czegledi Z, David G, Kispal Z, Kiss LS, Palatka K, Kristof T, Nagy F, Salamon A, Demeter P. Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease. J Crohns Colitis. 2010;4:283-290. [PMID: 21122517 DOI: 10.1016/j.crohns.2009.11.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
277 Russel MGVM, Volovics A, Schoon EJ, van Wijlick EHJ, Logan RF, Shivananda S, Stockbriigger RW. Inflammatory Bowel Disease: Is There Any Relation Between Smoking Status and Disease Presentation?: . Inflammatory Bowel Diseases 1998;4:182-6. [DOI: 10.1097/00054725-199808000-00002] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 3.6] [Reference Citation Analysis]
278 Lewis GJ, Massey DC, Zhang H, Bredin F, Tremelling M, Lee JC, Berzuini C, Parkes M. Genetic association between NLRP3 variants and Crohn's disease does not replicate in a large UK panel. Inflamm Bowel Dis. 2011;17:1387-1391. [PMID: 21560198 DOI: 10.1002/ibd.21499] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
279 Bourgonje AR, von Martels JZH, Gabriëls RY, Blokzijl T, Buist-Homan M, Heegsma J, Jansen BH, van Dullemen HM, Festen EAM, Ter Steege RWF, Visschedijk MC, Weersma RK, de Vos P, Faber KN, Dijkstra G. A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease. Front Med (Lausanne) 2019;6:251. [PMID: 31772929 DOI: 10.3389/fmed.2019.00251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
280 Tello-ruiz MK, Curley C, Delmonte T, Giallourakis C, Kirby A, Miller K, Wild G, Cohen A, Langelier D, Latiano A, Wedemeyer N, Lander E, Schreiber S, Annese V, Daly MJ, Rioux JD. Haplotype-based association analysis of 56 functional candidate genes in the IBD6 locus on chromosome 19. Eur J Hum Genet 2006;14:780-90. [DOI: 10.1038/sj.ejhg.5201612] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
281 Martinesi M, Treves C, d'Albasio G, Bagnoli S, Bonanomi AG, Stio M. Vitamin D derivatives induce apoptosis and downregulate ICAM-1 levels in peripheral blood mononuclear cells of inflammatory bowel disease patients. Inflamm Bowel Dis. 2008;14:597-604. [PMID: 18200516 DOI: 10.1002/ibd.20354] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
282 Vijgen L, Van Gysel M, Rector A, Thoelen I, Esters N, Ceelen T, Vangoidsenhoven E, Vermeire S, Rutgeerts P, Van Ranst M. Interleukin-1 receptor antagonist VNTR-polymorphism in inflammatory bowel disease. Genes Immun 2002;3:400-6. [PMID: 12424621 DOI: 10.1038/sj.gene.6363888] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
283 Hassan T, Kanisawa Y, Meyers S, Dasgupta A, Das KM. Expression of a unique protein on colon cancer cells that reacts with a novel monoclonal antibody and ulcerative colitis serum. Clin Exp Immunol 1995;100:457-62. [PMID: 7774056 DOI: 10.1111/j.1365-2249.1995.tb03722.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
284 Li G, Ren J, Wang G, Hu D, Gu G, Liu S, Ren H, Wu X, Li J. Preoperative exclusive enteral nutrition reduces the postoperative septic complications of fistulizing Crohn’s disease. Eur J Clin Nutr 2014;68:441-6. [DOI: 10.1038/ejcn.2014.16] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
285 Oostenbrug LE, Drenth JP, de Jong DJ, Nolte IM, Oosterom E, van Dullemen HM, van der Linde K, te Meerman GJ, van der Steege G, Kleibeuker JH. Association between Toll-like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:567-575. [PMID: 15905704 DOI: 10.1097/01.mib.0000161305.81198.0f] [Cited by in Crossref: 81] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
286 Pavlidis P, Shums Z, Koutsoumpas AL, Milo J, Papp M, Umemura T, Lakatos PL, Smyk DS, Bogdanos DP, Forbes A, Norman GL. Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA. Clin Chim Acta. 2015;441:176-181. [PMID: 25512163 DOI: 10.1016/j.cca.2014.12.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
287 Lee JC, Lennard-Jones JE, Cambridge G. Antineutrophil antibodies in familial inflammatory bowel disease. Gastroenterology. 1995;108:428-433. [PMID: 7835584 DOI: 10.1016/0016-5085(95)90070-5] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 1.9] [Reference Citation Analysis]
288 Blanco-Kelly F, Matesanz F, Alcina A, Teruel M, Díaz-Gallo LM, Gómez-García M, López-Nevot MA, Rodrigo L, Nieto A, Cardeña C, Alcain G, Díaz-Rubio M, de la Concha EG, Fernandez O, Arroyo R, Martín J, Urcelay E. CD40: novel association with Crohn's disease and replication in multiple sclerosis susceptibility. PLoS One 2010;5:e11520. [PMID: 20634952 DOI: 10.1371/journal.pone.0011520] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
289 Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s disease. Am J Gastroenterol. 2002;97:1458-1462. [PMID: 12094865 DOI: 10.1111/j.1572-0241.2002.05689.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 89] [Article Influence: 4.9] [Reference Citation Analysis]
290 Ferrante M, Declerck S, De Hertogh G, Van Assche G, Geboes K, Rutgeerts P, Penninckx F, Vermeire S, D'Hoore A. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis. 2008;14:20-28. [PMID: 17973304 DOI: 10.1002/ibd.20278] [Cited by in Crossref: 125] [Cited by in F6Publishing: 94] [Article Influence: 8.9] [Reference Citation Analysis]
291 Morgan AR, Lam WJ, Han DY, Fraser AG, Ferguson LR. Association Analysis of ULK1 with Crohn's Disease in a New Zealand Population. Gastroenterol Res Pract 2012;2012:715309. [PMID: 22536218 DOI: 10.1155/2012/715309] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
292 Jung ES, Choi KW, Kim SW, Hübenthal M, Mucha S, Park J, Park Z, Ellinghaus D, Schreiber S, Franke A, Oh WY, Cheon JH. ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases. J Gastroenterol Hepatol 2019;34:1727-35. [PMID: 30851117 DOI: 10.1111/jgh.14652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
293 Cámara RJ, Schoepfer AM, Pittet V, Begré S, von Känel R. Mood and nonmood components of perceived stress and exacerbation of Crohn’s disease. Inflamm Bowel Dis. 2011;17:2358-2365. [PMID: 21287671 DOI: 10.1002/ibd.21623] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
294 Aratari A, Papi C, Clemente V, Moretti A, Luchetti R, Koch M, Capurso L, Caprilli R. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis. 2008;40:821-826. [PMID: 18472316 DOI: 10.1016/j.dld.2008.03.014] [Cited by in Crossref: 115] [Cited by in F6Publishing: 105] [Article Influence: 8.2] [Reference Citation Analysis]
295 López-Palacios N, Mendoza JL, Taxonera C, Lana R, López-Jamar JM, Díaz-Rubio M. Mucosal healing for predicting clinical outcome in patients with ulcerative colitis using thiopurines in monotherapy. Eur J Intern Med 2011;22:621-5. [PMID: 22075292 DOI: 10.1016/j.ejim.2011.06.017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
296 Weldon MJ. 99m Tc-HMPAO Planar White Cell Scanning. Scandinavian Journal of Gastroenterology 2009;29:36-42. [DOI: 10.3109/00365529409091395] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
297 Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: A case-control study. Aliment Pharmacol Ther. 2000;14:145-153. [PMID: 10651654 DOI: 10.1046/j.1365-2036.2000.00698.x] [Cited by in Crossref: 390] [Cited by in F6Publishing: 358] [Article Influence: 17.7] [Reference Citation Analysis]
298 Lapidus A, Bernell O, Hellers G, Löfberg R. Clinical course of colorectal Crohn’s disease: a 35-year follow-up study of 507 patients. Gastroenterology. 1998;114:1151-1160. [PMID: 9609751 DOI: 10.1016/s0016-5085(98)70420-2] [Cited by in Crossref: 169] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
299 Vrij AA, Oberndorff-klein-woolthuis A, Dijkstra G, de Jong AE, Wagenvoord R, Hemker HC, Stockbrügger RW. Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. J Thromb Thrombolysis 2007;24:175-82. [DOI: 10.1007/s11239-006-9046-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
300 Peluso R, DI Minno MN, Bruner V, Soscia E, Castiglione F, Manguso F, Iervolino S, Scarpa R. Discovertebral erosions in patients with enteropathic spondyloarthritis. J Rheumatol 2012;39:2332-40. [PMID: 23070989 DOI: 10.3899/jrheum.120415] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
301 Leonetti D, Reimund JM, Tesse A, Viennot S, Martinez MC, Bretagne AL, Andriantsitohaina R. Circulating microparticles from Crohn's disease patients cause endothelial and vascular dysfunctions. PLoS One 2013;8:e73088. [PMID: 24019899 DOI: 10.1371/journal.pone.0073088] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
302 Horjus Talabur Horje CS, Meijer J, Rovers L, van Lochem EG, Groenen MJ, Wahab PJ. Prevalence of Upper Gastrointestinal Lesions at Primary Diagnosis in Adults with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22:1896-1901. [PMID: 27057685 DOI: 10.1097/mib.0000000000000786] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 8.3] [Reference Citation Analysis]
303 Lynch RW, Lowe D, Protheroe A, Driscoll R, Rhodes JM, Arnott ID. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther. 2013;38:935-945. [PMID: 24004000 DOI: 10.1111/apt.12473] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
304 Eriksson C, Cao Y, Rundquist S, Zhulina Y, Henriksson I, Montgomery S, Halfvarson J. Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963-2010. Aliment Pharmacol Ther 2017;46:748-57. [PMID: 28833287 DOI: 10.1111/apt.14268] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
305 Sood A, Singh A, Sudhakar R, Midha V, Mahajan R, Mehta V, Gupta YK, Kaur K. Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn's disease: the Indian experience. Intest Res 2020;18:184-91. [PMID: 32092799 DOI: 10.5217/ir.2019.00094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
306 Zhang S, Wu Z, Luo J, Ding X, Hu C, Li P, Deng C, Zhang F, Qian J, Li Y. Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease. Medicine (Baltimore). 2015;94:e1654. [PMID: 26496271 DOI: 10.1097/md.0000000000001654] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
307 Cosnes J, Seksik P, Nion-Larmurier I, Beaugerie L, Gendre JP. Prior appendectomy and the phenotype and course of Crohn’s disease. World J Gastroenterol 2006; 12(8): 1235-1242 [PMID: 16534877 DOI: 10.3748/wjg.v12.i8.1235] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
308 Lakatos PL, Lakatos L, Szalay F, Willheim-Polli C, Österreicher C, Tulassay Z, Molnar T, Reinisch W, Papp J, Mozsik G, Group HIS, Ferenci P. Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn’s disease: Phenotype-genotype correlations. World J Gastroenterol 2005; 11(10): 1489-1495 [PMID: 15770725 DOI: 10.3748/wjg.v11.i10.1489] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 86] [Article Influence: 4.6] [Reference Citation Analysis]
309 Hammada T, Lemdaoui M-, Boutra F, Zoughailech D, Asselah H. Aspects épidémiologiques des maladies inflammatoires chroniques de l’intestin dans une population algérienne. J Afr Hepato Gastroenterol 2011;5:293-302. [DOI: 10.1007/s12157-011-0327-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
310 Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123-128. [PMID: 17206703 DOI: 10.1002/ibd.20054] [Cited by in Crossref: 126] [Cited by in F6Publishing: 119] [Article Influence: 8.4] [Reference Citation Analysis]
311 Choi CH, Song ID, Kim YH, Koo JS, Kim YS, Kim JS, Kim N, Kim ES, Kim JH, Kim JW, Kim TO, Kim HS, Kim HJ, Park YS, Park DI, Park SJ, Song HJ, Shin SJ, Yang SK, Ye BD, Lee KM, Lee BI, Lee SY, Lee CK, Im JP, Jang BI, Jeon TJ, Cho YK, Chang SK, Jeon SR, Jung SA, Jeen YT, Cha JM, Han DS, Kim WH; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study. Yonsei Med J. 2016;57:1376-1385. [PMID: 27593865 DOI: 10.3349/ymj.2016.57.6.1376] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
312 Ye BD, Choi H, Hong M, Yun WJ, Low HQ, Haritunians T, Kim KJ, Park SH, Lee I, Bang SY, Kim TH, Shin HD, Kang D, Youn HS, Li Y, Liu J, McGovern DP, Yang SK, Song K. Identification of Ten Additional Susceptibility Loci for Ulcerative Colitis Through Immunochip Analysis in Koreans. Inflamm Bowel Dis. 2016;22:13-19. [PMID: 26398853 DOI: 10.1097/mib.0000000000000584] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
313 Aichbichler BW, Petritsch W, Reicht GA, Wenzl HH, Eherer AJ, Hinterleitner TA, Auer-Grumbach P, Krejs GJ. Anti-cardiolipin antibodies in patients with inflammatory bowel disease. Dig Dis Sci. 1999;44:852-856. [PMID: 10219848 DOI: 10.1023/a:1026646816672] [Cited by in Crossref: 48] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
314 Opheim R, Moum B, Grimstad BT, Jahnsen J, Prytz Berset I, Hovde Ø, Huppertz-Hauss G, Bernklev T, Jelsness-Jørgensen LP. Self-esteem in patients with inflammatory bowel disease. Qual Life Res 2020;29:1839-46. [PMID: 32144613 DOI: 10.1007/s11136-020-02467-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
315 Shi J, Huang Z, Wang Y, Huang Y. The Protective Effects of Exclusive Enteral Nutrition Formulas on Growth Factor Expression and the Proximal Tibial Epiphyseal Growth Plate in a TNBS-Induced IBD Rat Model. Dig Dis Sci 2015;60:1931-40. [DOI: 10.1007/s10620-015-3582-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
316 Jiang Y, Xia B, Jiang L, Lv M, Guo Q, Chen M, Li J, Xia HH, Wong BC. Association of CTLA-4 gene microsatellite polymorphism with ulcerative colitis in Chinese patients. Inflamm Bowel Dis. 2006;12:369-373. [PMID: 16670525 DOI: 10.1097/01.mib.0000217339.61183.dd] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
317 Hugot JP, Bellaiche M. Inflammatory bowel diseases: the paediatric gastroenterologist's perspective. Pediatr Radiol 2007;37:1065-70. [PMID: 17899060 DOI: 10.1007/s00247-007-0573-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
318 Juyal G, Amre D, Midha V, Sood A, Seidman E, Thelma BK. Evidence of allelic heterogeneity for associations between the NOD2/CARD15 gene and ulcerative colitis among North Indians. Aliment Pharmacol Ther. 2007;26:1325-1332. [PMID: 17892524 DOI: 10.1111/j.1365-2036.2007.03524.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
319 Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004;20:1347-1352. [PMID: 15606397 DOI: 10.1111/j.1365-2036.2004.02288.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 89] [Article Influence: 5.4] [Reference Citation Analysis]
320 Sewell GW, Hannun YA, Han X, Koster G, Bielawski J, Goss V, Smith PJ, Rahman FZ, Vega R, Bloom SL, Walker AP, Postle AD, Segal AW. Lipidomic profiling in Crohn's disease: abnormalities in phosphatidylinositols, with preservation of ceramide, phosphatidylcholine and phosphatidylserine composition. Int J Biochem Cell Biol 2012;44:1839-46. [PMID: 22728312 DOI: 10.1016/j.biocel.2012.06.016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
321 Chen Z, Lu Y, Wu J, Zhang H. Clinical significance of blood platelets and mean platelet volume in patients with ulcerative colitis. J Int Med Res 2021;49:3000605211009715. [PMID: 33884913 DOI: 10.1177/03000605211009715] [Reference Citation Analysis]
322 Chung BK, Henriksen EKK, Jørgensen KK, Karlsen TH, Hirschfield GM, Liaskou E. Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease. Hepatol Commun 2018;2:956-67. [PMID: 30094406 DOI: 10.1002/hep4.1200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
323 Heijckmann AC, Dumitrescu B, Nieuwenhuijzen Kruseman AC, Geusens P, Wolffenbuttel BH, De Vries J, Drent M, Huijberts MS. Quantitative ultrasound does not identify patients with an inflammatory disease at risk of vertebral deformities. BMC Musculoskelet Disord 2008;9:72. [PMID: 18492278 DOI: 10.1186/1471-2474-9-72] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
324 Minderhoud IM, Smout AJ, Oldenburg B, Samsom M. A pilot study on chemospecific duodenal visceral sensitivity in inflammatory bowel disease in remission. Digestion. 2006;73:151-159. [PMID: 16837799 DOI: 10.1159/000094522] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
325 Saro C, da la Coba C, Casado MA, Morales JM, Otero B. Resource use in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Ther. 2007;26:1313-1323. [PMID: 17850419 DOI: 10.1111/j.1365-2036.2007.03507.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
326 Lakatos L, Mester G, Erdelyi Z, David G, Pandur T, Balogh M, Fischer S, Vargha P, Lakatos PL. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis. 2006;12:205-211. [PMID: 16534422 DOI: 10.1097/01.mib.0000217770.21261.ce] [Cited by in Crossref: 145] [Cited by in F6Publishing: 60] [Article Influence: 9.1] [Reference Citation Analysis]
327 Frigstad SO, Høivik M, Jahnsen J, Dahl SR, Cvancarova M, Grimstad T, Berset IP, Huppertz-Hauss G, Hovde Ø, Torp R, Bernklev T, Moum B, Jelsness-Jørgensen LP. Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population. Scand J Gastroenterol 2017;52:100-6. [PMID: 27603182 DOI: 10.1080/00365521.2016.1233577] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
328 Dresner-Pollak R, Ackerman Z, Eliakim R, Karban A, Chowers Y, Fidder HH. The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients. Genet Test. 2004;8:417-420. [PMID: 15684874 DOI: 10.1089/gte.2004.8.417] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 3.0] [Reference Citation Analysis]
329 Seo N, Park SH, Kim KJ, Kang BK, Lee Y, Yang SK, Ye BD, Park SH, Kim SY, Baek S, Han K, Ha HK. MR Enterography for the Evaluation of Small-Bowel Inflammation in Crohn Disease by Using Diffusion-weighted Imaging without Intravenous Contrast Material: A Prospective Noninferiority Study. Radiology. 2016;278:762-772. [PMID: 26348103 DOI: 10.1148/radiol.2015150809] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 12.0] [Reference Citation Analysis]
330 Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, Marmo R, Massari A, Molteni P, Maconi G, Porro GB. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9: 483-489. e3. [PMID: 21195796 DOI: 10.1016/j.cgh.2010.12.028] [Cited by in Crossref: 169] [Cited by in F6Publishing: 157] [Article Influence: 14.1] [Reference Citation Analysis]
331 Vatn MH. Environmental Factors in the Epidemiology of Inflammatory Bowel Disease. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Boston: Springer US; 2012. pp. 17-38. [DOI: 10.1007/978-1-4614-0998-4_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
332 Jafri L, Siddiqui A, Sidddique S, Parkash O, Kausar R, Majid H. Clinical Spectrum in a Cohort of Patients With High Fecal Calprotectin Levels. Cureus 2020;12:e11314. [PMID: 33282590 DOI: 10.7759/cureus.11314] [Reference Citation Analysis]
333 Van Bodegraven AA, Tuynman HA, Schoorl M, Kruishoop AM, Bartels PC. Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease. Scand J Gastroenterol. 1995;30:580-585. [PMID: 7569767 DOI: 10.3109/00365529509089793] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 0.8] [Reference Citation Analysis]
334 Flores C, Francesconi CF, Meurer L. Quantitative assessment of CD30+ lymphocytes and eosinophils for the histopathological differential diagnosis of inflammatory bowel disease. J Crohns Colitis 2015;9:763-8. [PMID: 26048916 DOI: 10.1093/ecco-jcc/jjv097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
335 Cagliani R, Pozzoli U, Forni D, Cassinotti A, Fumagalli M, Giani M, Fichera M, Lombardini M, Ardizzone S, Asselta R, de Franchis R, Riva S, Biasin M, Comi GP, Bresolin N, Clerici M, Sironi M. Crohn's disease loci are common targets of protozoa-driven selection. Mol Biol Evol 2013;30:1077-87. [PMID: 23389767 DOI: 10.1093/molbev/mst020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
336 Nic Suibhne T, Raftery TC, McMahon O, Walsh C, O'Morain C, O'Sullivan M. High prevalence of overweight and obesity in adults with Crohn's disease: associations with disease and lifestyle factors. J Crohns Colitis. 2013;7:e241-e248. [PMID: 23040290 DOI: 10.1016/j.crohns.2012.09.009] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 7.8] [Reference Citation Analysis]
337 Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol 2018;52:e53-62. [PMID: 28723856 DOI: 10.1097/MCG.0000000000000837] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
338 Parisinos CA, McIntyre VE, Heron T, Subedi D, Arnott ID, Mowat C, Wilson DC, McGurk S, Glancy S, Zealley IA, Satsangi J, Lees CW. Magnetic resonance follow-through imaging for evaluation of disease activity in ileal Crohn's disease: an observational, retrospective cohort study. Inflamm Bowel Dis. 2010;16:1219-1226. [PMID: 19924804 DOI: 10.1002/ibd.21168] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
339 Lawrance IC, Murray K, Batman B, Gearry RB, Grafton R, Krishnaprasad K, Andrews JM, Prosser R, Bampton PA, Cooke SE, Mahy G, Radford-Smith G, Croft A, Hanigan K. Crohn's disease and smoking: is it ever too late to quit? J Crohns Colitis 2013;7:e665-71. [PMID: 23790611 DOI: 10.1016/j.crohns.2013.05.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
340 Franke A, Fischer A, Nothnagel M, Becker C, Grabe N, Till A, Lu T, Müller-Quernheim J, Wittig M, Hermann A. Genome-wide association analysis in sarcoidosis and Crohn’s disease unravels a common susceptibility locus on 10p12.2. Gastroenterology. 2008;135:1207-1215. [PMID: 18723019 DOI: 10.1053/j.gastro.2008.07.017] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 4.0] [Reference Citation Analysis]
341 Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; en representació del Grupo Espa˜nol de Trabajode Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’sDisease and Ulcerative Colitis (GETECCU). [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. Gastroenterol Hepatol 2013;36:e1-47. [PMID: 24215088 DOI: 10.1016/j.gastrohep.2012.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
342 Lakatos L, Mester G, Erdelyi Z, Balogh M, Szipocs I, Kamaras G, Lakatos PL. Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World J Gastroenterol 2004; 10(3): 404-409 [PMID: 14760767 DOI: 10.3748/wjg.v10.i3.404] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 78] [Article Influence: 3.9] [Reference Citation Analysis]
343 Aldhous MC, Prescott RJ, Roberts S, Samuel K, Waterfall M, Satsangi J. Does nicotine influence cytokine profile and subsequent cell cycling/apoptotic responses in inflammatory bowel disease?: . Inflammatory Bowel Diseases 2008;14:1469-82. [DOI: 10.1002/ibd.20523] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
344 Mandel MD, Bálint A, Lovász BD, Gulácsi L, Strbák B, Golovics PA, Farkas K, Kürti Z, Szilágyi BK, Mohás A. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ. 2014;15 Suppl 1:S121-S128. [PMID: 24832845 DOI: 10.1007/s10198-014-0603-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
345 Zhou F, Xia B, Wang F, Shrestha UK, Chen M, Wang H, Shi X, Chen Z, Li J. The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China. Clin Chim Acta. 2010;411:1461-1465. [PMID: 20570669 DOI: 10.1016/j.cca.2010.05.041] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
346 Baptista ML, Amarante H, Picheth G, Sdepanian VL, Peterson N, Babasukumar U, Lima HC, Kugathasan S. CARD15 and IL23R influences Crohn's disease susceptibility but not disease phenotype in a Brazilian population. Inflamm Bowel Dis 2008;14:674-9. [PMID: 18200510 DOI: 10.1002/ibd.20372] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
347 Li Q, Wang C, Tang C, He Q, Li N, Li J. Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn's disease. J Clin Gastroenterol. 2014;48:513-523. [PMID: 24275714 DOI: 10.1186/s40168-015-0084-7] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 11.1] [Reference Citation Analysis]
348 García-Sánchez V, Iglesias-Flores E, González R, Gisbert JP, Gallardo-Valverde JM, González-Galilea A, Naranjo-Rodríguez A, de Dios-Vega JF, Muntané J, Gómez-Camacho F. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis. 2010;4:144-152. [PMID: 21122498 DOI: 10.1016/j.crohns.2009.09.008] [Cited by in Crossref: 108] [Cited by in F6Publishing: 102] [Article Influence: 8.3] [Reference Citation Analysis]
349 Newman B, Gu X, Wintle R, Cescon D, Yazdanpanah M, Liu X, Peltekova V, Van Oene M, Amos CI, Siminovitch KA. A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's disease. Gastroenterology 2005;128:260-9. [PMID: 15685536 DOI: 10.1053/j.gastro.2004.11.056] [Cited by in Crossref: 90] [Cited by in F6Publishing: 91] [Article Influence: 5.3] [Reference Citation Analysis]
350 Fischer S, Lakatos PL, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Szilvasi A, Tulassay Z, Osztovits J. ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases. Scand J Gastroenterol. 2007;42:726-733. [PMID: 17505995 DOI: 10.1080/00365520601101559] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
351 Park SH, Hong M, Lee HS, Ye BD, Hwang SW, Jung S, Baek J, Moon JW, Kim BM, Oh SH, Kim KM, Lee I, Im CN, Liu J, McGovern DPB, Yang SK, Song K. Association of TRAP1 with infliximab-induced mucosal healing in Crohn's disease. J Gastroenterol Hepatol 2019;34:2118-25. [PMID: 31039275 DOI: 10.1111/jgh.14696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
352 Borley NR, Mortensen NJ, Jewell DP. Preventing postoperative recurrence of Crohn's disease. Br J Surg 1997;84:1493-502. [DOI: 10.1002/bjs.1800841104] [Cited by in Crossref: 97] [Cited by in F6Publishing: 62] [Article Influence: 3.9] [Reference Citation Analysis]
353 Tan MC, El-serag HB, Hou JK. Determinants of Healthcare Utilization Among Veterans with Inflammatory Bowel Disease. Dig Dis Sci 2017;62:607-14. [DOI: 10.1007/s10620-016-4414-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
354 Arnott IDR, Nimmo ER, Drummond HE, Fennell J, Smith BRK, Mackinlay E, Morecroft J, Anderson N, Kelleher D, O'sullivan M, Mcmanus R, Satsangi J. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun 2004;5:417-25. [DOI: 10.1038/sj.gene.6364111] [Cited by in Crossref: 146] [Cited by in F6Publishing: 149] [Article Influence: 8.1] [Reference Citation Analysis]
355 Vasiliauskas E. Recent advances in the diagnosis and classification of inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:493-500. [PMID: 14602059 DOI: 10.1007/s11894-003-0039-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
356 Bondarenko KR, Dobrokhotova YE, Rumyantseva TA, Nasyrova NI. Crohn's disease of the vulva: A tough diagnosis (a case report of a 47 y.o. patient). Clin Case Rep 2020;8:563-7. [PMID: 32185060 DOI: 10.1002/ccr3.2707] [Reference Citation Analysis]
357 Russel MG, Dorant E, Volovics A, Brummer RJ, Pop P, Muris JW, Bos LP, Limonard CB, Stockbrügger RW. High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. The South Limburg IBD Study Group. Dis Colon Rectum. 1998;41:33-40. [PMID: 9510308 DOI: 10.1007/bf02236893] [Cited by in Crossref: 64] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
358 Simsek M, Deben DS, Horjus CS, Bénard MV, Lissenberg-Witte BI, Buiter HJC, van Luin M, Seinen ML, Mulder CJJ, Wong DR, de Boer NKH, van Bodegraven AA. Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. Aliment Pharmacol Ther 2019;50:54-65. [PMID: 31094013 DOI: 10.1111/apt.15280] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
359 Muñoz Villafranca C, Bravo Rodríguez MT, Ortiz de Zárate J, Arreba González P, García Kamiruaga I, Heras Martín JI, Cabezudo Gil P, Orive Cura V. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission]. Gastroenterol Hepatol 2016;39:442-8. [PMID: 26948837 DOI: 10.1016/j.gastrohep.2015.11.011] [Reference Citation Analysis]
360 Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241. [PMID: 15647188 DOI: 10.1136/gut.2004.045294] [Cited by in Crossref: 466] [Cited by in F6Publishing: 418] [Article Influence: 27.4] [Reference Citation Analysis]
361 Grössner-Schreiber B, Fetter T, Hedderich J, Kocher T, Schreiber S, Jepsen S. Prevalence of dental caries and periodontal disease in patients with inflammatory bowel disease: a case-control study. J Clin Periodontol. 2006;33:478-484. [PMID: 16820035 DOI: 10.1111/j.1600-051x.2006.00942.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
362 Parente F, Molteni M, Marino B, Colli A, Ardizzone S, Greco S, Sampietro G, Foschi D, Gallus S. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis? Am J Gastroenterol. 2010;105:1150-1157. [PMID: 19997096 DOI: 10.1038/ajg.2009.672] [Cited by in Crossref: 81] [Cited by in F6Publishing: 64] [Article Influence: 6.2] [Reference Citation Analysis]
363 Vatn S, Carstens A, Kristoffersen AB, Bergemalm D, Casén C, Moen AEF, Tannaes TM, Lindstrøm J, Detlie TE, Olbjørn C, Lindquist CM, Söderholm JD, Gomollón F, Kalla R, Satsangi J, Vatn MH, Jahnsen J, Halfvarson J, Ricanek P; IBD-Character Consortium. Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character). Scand J Gastroenterol 2020;55:1146-56. [PMID: 32780604 DOI: 10.1080/00365521.2020.1803396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
364 Yang J, Kim M, Kim E, Cheon J, Lee Y, Kim Y, Lee S, Seo S, Shin S, Choi S, Kim B, Chang S, Ko H, Bae J, Kweon M. Enteric Viruses Ameliorate Gut Inflammation via Toll-like Receptor 3 and Toll-like Receptor 7-Mediated Interferon-β Production. Immunity 2016;44:889-900. [DOI: 10.1016/j.immuni.2016.03.009] [Cited by in Crossref: 108] [Cited by in F6Publishing: 94] [Article Influence: 18.0] [Reference Citation Analysis]
365 Zamora C, Canto E, Nieto JC, Garcia-planella E, Gordillo J, Ortiz MA, Suarez-calvet X, Perea L, Julia G, Juarez C, Vidal S. Inverse Association Between Circulating Monocyte-Platelet Complexes and Inflammation in Ulcerative Colitis Patients. Inflammatory Bowel Diseases 2018;24:818-28. [DOI: 10.1093/ibd/izx106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
366 Hirv K, Seyfarth M, Uibo R, Kull K, Salupere R, Latza U, Rink L. Polymorphisms in tumour necrosis factor and adhesion molecule genes in patients with inflammatory bowel disease: associations with HLA-DR and -DQ alleles and subclinical markers. Scand J Gastroenterol. 1999;34:1025-1032. [PMID: 10563674 DOI: 10.1080/003655299750025147] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
367 Green JT, Rhodes J, Ragunath K, Thomas GA, Williams GT, Mani V, Feyerabend C, Russell MA. Clinical status of ulcerative colitis in patients who smoke. Am J Gastroenterol 1998;93:1463-7. [PMID: 9732926 DOI: 10.1111/j.1572-0241.1998.00464.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
368 Freire P, Cardoso R, Figueiredo P, Donato MM, Ferreira M, Mendes S, Ferreira AM, Vasconcelos H, Portela F, Sofia C. NOD2 gene mutations in ulcerative colitis: useless or misunderstood? Int J Colorectal Dis. 2014;29:653-661. [PMID: 24651958 DOI: 10.1007/s00384-014-1850-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
369 Julià A, Domènech E, Ricart E, Tortosa R, García-Sánchez V, Gisbert JP, Nos Mateu P, Gutiérrez A, Gomollón F, Mendoza JL. A genome-wide association study on a southern European population identifies a new Crohn’s disease susceptibility locus at RBX1-EP300. Gut. 2013;62:1440-1445. [PMID: 22936669 DOI: 10.1136/gutjnl-2012-302865] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
370 Jelsness-Jørgensen LP, Moum B, Grimstad T, Jahnsen J, Opheim R, Prytz Berset I, Hovde Ø, Torp R, Frigstad SO, Huppertz-Hauss G, Bernklev T. Validity, Reliability, and Responsiveness of the Brief Pain Inventory in Inflammatory Bowel Disease. Can J Gastroenterol Hepatol 2016;2016:5624261. [PMID: 27446848 DOI: 10.1155/2016/5624261] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
371 Herzog D, Fournier N, Buehr P, Koller R, Rueger V, Heyland K, Nydegger A, Spalinger J, Schibli S, Braegger C. Early-onset Crohn's disease is a risk factor for smaller final height. Eur J Gastroenterol Hepatol. 2014;26:1234-1239. [PMID: 25089544 DOI: 10.1097/MEG.0000000000000169] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
372 Cacheux W, Seksik P, Lemann M, Marteau P, Nion-Larmurier I, Afchain P, Daniel F, Beaugerie L, Cosnes J. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008;103:637-42. [PMID: 18047542 DOI: 10.1111/j.1572-0241.2007.01653.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
373 Grant RK, Jones GR, Plevris N, Lynch RW, Jenkinson PW, Lees CW, Manship TA, Jagger FAM, Brindle WM, Shivakumar M, Satsangi J, Arnott IDR. The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis. Inflamm Bowel Dis 2021;27:451-7. [PMID: 32572468 DOI: 10.1093/ibd/izaa088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
374 Moum B, Ekbom A. Epidemiology of inflammatory bowel disease — methodological considerations. Digestive and Liver Disease 2002;34:364-9. [DOI: 10.1016/s1590-8658(02)80131-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
375 Serrano-montalbán B, Arias Á, Friginal-ruiz AB, Lucendo AJ. The Use of the Fracture Risk Assessment (FRAX®) Tool in Predicting Risk of Fractures in Patients With Inflammatory Bowel Disease: A Systematic Review. Journal of Clinical Densitometry 2017;20:180-7. [DOI: 10.1016/j.jocd.2016.08.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
376 Freire P, Figueiredo P, Cardoso R, Manuel Donato M, Ferreira M, Mendes S, Silva MR, Cipriano MA, Ferreira AM, Vasconcelos H, Portela F, Sofia C. Predictive value of rectal aberrant crypt foci for intraepithelial neoplasia in ulcerative colitis – a cross-sectional study. Scandinavian Journal of Gastroenterology 2014;49:1219-29. [DOI: 10.3109/00365521.2014.951390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
377 Leclerc-jacob S, Lux G, Rat AC, Laurent V, Blum A, Chary-valckenaere I, Peyrin-biroulet L, Loeuille D. The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients. Aliment Pharmacol Ther 2014;39:957-62. [DOI: 10.1111/apt.12680] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
378 Angriman I, Scarpa M, Ruffolo C, Pomerri F, Filosa T, Polese L, Pagano D, Norberto L, D’amico DF. Double contrast small-bowel radiography in the preoperative assessment of Crohn’s disease: Is it still useful? Surg Today 2008;38:700-4. [DOI: 10.1007/s00595-007-3700-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
379 Nemetz A, Tóth M, García-González MA, Zágoni T, Fehér J, Peña AS, Tulassay Z. Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut 2001;49:644-9. [PMID: 11600466 DOI: 10.1136/gut.49.5.644] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.1] [Reference Citation Analysis]
380 Moum B, Vatn MH, Ekbom A, Aadland E, Fausa O, Lygren I, Sauar J, Schulz T, Stray N. Incidence of ulcerative colitis and indeterminate colitis in four counties of southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists. Scand J Gastroenterol. 1996;31:362-366. [PMID: 8726304 DOI: 10.3109/00365529609006411] [Cited by in Crossref: 133] [Cited by in F6Publishing: 122] [Article Influence: 5.1] [Reference Citation Analysis]
381 Papp M, Sipeki N, Tornai T, Altorjay I, Norman GL, Shums Z, Roggenbuck D, Fechner K, Stöcker W, Antal-Szalmas P, Veres G, Lakatos PL. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1]. J Crohns Colitis 2015;9:659-68. [PMID: 25968583 DOI: 10.1093/ecco-jcc/jjv087] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
382 Amre DK, Lambrette P, Law L, Krupoves A, Chotard V, Costea F, Grimard G, Israel D, Mack D, Seidman EG. Investigating the hygiene hypothesis as a risk factor in pediatric onset Crohn’s disease: a case-control study. Am J Gastroenterol. 2006;101:1005-1011. [PMID: 16573775 DOI: 10.1111/j.1572-0241.2006.00526.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 5.4] [Reference Citation Analysis]
383 Schinke S, Fellermann K, Herlyn K, Reichel PH, Fundke R, Stange EF, Gross WL, Schultz H. Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein. Inflamm Bowel Dis 2004;10:763-70. [PMID: 15626895 DOI: 10.1097/00054725-200411000-00011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
384 Stein JM, Lammert F, Zimmer V, Granzow M, Reichert S, Schulz S, Ocklenburg C, Conrads G. Clinical periodontal and microbiologic parameters in patients with Crohn’s disease with consideration of the CARD15 genotype. J Periodontol. 2010;81:535-545. [PMID: 20373538 DOI: 10.1902/jop.2009.090563] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
385 Khorasani HM, Usefi H, Peña-Castillo L. Detecting ulcerative colitis from colon samples using efficient feature selection and machine learning. Sci Rep 2020;10:13744. [PMID: 32792678 DOI: 10.1038/s41598-020-70583-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
386 Lakatos PL, Golovics PA, David G, Pandur T, Erdelyi Z, Horvath A, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Veres G, Lovasz BD, Szathmari M, Kiss LS, Lakatos L. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol. 2012;107:579-588. [PMID: 22233693 DOI: 10.1038/ajg.2011.448] [Cited by in Crossref: 157] [Cited by in F6Publishing: 147] [Article Influence: 15.7] [Reference Citation Analysis]
387 Stio M, Retico L, Annese V, Bonanomi AG. Vitamin D regulates the tight-junction protein expression in active ulcerative colitis. Scand J Gastroenterol 2016;51:1193-9. [PMID: 27207502 DOI: 10.1080/00365521.2016.1185463] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
388 Hinojosa J, Nos P, Ramírez JJ, Hoyos M, Molés JR, Ponce J, Berenguer J. Evolutive pattern in Crohn's disease: a simplified index using clinical parameters predicts obstructive behaviour: . European Journal of Gastroenterology & Hepatology 2001;13:245-9. [DOI: 10.1097/00042737-200103000-00005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
389 Yang Q, Gao X, Chen H, Li M, Wu X, Zhi M, Lan P, Hu P. Efficacy of exclusive enteral nutrition in complicated Crohn's disease. Scand J Gastroenterol. 2017;52:995-1001. [PMID: 28598298 DOI: 10.1080/00365521.2017.1335770] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
390 Park JJ, Cheon JH, Kim BY, Kim DH, Kim ES, Kim TI, Lee KR, Kim WH. Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease. Dig Dis Sci. 2009;54:1525-1531. [PMID: 18975078 DOI: 10.1007/s10620-008-0514-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 3.6] [Reference Citation Analysis]
391 Jiang L, Xia B, Li J, Ye M, Yan W, Deng C, Ding Y, Luo H, Hou W, Zhao Q, Liu N, Ren H, Hou X, Xu H. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 2006;12:212-7. [PMID: 16534423 DOI: 10.1097/01.MIB.0000201098.26450.ae] [Cited by in Crossref: 107] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
392 Riis L, Vind I, Vermeire S, Wolters F, Katsanos K, Politi P, Freitas J, Mouzas IA, O'Morain C, Ruiz-Ochoa V. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis. 2007;13:24-32. [PMID: 17206636 DOI: 10.1002/ibd.20047] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 3.5] [Reference Citation Analysis]
393 Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, Andersen V, Andrews JM, Annese V, Brand S, Brant SR, Cho JH, Daly MJ, Dubinsky M, Duerr RH, Ferguson LR, Franke A, Gearry RB, Goyette P, Hakonarson H, Halfvarson J, Hov JR, Huang H, Kennedy NA, Kupcinskas L, Lawrance IC, Lee JC, Satsangi J, Schreiber S, Théâtre E, van der Meulen-de Jong AE, Weersma RK, Wilson DC, Parkes M, Vermeire S, Rioux JD, Mansfield J, Silverberg MS, Radford-Smith G, McGovern DP, Barrett JC, Lees CW; International Inflammatory Bowel Disease Genetics Consortium. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet 2016;387:156-67. [PMID: 26490195 DOI: 10.1016/S0140-6736(15)00465-1] [Cited by in Crossref: 394] [Cited by in F6Publishing: 191] [Article Influence: 56.3] [Reference Citation Analysis]
394 Kolho K, Klemola P, Simonen-tikka M, Ollonen M, Roivainen M. Enteric viral pathogens in children with inflammatory bowel disease. J Med Virol 2012;84:345-7. [DOI: 10.1002/jmv.23193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
395 Fidder HH, Nadler M, Lahat A, Lahav M, Bardan E, Avidan B, Bar-meir S. The Utility of Capsule Endoscopy in the Diagnosis of Crohn's Disease Based on Patient's Symptoms. Journal of Clinical Gastroenterology 2007;41:384-7. [DOI: 10.1097/01.mcg.0000225621.02094.8a] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
396 Arias-Loste MT, Bonilla G, Moraleja I, Mahler M, Mieses MA, Castro B, Rivero M, Crespo J, López-Hoyos M. Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease. Clin Rev Allergy Immunol 2013;45:109-16. [PMID: 23345025 DOI: 10.1007/s12016-012-8349-4] [Cited by in F6Publishing: 40] [Reference Citation Analysis]
397 Schad CA, Haac BE, Cross RK, Syed A, Lonsako S, Bafford AC. Early Postoperative Anti-TNF Therapy Does Not Increase Complications Following Abdominal Surgery in Crohn’s Disease. Dig Dis Sci 2019;64:1959-66. [DOI: 10.1007/s10620-019-5476-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
398 Zouiten-Mekki L, Zaouali H, Boubaker J, Karoui S, Fekih M, Matri S, Hamzaoui S, Filali A, Chaabouni H, Hugot JP. CARD15/NOD2 in a Tunisian population with Crohn’s disease. Dig Dis Sci. 2005;50:130-135. [PMID: 15712650 DOI: 10.1007/s10620-005-1290-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
399 Eglinton TW, Gearry RB. Clinical factors predicting disease course in Crohn’s disease. Expert Review of Clinical Immunology 2014;6:41-5. [DOI: 10.1586/eci.09.76] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
400 Franke A, Hampe J, Rosenstiel P, Becker C, Wagner F, Häsler R, Little RD, Huse K, Ruether A, Balschun T, Wittig M, Elsharawy A, Mayr G, Albrecht M, Prescott NJ, Onnie CM, Fournier H, Keith T, Radelof U, Platzer M, Mathew CG, Stoll M, Krawczak M, Nürnberg P, Schreiber S. Systematic association mapping identifies NELL1 as a novel IBD disease gene. PLoS One 2007;2:e691. [PMID: 17684544 DOI: 10.1371/journal.pone.0000691] [Cited by in Crossref: 98] [Cited by in F6Publishing: 87] [Article Influence: 6.5] [Reference Citation Analysis]
401 Stevenson AW, Randall SM, Boyd JH, Wood FM, Fear MW, Duke JM. Burn leads to long-term elevated admissions to hospital for gastrointestinal disease in a West Australian population based study. Burns 2017;43:665-73. [PMID: 27720266 DOI: 10.1016/j.burns.2016.09.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
402 Guerra I, Algaba A, Pérez-Calle JL, Chaparro M, Marín-Jiménez I, García-Castellanos R, González-Lama Y, López-Sanromán A, Manceñido N, Martínez-Montiel P, Quintanilla E, Taxonera C, Villafruela M, Romero-Maté A, López-Serrano P, Gisbert JP, Bermejo F. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis 2012;6:518-23. [PMID: 22398059 DOI: 10.1016/j.crohns.2011.10.007] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
403 Hazlewood GS, Pokharel G, Deardon R, Marshall DA, Bombardier C, Tomlinson G, Ma C, Seow CH, Panaccione R, Kaplan GG. Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment. PLoS One 2020;15:e0227635. [PMID: 31945089 DOI: 10.1371/journal.pone.0227635] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
404 Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010;13:259-265. [PMID: 20704624 DOI: 10.1111/j.1756-185x.2010.01542.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
405 Höie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, Odes S, Mouzas IA, Beltrami M, Langholz E, Stockbrügger R, Vatn M, Moum B; European Collaborative Study Group of Inflammatory Bowel Disease (EC-IBD). Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007;102:1692-701. [PMID: 17555460 DOI: 10.1111/j.1572-0241.2007.01265.x] [Cited by in Crossref: 144] [Cited by in F6Publishing: 137] [Article Influence: 9.6] [Reference Citation Analysis]
406 Saitoh H, Takagaki K, Nakamura T, Munakata A, Yoshida Y, Endo M. Characterization of mucin in whole-gut lavage fluid obtained from patients with inflammatory bowel disease. Digest Dis Sci 1996;41:1768-74. [DOI: 10.1007/bf02088743] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
407 Opstelten JL, Plassais J, van Mil SW, Achouri E, Pichaud M, Siersema PD, Oldenburg B, Cervino AC. Gut Microbial Diversity Is Reduced in Smokers with Crohn's Disease. Inflamm Bowel Dis 2016;22:2070-7. [PMID: 27542127 DOI: 10.1097/MIB.0000000000000875] [Cited by in Crossref: 47] [Cited by in F6Publishing: 28] [Article Influence: 11.8] [Reference Citation Analysis]
408 Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10:639-645. [PMID: 22289873 DOI: 10.1016/j.cgh.2012.01.010] [Cited by in Crossref: 469] [Cited by in F6Publishing: 426] [Article Influence: 46.9] [Reference Citation Analysis]
409 Ding Y, Xia B, Lü M, Zhang Y, Li J, Ye M, Luo H, Yu J, Zhang X, Tan J. MHC class I chain-related gene A-A5.1 allele is associated with ulcerative colitis in Chinese population. Clin Exp Immunol. 2005;142:193-198. [PMID: 16178876 DOI: 10.1111/j.1365-2249.2005.02907.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
410 Pichler J, Hanslik A, Huber WD, Aufricht C, Bidmon-Fliegenschnee B. Paediatric patients with inflammatory bowel disease who received infliximab experienced improved growth and bone health. Acta Paediatr. 2014;103:e69-e75. [PMID: 24237381 DOI: 10.1111/apa.12448] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
411 Gao X, Zhang FB, Ding L, Liu H, Wang XD, Chen BL, Bi HC, Xiao YL, Zhao LZ, Chen MH. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol. 2012;24:958-964. [PMID: 22664938 DOI: 10.1097/meg.0b013e3283545ae3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
412 Coruzzi P, Castiglioni P, Parati G, Brambilla V, Brambilla L, Gualerzi M, Cademartiri F, Franzè A, De Angelis G, Di Rienzo M. Autonomic cardiovascular regulation in quiescent ulcerative colitis and Crohn’s disease. Eur J Clin Invest. 2007;37:964-970. [PMID: 18036030 DOI: 10.1111/j.1365-2362.2007.01887.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
413 Sidoroff M, Karikoski R, Raivio T, Savilahti E, Kolho KL. High-sensitivity C-reactive protein in paediatric inflammatory bowel disease. World J Gastroenterol 2010; 16(23): 2901-2906 [PMID: 20556836 DOI: 10.3748/wjg.v16.i23.2901] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
414 Yang QF, Chen BL, Zhang QS, Zhu ZH, Hu B, He Y, Gao X, Wang YM, Hu PJ, Chen MH. Contribution of MDR1 gene polymorphisms on IBD predisposition and response to glucocorticoids in IBD in a Chinese population. J Dig Dis. 2015;16:22-30. [PMID: 25346426 DOI: 10.1111/1751-2980.12205] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
415 Forni D, Cleynen I, Ferrante M, Cassinotti A, Cagliani R, Ardizzone S, Vermeire S, Fichera M, Lombardini M, Maconi G. ABO histo-blood group might modulate predisposition to Crohn's disease and affect disease behavior. J Crohns Colitis. 2014;8:489-494. [PMID: 24268527 DOI: 10.1016/j.crohns.2013.10.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
416 Zhou Y, He Y, Liu L, Zhou W, Wang P, Hu H, Nie Y, Chen Y. Alterations in Gut Microbial Communities Across Anatomical Locations in Inflammatory Bowel Diseases. Front Nutr 2021;8:615064. [PMID: 33718417 DOI: 10.3389/fnut.2021.615064] [Reference Citation Analysis]
417 Asano K, Matsushita T, Umeno J, Hosono N, Takahashi A, Kawaguchi T, Matsumoto T, Matsui T, Kakuta Y, Kinouchi Y, Shimosegawa T, Hosokawa M, Arimura Y, Shinomura Y, Kiyohara Y, Tsunoda T, Kamatani N, Iida M, Nakamura Y, Kubo M. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet. 2009;41:1325-1329. [PMID: 19915573 DOI: 10.1038/ng.482] [Cited by in Crossref: 178] [Cited by in F6Publishing: 164] [Article Influence: 13.7] [Reference Citation Analysis]
418 Khademi Z, Saneei P, Hassanzadeh-Keshteli A, Daghaghzadeh H, Tavakkoli H, Adibi P, Esmaillzadeh A. Association Between Inflammatory Potential of the Diet and Ulcerative Colitis: A Case-Control Study. Front Nutr 2020;7:602090. [PMID: 33681269 DOI: 10.3389/fnut.2020.602090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
419 Lee SH, Kim MJ, Chang K, Song EM, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. BMC Gastroenterol 2017;17:110. [PMID: 29061121 DOI: 10.1186/s12876-017-0669-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
420 Koutroubakis IE, Karmiris K, Makreas S, Xidakis C, Niniraki M, Kouroumalis EA. Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study. Eur J Gastroenterol Hepatol. 2006;18:421-425. [PMID: 16538115 DOI: 10.1097/00042737-200604000-00017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
421 Hu D, Zhang D, Zheng S, Guo M, Lin X, Jiang Y. Association of Ulcerative Colitis with FUT2 and FUT3 Polymorphisms in Patients from Southeast China. PLoS One. 2016;11:e0146557. [PMID: 26766790 DOI: 10.1371/journal.pone.0146557] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
422 Tarrant KM, Barclay ML, Frampton CM, Gearry RB. Perianal disease predicts changes in Crohn’s disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol. 2008;103:3082-3093. [PMID: 19086959 DOI: 10.1111/j.1572-0241.2008.02212.x] [Cited by in Crossref: 153] [Cited by in F6Publishing: 141] [Article Influence: 11.8] [Reference Citation Analysis]
423 Oostenbrug L, Nolte I, Oosterom E, van der Steege G, te Meerman G, van Dullemen H, Drenth J, de Jong D, van der Linde K, Jansen P, Kleibeuker J. CARD15 in inflammatory bowel disease and Crohn's disease phenotypes: An association study and pooled analysis. Digestive and Liver Disease 2006;38:834-45. [DOI: 10.1016/j.dld.2006.06.042] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
424 Glas J, Stallhofer J, Ripke S, Wetzke M, Pfennig S, Klein W, Epplen JT, Griga T, Schiemann U, Lacher M, Koletzko S, Folwaczny M, Lohse P, Göke B, Ochsenkühn T, Müller-Myhsok B, Brand S. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am J Gastroenterol 2009;104:1737-44. [PMID: 19455118 DOI: 10.1038/ajg.2009.163] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 4.5] [Reference Citation Analysis]
425 Cappello M, Randazzo C, Bravatà I, Licata A, Peralta S, Craxì A, Almasio PL. Liver Function Test Abnormalities in Patients with Inflammatory Bowel Diseases: A Hospital-based Survey. Clin Med Insights Gastroenterol. 2014;7:25-31. [PMID: 24966712 DOI: 10.4137/cgast.s13125] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
426 Chudy-Onwugaje K, Mamunes AP, Schwartz DA, Horst S, Cross RK. Predictors of High Health Care Utilization in Patients With Inflammatory Bowel Disease Within 1 Year of Establishing Specialist Care. Inflamm Bowel Dis 2021;27:325-35. [PMID: 32488231 DOI: 10.1093/ibd/izaa070] [Reference Citation Analysis]
427 Sivasailam B, Manski S, Wentz A, Cross RK. Presence of Obstructive Symptoms and Absence of Perianal Crohn Disease Is Predictive of Surgery After Endoscopic Balloon Dilation. Inflamm Bowel Dis 2021;27:1230-6. [PMID: 33165536 DOI: 10.1093/ibd/izaa276] [Reference Citation Analysis]
428 Manninen P, Karvonen AL, Laukkarinen J, Aitola P, Huhtala H, Collin P. Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease. Scand J Gastroenterol. 2015;50:423-428. [PMID: 25636976 DOI: 10.3109/00365521.2014.946085] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
429 Hou JK, Malaty HM, Thirumurthi S. Radiation exposure from diagnostic imaging studies among patients with inflammatory bowel disease in a safety-net health-care system. Dig Dis Sci. 2014;59:546-553. [PMID: 24026402 DOI: 10.1007/s10620-013-2852-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
430 Rodríguez-Carrio J, Mozo L, López P, Nikiphorou E, Suárez A. Anti-High-Density Lipoprotein Antibodies and Antioxidant Dysfunction in Immune-Driven Diseases. Front Med (Lausanne) 2018;5:114. [PMID: 29740582 DOI: 10.3389/fmed.2018.00114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
431 Binder V. Epidemiology of IBD during the twentieth century: an integrated view. Best Pract Res Clin Gastroenterol. 2004;18:463-479. [PMID: 15157821 DOI: 10.1016/j.bpg.2003.12.002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 6.3] [Reference Citation Analysis]
432 Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, Munkholm P, Bodini P, O’Morain C, Mouzas IA. Crohn’s disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut. 2006;55:510-518. [PMID: 16150857 DOI: 10.1136/gut.2005.072793] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 5.4] [Reference Citation Analysis]
433 Pearce AV, Fisher SA, Prescott NJ, Onnie CM, Pattni R, Green P, Forbes A, Mansfield J, Sanderson J, Schreiber S. Investigation of association of the DLG5 gene with phenotypes of inflammatory bowel disease in the British population. Int J Colorectal Dis. 2007;22:419-424. [PMID: 16944184 DOI: 10.1007/s00384-006-0151-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
434 Glas J, Konrad A, Schmechel S, Dambacher J, Seiderer J, Schroff F, Wetzke M, Roeske D, Török HP, Tonenchi L. The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn’s disease in the German population. Am J Gastroenterol. 2008;103:682-691. [PMID: 18162085 DOI: 10.1111/j.1572-0241.2007.01694.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 80] [Article Influence: 4.9] [Reference Citation Analysis]
435 Behari A, Kapoor VK. Does gallbladder cancer divide India? Indian J Gastroenterol 2010;29:3-7. [PMID: 20373078 DOI: 10.1007/s12664-010-0008-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
436 Mallant-Hent R, Mooij M, Blomberg BV, Linskens R, Bodegraven AV, Savelkoul P. Correlation between Saccharomyces cerevisiae DNA in intestinal mucosal samples and anti-Saccharomyces cerevisiae antibodies in serum of patients with IBD. World J Gastroenterol 2006; 12(2): 292-297 [PMID: 16482632 DOI: 10.3748/wjg.v12.i2.292] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
437 Henriksen M, Jahnsen J, Lygren I, Sauar J, Schulz T, Stray N, Vatn MH, Moum B;  Ibsen Study Group. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study). Scand J Gastroenterol. 2006;41:1037-1043. [PMID: 16938716 DOI: 10.1080/00365520600554527] [Cited by in Crossref: 75] [Cited by in F6Publishing: 61] [Article Influence: 4.7] [Reference Citation Analysis]
438 Heijckmann AC, Huijberts MS, Schoon EJ, Geusens P, de Vries J, Menheere PP, van der Veer E, Wolffenbuttel BH, Stockbrugger RW, Dumitrescu B, Nieuwenhuijzen Kruseman AC. High prevalence of morphometric vertebral deformities in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2008;20:740-7. [PMID: 18617778 DOI: 10.1097/MEG.0b013e3282f8888b] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
439 Maus B, Jung C, Mahachie John JM, Hugot JP, Génin E, Van Steen K. Molecular reclassification of Crohn's disease: a cautionary note on population stratification. PLoS One 2013;8:e77720. [PMID: 24147066 DOI: 10.1371/journal.pone.0077720] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
440 Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, Baldo V. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100:1516-1522. [PMID: 15984974 DOI: 10.1111/j.1572-0241.2005.41841.x] [Cited by in Crossref: 155] [Cited by in F6Publishing: 126] [Article Influence: 9.1] [Reference Citation Analysis]
441 Seksik P, Sokol H, Grondin V, Adrie C, Duboc H, Pigneur B, Thomas G, Beaugerie L, Trugnan G, Masliah J, Bachelet M. Sera from patients with Crohn’s disease break bacterial lipopolysaccharide tolerance of human intestinal epithelial cells via MD-2 activity. Innate Immun 2010;16:381-90. [DOI: 10.1177/1753425909357076] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
442 Van Limbergen J, Russell RK, Nimmo ER, Drummond HE, Smith L, Anderson NH, Davies G, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Wilson DC, Satsangi J. Autophagy gene ATG16L1 influences susceptibility and disease location but not childhood-onset in Crohn's disease in Northern Europe. Inflamm Bowel Dis 2008;14:338-46. [PMID: 18088053 DOI: 10.1002/ibd.20340] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
443 Ruan J, Chen Y, Zhou Y. Development and Validation of a Questionnaire to Assess the Quality of Life in Patients with Inflammatory Bowel Disease in Mainland China. Inflamm Bowel Dis 2017;23:431-9. [PMID: 28129287 DOI: 10.1097/MIB.0000000000001024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
444 Lees CW, Zacharias WJ, Tremelling M, Noble CL, Nimmo ER, Tenesa A, Cornelius J, Torkvist L, Kao J, Farrington S. Analysis of germline GLI1 variation implicates hedgehog signalling in the regulation of intestinal inflammatory pathways. PLoS Med. 2008;5:e239. [PMID: 19071955 DOI: 10.1371/journal.pmed.0050239] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.7] [Reference Citation Analysis]
445 Armitage E, Drummond H, Ghosh S, Ferguson A. Incidence of juvenile-onset Crohn's disease in Scotland. Lancet 1999;353:1496-7. [PMID: 10232323 DOI: 10.1016/S0140-6736(99)00333-5] [Cited by in Crossref: 61] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
446 Spooren CE, Wintjens DS, de Jong MJ, van der Meulen-de Jong AE, Romberg-camps MJ, Becx MC, Maljaars JP, van Bodegraven AA, Mahmmod N, Markus T, Hameeteman WM, Masclee AA, Winkens B, Jonkers DM, Pierik MJ. Risk of impaired nutritional status and flare occurrence in IBD outpatients. Digestive and Liver Disease 2019;51:1265-9. [DOI: 10.1016/j.dld.2019.05.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
447 Koutroubakis IE, Theodoropoulou A, Xidakis C, Sfiridaki A, Notas G, Kolios G, Kouroumalis EA. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004;16:1147-1152. [PMID: 15489574 DOI: 10.1097/00042737-200411000-00011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
448 Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002;122:867-874. [PMID: 11910337 DOI: 10.1053/gast.2002.32415] [Cited by in Crossref: 465] [Cited by in F6Publishing: 453] [Article Influence: 23.3] [Reference Citation Analysis]
449 Zhou Y, Xu ZZ, He Y, Yang Y, Liu L, Lin Q, Nie Y, Li M, Zhi F, Liu S, Amir A, González A, Tripathi A, Chen M, Wu GD, Knight R, Zhou H, Chen Y. Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction. mSystems 2018;3:e00188-17. [PMID: 29404425 DOI: 10.1128/mSystems.00188-17] [Cited by in Crossref: 85] [Cited by in F6Publishing: 52] [Article Influence: 21.3] [Reference Citation Analysis]
450 Bond A, Alavi A, Axford JS, Bourke BE, Bruckner FE, Kerr MA, Maxwell J, Tweed KJ, Weldon MJ, Youinou P, Hay FC. A Detailed Lectin Analysis of IgG Glycosylation, Demonstrating Disease Specific Changes in Terminal Galactose and N-acetylglucosamine. Journal of Autoimmunity 1997;10:77-85. [DOI: 10.1006/jaut.1996.0104] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 2.2] [Reference Citation Analysis]
451 Moon CM, Shin DJ, Son NH, Shin ES, Hong SP, Kim TI, Kim WH, Cheon JH. Genetic variants in the IL12B gene are associated with inflammatory bowel diseases in the Korean population. J Gastroenterol Hepatol 2013;28:1588-94. [PMID: 23573954 DOI: 10.1111/jgh.12214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
452 Costea I, Mack DR, Israel D, Morgan K, Krupoves A, Seidman E, Deslandres C, Lambrette P, Grimard G, Levy E, Amre DK. Genes involved in the metabolism of poly-unsaturated fatty-acids (PUFA) and risk for Crohn's disease in children & young adults. PLoS One. 2010;5:e15672. [PMID: 21187935 DOI: 10.1371/journal.pone.0015672] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
453 Russell RK, Drummond HE, Nimmo EE, Anderson N, Smith L, Wilson DC, Gillett PM, Mcgrogan P, Hassan K, Weaver LT, Bisset M, Mahdi G, Satsangi J. Genotype-phenotype Analysis in Childhood-onset Crohnʼs Disease: NOD2/CARD15 Variants Consistently Predict Phenotypic Characteristics of Severe Disease: . Inflammatory Bowel Diseases 2005;11:955-64. [DOI: 10.1097/01.mib.0000183423.38037.f3] [Cited by in Crossref: 88] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
454 Carbonnel F, Gargouri D, Lémann M, Beaugerie L, Cattan S, Cosnes J, Gendre JP. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther. 2000;14:273-279. [PMID: 10735919 DOI: 10.1046/j.1365-2036.2000.00705.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 4.0] [Reference Citation Analysis]
455 Jeong SH, Choi JS, Kim JW, Kim HM, Kim HS, Im JP, Kim JS, Kim YS, Cheon JH, Kim WH, Ye BD, Kim YH, Han DS. Clinical Features of Intra-Abdominal Abscess and Intestinal Free-Wall Perforation in Korean Patients with Crohn's Disease: Results from the CONNECT Study. J Clin Med 2020;10:E116. [PMID: 33396251 DOI: 10.3390/jcm10010116] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
456 Russel MG, Ryan BM, Dagnelie PC, de Rooij M, Sijbrandij J, Feleus A, Hesselink M, Muris JW, Stockbrugger R. Insurance problems among inflammatory bowel disease patients: results of a Dutch population based study. Gut 2003;52:358-62. [PMID: 12584216 DOI: 10.1136/gut.52.3.358] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
457 Yang SK, Jung Y, Kim H, Hong M, Ye BD, Song K. Association of FCGR2A, JAK2 or HNF4A variants with ulcerative colitis in Koreans. Dig Liver Dis. 2011;43:856-861. [PMID: 21831733 DOI: 10.1016/j.dld.2011.07.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
458 Kontiainen S, Scheinin T, Halme L. Number of activated T-helper cells and NK cells in peripheral blood is decreased in severe Crohn's disease. APMIS 1996;104:355-61. [DOI: 10.1111/j.1699-0463.1996.tb00727.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
459 Alonso A, Domènech E, Julià A, Panés J, García-Sánchez V, Mateu PN, Gutiérrez A, Gomollón F, Mendoza JL, Garcia-Planella E, Barreiro-de Acosta M, Muñoz F, Vera M, Saro C, Esteve M, Andreu M, Chaparro M, Manyé J, Cabré E, López-Lasanta M, Tortosa R, Gelpí JL, García-Montero AC, Bertranpetit J, Absher D, Myers RM, Marsal S, Gisbert JP. Identification of risk loci for Crohn's disease phenotypes using a genome-wide association study. Gastroenterology 2015;148:794-805. [PMID: 25557950 DOI: 10.1053/j.gastro.2014.12.030] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
460 Nielsen NK, Wewer V, Skafte L, Paerregaard A. Response pattern recognition in paediatric Crohn's disease patients treated with enteral nutrition. Journal of Crohn's and Colitis 2008;2:233-6. [DOI: 10.1016/j.crohns.2008.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
461 Hou W, Xia B, Yuan A, Li J, Yang Z, Mao L. CTLA-4 gene polymorphisms in Chinese patients with ulcerative colitis. Inflamm Bowel Dis. 2005;11:653-656. [PMID: 15973119 DOI: 10.1097/01.MIB.0000165112.25934.36] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
462 Eri R, Jonsson JR, Pandeya N, Purdie DM, Clouston AD, Martin N, Duffy D, Powell EE, Fawcett J, Florin TH, Radford-Smith GL. CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. Genes Immun 2004;5:444-50. [PMID: 15215889 DOI: 10.1038/sj.gene.6364113] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
463 Fowler EV, Doecke J, Simms LA, Zhao ZZ, Webb PM, Hayward NK, Whiteman DC, Florin TH, Montgomery GW, Cavanaugh JA, Radford-Smith GL. ATG16L1 T300A shows strong associations with disease subgroups in a large Australian IBD population: further support for significant disease heterogeneity. Am J Gastroenterol 2008;103:2519-26. [PMID: 18671817 DOI: 10.1111/j.1572-0241.2008.02023.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 61] [Article Influence: 3.9] [Reference Citation Analysis]
464 Li Q, Wang C, Tang C, He Q, Li N, Li J. Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn's disease. J Clin Gastroenterol 2014;48:513-23. [PMID: 24275714 DOI: 10.1097/MCG.0000000000000035] [Cited by in Crossref: 130] [Cited by in F6Publishing: 86] [Article Influence: 18.6] [Reference Citation Analysis]
465 Leong RW, Lawrance IC, Ching JY, Cheung CM, Fung SS, Ho JN, Philpott J, Wallace AR, Sung JJ. Knowledge, quality of life, and use of complementary and alternative medicine and therapies in inflammatory bowel disease: a comparison of Chinese and Caucasian patients. Dig Dis Sci. 2004;49:1672-1676. [PMID: 15573925 DOI: 10.1023/b:ddas.0000043384.26092.f4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
466 Al-Jarallah K, Shehab D, Al-Azmi W, Al-Fadli A. Rheumatic complications of inflammatory bowel disease among Arabs: a hospital-based study in Kuwait. Int J Rheum Dis. 2013;16:134-138. [PMID: 23773636 DOI: 10.1111/j.1756-185x.2012.01811.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
467 Hughes DJ, McManus R, Neary P, O'morain C, O'sullivan M. Common variation in the vitamin D receptor gene and risk of inflammatory bowel disease in an Irish case-control study. Eur J Gastroenterol Hepatol. 2011;23:807-812. [PMID: 21818054 DOI: 10.1097/meg.0b013e328349283e] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
468 Girardin M, Dionne S, Goyette P, Rioux J, Bitton A, Elimrani I, Charlebois P, Qureshi I, Levy E, Seidman EG. Expression and functional analysis of intestinal organic cation/L-carnitine transporter (OCTN) in Crohn's disease. J Crohns Colitis. 2012;6:189-197. [PMID: 22325173 DOI: 10.1016/j.crohns.2011.08.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
469 Jang HM, Kim JK, Joo MK, Shin YJ, Lee CK, Kim HJ, Kim DH. Transplantation of fecal microbiota from patients with inflammatory bowel disease and depression alters immune response and behavior in recipient mice. Sci Rep 2021;11:20406. [PMID: 34650107 DOI: 10.1038/s41598-021-00088-x] [Reference Citation Analysis]
470 Stoll M, Corneliussen B, Costello CM, Waetzig GH, Mellgard B, Koch WA, Rosenstiel P, Albrecht M, Croucher PJ, Seegert D, Nikolaus S, Hampe J, Lengauer T, Pierrou S, Foelsch UR, Mathew CG, Lagerstrom-Fermer M, Schreiber S. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet. 2004;36:476-480. [PMID: 15107852 DOI: 10.1038/ng1345] [Cited by in Crossref: 336] [Cited by in F6Publishing: 300] [Article Influence: 18.7] [Reference Citation Analysis]
471 Eren F, Akkiprik M, Atuğ O, Sönmez O, Tahan G, Ozdemir F, Hamzaoğlu HO, Celikel CA, Imeryüz N, Avşar E, Ozer A. R72P polymorphism of TP53 in ulcerative colitis patients is associated with the incidence of colectomy, use of steroids and the presence of a positive family history. Pathol Oncol Res 2010;16:563-8. [PMID: 20309662 DOI: 10.1007/s12253-010-9255-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
472 de Ridder L, Weersma RK, Dijkstra G, van der Steege G, Benninga MA, Nolte IM, Taminiau JA, Hommes DW, Stokkers PC. Genetic susceptibility has a more important role in pediatric-onset Crohn's disease than in adult-onset Crohn's disease. Inflamm Bowel Dis 2007;13:1083-92. [PMID: 17476680 DOI: 10.1002/ibd.20171] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 5.0] [Reference Citation Analysis]
473 Oostlander AE, Bravenboer N, Sohl E, Holzmann PJ, van der Woude CJ, Dijkstra G, Stokkers PC, Oldenburg B, Netelenbos JC, Hommes DW, van Bodegraven AA, Lips P. Histomorphometric Analysis Reveals Reduced Bone Mass and Bone Formation in Patients With Quiescent Crohn's Disease. Gastroenterology 2011;140:116-23. [DOI: 10.1053/j.gastro.2010.09.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
474 Kocsis AK, Lakatos PL, Somogyvári F, Fuszek P, Papp J, Fischer S, Szamosi T, Lakatos L, Kovacs A, Hofner P, Mándi Y. Association of beta-defensin 1 single nucleotide polymorphisms with Crohn's disease. Scand J Gastroenterol 2008;43:299-307. [PMID: 18938660 DOI: 10.1080/00365520701682615] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
475 Li Q, Wang C, Tang C, Li N, Li J. Molecular-phylogenetic characterization of the microbiota in ulcerated and non-ulcerated regions in the patients with Crohn’s disease. PLoS One. 2012;7:e34939. [PMID: 22529960 DOI: 10.1371/journal.pone.0034939] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
476 Deng C, Li W, Li J, Zhang S, Li Y. Diagnostic value of the antiglycoprotein-2 antibody for Crohn's disease: a PRISMA-compliant systematic review and meta-analysis. BMJ Open. 2017;7:e014843. [PMID: 28601823 DOI: 10.1136/bmjopen-2016-014843] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
477 Firouzi F, Bahari A, Aghazadeh R, Zali MR. Appendectomy, tonsillectomy, and risk of inflammatory bowel disease: a case control study in Iran. Int J Colorectal Dis 2006;21:155-9. [DOI: 10.1007/s00384-005-0760-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
478 Yang SK, Kim H, Hong M, Lim J, Choi E, Ye BD, Park SK, Song K. Association of CARD8 with inflammatory bowel disease in Koreans. J Hum Genet 2011;56:217-23. [PMID: 21248762 DOI: 10.1038/jhg.2010.170] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
479 Sempere L, Almenta I, Barrenengoa J, Gutiérrez A, Villanueva CO, de-Madaria E, García V, Sánchez-payá J. Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease. Vaccine 2013;31:3065-71. [DOI: 10.1016/j.vaccine.2013.04.059] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
480 Calenda KA, Schornagel IL, Sadeghi-Nejad A, Grand RJ. Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study. Inflamm Bowel Dis 2005;11:435-41. [PMID: 15867582 DOI: 10.1097/01.mib.0000159321.58773.a6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
481 Törkvist L, Noble CL, Lördal M, Sjöqvist U, Lindforss U, Nimmo ER, Löfberg R, Russell RK, Satsangi J. Contribution of the IBD5 locus to Crohn's disease in the Swedish population. Scand J Gastroenterol. 2007;42:200-206. [PMID: 17340776 DOI: 10.1080/00365520600842278] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
482 Ideström M, Rubio C, Granath F, Finkel Y, Hugot JP. CARD15 mutations are rare in Swedish pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2005;40:456-460. [PMID: 15795594 DOI: 10.1097/01.mpg.0000150423.38210.2e] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
483 Larussa T, Oliverio M, Suraci E, Greco M, Placida R, Gervasi S, Marasco R, Imeneo M, Paolino D, Tucci L, Gulletta E, Fresta M, Procopio A, Luzza F. Oleuropein Decreases Cyclooxygenase-2 and Interleukin-17 Expression and Attenuates Inflammatory Damage in Colonic Samples from Ulcerative Colitis Patients. Nutrients 2017;9:E391. [PMID: 28420140 DOI: 10.3390/nu9040391] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
484 Kolek A, Janout V, Tichý M, Grepl M. The incidence of inflammatory bowel disease is increasing among children 15 years old and younger in the Czech Republic. J Pediatr Gastroenterol Nutr 2004;38:362-3. [PMID: 15076645 DOI: 10.1097/00005176-200403000-00028] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
485 Armuzzi A, Fiorino G, Variola A, Manetti N, Fries W, Orlando A, Maconi G, Bossa F, Cappello M, Biancone L, Cantoro L, Costa F, D’incà R, Lionetti P, Principi M, Castiglione F, Annunziata ML, Di Sabatino A, Di Girolamo M, Terpin MM, Cortelezzi CC, Saibeni S, Amato A, Ardizzone S, Guidi L, Danese S, Massella A, Ventra A, Rizzuto G, Massari A, Perri F, Annese V, Saettone S, Tari R, Petruzzellis C, Meucci G, Imperiali G, Guglielmi FW, Mazzuoli S, Caserta L, Caterina Parodi M, Colli A, Ronchetti A, Pugliese D, Geccherle A, Rogai F, Milani S, Renna S, Cassinotti A, Andriulli A, Martino G, Scrivo B, Troncone E, Kohn A, Bertani L, Lorenzon G, Ghione S, Nardone O, Vecchi M, Bertani A, Bosani MA, Bezzio C, Salerno R; PROSIT Investigators. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases 2019;25:568-79. [DOI: 10.1093/ibd/izy264] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
486 Florin TH, Paterson EW, Fowler EV, Radford-Smith GL. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol 2006;41:306-11. [PMID: 16497618 DOI: 10.1080/00365520500217118] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 4.9] [Reference Citation Analysis]
487 Bastida G, Nos P, Aguas M, Beltrán B, Rubín A, Dasí F, Ponce J. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:775-782. [PMID: 16225485 DOI: 10.1111/j.1365-2036.2005.02636.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 4.9] [Reference Citation Analysis]
488 Broide E, Dotan I, Weiss B, Wilschanski M, Yerushalmi B, Klar A, Levine A. Idiopathic pancreatitis preceding the diagnosis of inflammatory bowel disease is more frequent in pediatric patients. J Pediatr Gastroenterol Nutr. 2011;52:714-717. [PMID: 21478760 DOI: 10.1097/mpg.0b013e3182065cad] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
489 Thomas D, Gazouli M, Karantanos T, Rigoglou S, Karamanolis G, Bramis K, Zografos G, Theodoropoulos GE. Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn’s disease. World J Gastroenterol 2014; 20(13): 3609-3614 [PMID: 24707144 DOI: 10.3748/wjg.v20.i13.3609] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
490 Reenaers C, Pirard C, Vankemseke C, Latour P, Belaiche J, Louis E. Long-term evolution and predictive factors of mild inflammatory bowel disease. Scand J Gastroenterol 2016;51:712-9. [PMID: 26815198 DOI: 10.3109/00365521.2015.1128965] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
491 Martelli L, Colard A, Fontaine F, Deflandre J, Bastens B, Louis E. Evaluation of the efficacy of octreotide LAR in the treatment of Crohn's disease associated refractory diarrhea. Scand J Gastroenterol 2017;52:564-9. [PMID: 28270045 DOI: 10.1080/00365521.2017.1284893] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
492 Viola A, Monterubbianesi R, Scalisi G, Furfaro F, Rea M, Saibeni S, Aratari A, Bringiotti R, Casella G, Cantoro L, Frankovic I, Calella F, Pugliese D, Orlando S, Samperi L, Cappello M, Mocci G, Manetti N, Annese V, Privitera AC, Inserra G, Caprioli F, D’incà R, Principi M, Papi C, Castiglione F, Danese S, Ardizzone S, Bossa F, Kohn A, Manguso F, Alibrandi A, Fiorino G, Armuzzi A, Fries W. Late-onset Crohn’s disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease ‘AGED’ study. European Journal of Gastroenterology & Hepatology 2019;31:1361-9. [DOI: 10.1097/meg.0000000000001546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
493 Dechairo B, Dimon C, van Heel D, Mackay I, Edwards M, Scambler P, Jewell D, Cardon L, Lench N, Carey A. Replication and extension studies of inflammatory bowel disease susceptibility regions confirm linkage to chromosome 6p (IBD3). Eur J Hum Genet. 2001;9:627-633. [PMID: 11528509 DOI: 10.1038/sj.ejhg.5200687] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 2.3] [Reference Citation Analysis]
494 Scarpa M, Bortolami M, Cecchetto A, Faggian D, Kotsafti A, Ruffolo C, Navaglia F, Pozza A, D’Incà R, Plebani M. Mucosal immune environment in colonic carcinogenesis: CD80 up-regulation in colonic dysplasia in ulcerative colitis. Eur J Cancer. 2011;47:611-619. [PMID: 21067914 DOI: 10.1016/j.ejca.2010.10.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
495 Martinez A, Sanchez-lopez M, Varade J, Mas A, Carmen Martin M, de las Heras V, Arroyo R, Luis Mendoza J, Diaz-rubio M, Fernandez-gutierrez B, de la Concha EG, Urcelay E. Role of the MHC2TA gene in autoimmune diseases. Annals of the Rheumatic Diseases 2007;66:325-9. [DOI: 10.1136/ard.2006.059428] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 1.8] [Reference Citation Analysis]
496 Algaba A, Guerra I, Marín-Jiménez I, Quintanilla E, López-Serrano P, García-Sánchez MC, Casis B, Taxonera C, Moral I, Chaparro M, Martín-Rodríguez D, Martín-Arranz MD, Manceñido N, Menchén L, López-Sanromán A, Castaño Á, Bermejo F. Incidence, management, and course of cancer in patients with inflammatory bowel disease. J Crohns Colitis 2015;9:326-33. [PMID: 25687203 DOI: 10.1093/ecco-jcc/jjv032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
497 Sironi M, Guerini FR, Agliardi C, Biasin M, Cagliani R, Fumagalli M, Caputo D, Cassinotti A, Ardizzone S, Zanzottera M, Bolognesi E, Riva S, Kanari Y, Miyazawa M, Clerici M. An Evolutionary Analysis of RAC2 Identifies Haplotypes Associated with Human Autoimmune Diseases. Molecular Biology and Evolution 2011;28:3319-29. [DOI: 10.1093/molbev/msr164] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
498 Lopez RN, Evans HM, Appleton L, Bishop J, Chin S, Mouat S, Gearry RB, Day AS. Prospective Incidence of Paediatric Inflammatory Bowel Disease in New Zealand in 2015: Results From the Paediatric Inflammatory Bowel Disease in New Zealand (PINZ) Study. J Pediatr Gastroenterol Nutr. 2018;66:e122-e126. [PMID: 29077643 DOI: 10.1097/mpg.0000000000001806] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
499 Liu H, Liu W, Huang X, Feng Y, Lu J, Gao F. Intestinal flora differences between patients with ulcerative colitis of different ethnic groups in China. Medicine (Baltimore) 2021;100:e26932. [PMID: 34397940 DOI: 10.1097/MD.0000000000026932] [Reference Citation Analysis]
500 Hansen R, Russell RK, Reiff C, Louis P, Mcintosh F, Berry SH, Mukhopadhya I, Bisset MW, Barclay AR, Bishop J, Flynn DM, Mcgrogan P, Loganathan S, Mahdi G, Flint HJ, El-omar EM, Hold GL. Microbiota of De-Novo Pediatric IBD: Increased Faecalibacterium Prausnitzii and Reduced Bacterial Diversity in Crohn's But Not in Ulcerative Colitis. American Journal of Gastroenterology 2012;107:1913-22. [DOI: 10.1038/ajg.2012.335] [Cited by in Crossref: 188] [Cited by in F6Publishing: 175] [Article Influence: 18.8] [Reference Citation Analysis]
501 Horjus Talabur Horje CS, Bruijnen R, Roovers L, Groenen MJ, Joosten FB, Wahab PJ. Contrast Enhanced Abdominal Ultrasound in the Assessment of Ileal Inflammation in Crohn's Disease: A Comparison with MR Enterography. PLoS One 2015;10:e0136105. [PMID: 26322970 DOI: 10.1371/journal.pone.0136105] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
502 Vidal Á, Gómez-gil E, Sans M, Portella MJ, Salamero M, Piqué JM, Panés J. El papel de la ansiedad y la depresión en las recidivas de la enfermedad inflamatoria intestinal. Medicina Clínica 2009;132:298-302. [DOI: 10.1016/j.medcli.2008.07.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
503 Lunney PC, Kariyawasam VC, Wang RR, Middleton KL, Huang T, Selinger CP, Andrews JM, Katelaris PH, Leong RW. Smoking prevalence and its influence on disease course and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2015;42:61-70. [PMID: 25968332 DOI: 10.1111/apt.13239] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 8.3] [Reference Citation Analysis]
504 Attauabi M, Zhao M, Bendtsen F, Burisch J. Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn's disease. Therap Adv Gastroenterol 2021;14:17562848211004839. [PMID: 34234844 DOI: 10.1177/17562848211004839] [Reference Citation Analysis]
505 Holgersen K, Kvist PH, Markholst H, Hansen AK, Holm TL. Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse--a model mimicking inflammatory bowel disease. J Crohns Colitis 2014;8:147-60. [PMID: 23994255 DOI: 10.1016/j.crohns.2013.08.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
506 Mowat C, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S, Travis S, Morris J, Hamlin J, Dhar A, Nwokolo C, Edwards C, Creed T, Bloom S, Yousif M, Thomas L, Campbell S, Lewis SJ, Sebastian S, Sen S, Lal S, Hawkey C, Murray C, Cummings F, Goh J, Lindsay JO, Arebi N, Potts L, McKinley AJ, Thomson JM, Todd JA, Collie M, Dunlop MG, Mowat A, Gaya DR, Winter J, Naismith GD, Ennis H, Keerie C, Lewis S, Prescott RJ, Kennedy NA, Satsangi J; TOPPIC Study Group. Mercaptopurine vs placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomized controlled trial. Lancet Gastroenterol Hepatol. 2016;1:273-282. [PMID: 28404197 DOI: 10.1016/s2468-1253(16)30078-4] [Cited by in Crossref: 60] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
507 Niv Y, Abuksis G, Fraser GM. Epidemiology of Crohn's disease in Israel: a survey of Israeli kibbutz settlements. Am J Gastroenterol. 1999;94:2961-2965. [PMID: 10520852 DOI: 10.1111/j.1572-0241.1999.01371.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 1.6] [Reference Citation Analysis]
508 Aune TM, Crooke PS 3rd, Patrick AE, Tossberg JT, Olsen NJ, Spurlock CF 3rd. Expression of long non-coding RNAs in autoimmunity and linkage to enhancer function and autoimmune disease risk genetic variants. J Autoimmun 2017;81:99-109. [PMID: 28420548 DOI: 10.1016/j.jaut.2017.03.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
509 Gazouli M, Pachoula I, Panayotou I, Chouliaras G, Anagnou NP, Chroussos G, Roma E. Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease. Ann Gastroenterol. 2012;25:249-253. [PMID: 24714152 DOI: 10.1016/s1873-9946(12)60248-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
510 Alharbi OR, Azzam NA, Almalki AS, Almadi MA, Alswat KA, Sadaf N, Aljebreen AM. Clinical epidemiology of ulcerative colitis in Arabs based on the Montréal classification. World J Gastroenterol 2014; 20(46): 17525-17531 [PMID: 25516667 DOI: 10.3748/wjg.v20.i46.17525] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
511 Shaye OA, Yadegari M, Abreu MT, Poordad F, Simon K, Martin P, Papadakis KA, Ippoliti A, Vasiliauskas E, Tran TT. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol. 2007;102:2488-2494. [PMID: 17764490 DOI: 10.1111/j.1572-0241.2007.01515.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
512 Werner H, Landolt MA, Buehr P, Koller R, Nydegger A, Spalinger J, Heyland K, Schibli S, Braegger CP; The Swiss IBD Cohort Study Group. Changes in health-related quality of life over a 1-year follow-up period in children with inflammatory bowel disease. Qual Life Res 2017;26:1617-26. [DOI: 10.1007/s11136-017-1513-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
513 Rezaie A, Khalaj S, Shabihkhani M, Nikfar S, Zamani MJ, Mohammadirad A, Daryani NE, Abdollahi M. Study on the Correlations among Disease Activity Index and Salivary Transforming Growth Factor-beta1 and Nitric Oxide in Ulcerative Colitis Patients. Annals of the New York Academy of Sciences 2007;1095:305-14. [DOI: 10.1196/annals.1397.034] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
514 Shi HY, Chan FK, Leung WK, Li MK, Leung CM, Sze SF, Ching JY, Lo FH, Tsang SW, Shan EH, Mak LY, Lam BC, Hui AJ, Chow WH, Wong MT, Hung IF, Hui YT, Chan YK, Chan KH, Loo CK, Ng CK, Lao WC, Harbord M, Wu JC, Sung JJ, Ng SC. Low-dose azathioprine is effective in maintaining remission in steroid-dependent ulcerative colitis: results from a territory-wide Chinese population-based IBD registry. Therap Adv Gastroenterol. 2016;9:449-456. [PMID: 27366213 DOI: 10.1177/1756283x16643509] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
515 Carvalho RDO, do Carmo FLR, de Oliveira Junior A, Langella P, Chatel JM, Bermúdez-Humarán LG, Azevedo V, de Azevedo MS. Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis. Front Microbiol 2017;8:800. [PMID: 28536562 DOI: 10.3389/fmicb.2017.00800] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
516 Witte J, Shivananda S, Lennard-Jones JE, Beltrami M, Politi P, Bonanomi A, Tsianos EV, Mouzas I, Schulz TB, Monteiro E. Disease outcome in inflammatory bowel disease: mortality, morbidity and therapeutic management of a 796-person inception cohort in the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Scand J Gastroenterol. 2000;35:1272-1277. [PMID: 11199366 DOI: 10.1080/003655200453610] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 2.4] [Reference Citation Analysis]
517 de la Morena López F, Gisbert JP. Prevalencia y características de la anemia en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2009;32:591-9. [DOI: 10.1016/j.gastrohep.2009.05.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
518 Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T. Adalimumab in patients with Crohn’s disease--safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther. 2007;25:787-796. [PMID: 17373917 DOI: 10.1111/j.1365-2036.2007.03253.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
519 Rawal KK, Shukla VP, Chikani S, Thakkar M, Ruparelia M, Chudasama RK. Prevalence of extraintestinal manifestations in ulcerative colitis and associated risk factors. Indian J Gastroenterol 2021. [PMID: 34569013 DOI: 10.1007/s12664-021-01181-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
520 Kalaria R, Desai D, Abraham P, Joshi A, Gupta T, Shah S. Temporal Change in Phenotypic Behaviour in Patients with Crohn's Disease: Do Indian Patients Behave Differently from Western and Other Asian Patients? J Crohns Colitis. 2016;10:255-261. [PMID: 26519461 DOI: 10.1093/ecco-jcc/jjv202] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
521 Kariyawasam VC, Selinger CP, Katelaris PH, Jones DB, Mcdonald C, Barr G, Chapman G, Colliwshaw J, Lunney PC, Middleton K, Wang RR, Huang T, Andrews J, Leong RW. Early Use of Thiopurines or Methotrexate Reduces Major Abdominal and Perianal Surgery in Crohnʼs Disease: . Inflammatory Bowel Diseases 2014;20:1382-90. [DOI: 10.1097/mib.0000000000000119] [Cited by in Crossref: 43] [Cited by in F6Publishing: 9] [Article Influence: 5.4] [Reference Citation Analysis]
522 de la Poza G, López-Sanroman A, Taxonera C, Marín-Jimenez I, Gisbert JP, Bermejo F, Opio V, Muriel A. Genital fistulas in female Crohn's disease patients.: clinical characteristics and response to therapy. J Crohns Colitis 2012;6:276-80. [PMID: 22405162 DOI: 10.1016/j.crohns.2011.08.015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
523 Matsuoka K, Inoue N, Sato T, Okamoto S, Hisamatsu T, Kishi Y, Sakuraba A, Hitotsumatsu O, Ogata H, Koganei K, Fukushima T, Kanai T, Watanabe M, Ishii H, Hibi T. T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. Gut. 2004;53:1303-1308. [PMID: 15306590 DOI: 10.1136/gut.2003.024190] [Cited by in Crossref: 97] [Cited by in F6Publishing: 94] [Article Influence: 5.4] [Reference Citation Analysis]
524 Papadakis KA, Treyzon L, Abreu MT, Fleshner PR, Targan SR, Vasiliauskas EA. Infliximab in the treatment of medically refractory indeterminate colitis: INFLIXIMAB FOR INDETERMINATE COLITIS. Alimentary Pharmacology & Therapeutics 2003;18:741-7. [DOI: 10.1046/j.1365-2036.2003.01739.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
525 Alenazi N, Alsaeed H, Alsulami A, Alanzi T. A Review of Hyperbaric Oxygen Therapy for Inflammatory Bowel Disease. Int J Gen Med 2021;14:7099-105. [PMID: 34729019 DOI: 10.2147/IJGM.S336678] [Reference Citation Analysis]
526 Andersson E, Bergemalm D, Kruse R, Neumann G, D'Amato M, Repsilber D, Halfvarson J. Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles. PLoS One 2017;12:e0186142. [PMID: 28982144 DOI: 10.1371/journal.pone.0186142] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
527 Zhou Y, Chen H, He H, Du Y, Hu J, Li Y, Li Y, Zhou Y, Wang H, Chen Y, Nie Y. Increased Enterococcus faecalis infection is associated with clinically active Crohn disease. Medicine (Baltimore) 2016;95:e5019. [PMID: 27684872 DOI: 10.1097/MD.0000000000005019] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
528 Höie O, Schouten LJ, Wolters FL, Solberg IC, Riis L, Mouzas IA, Politi P, Odes S, Langholz E, Vatn M, Stockbrügger RW, Moum B; European Collaborative Study Group of Inflammatory Bowel Disease (EC-IBD). Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis. Gut 2007;56:497-503. [PMID: 17028127 DOI: 10.1136/gut.2006.101519] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 3.4] [Reference Citation Analysis]
529 Vietri MT, Riegler G, Ursillo A, Caserta L, Cioffi M, Molinari AM. p53 codon 72 polymorphism in patients affected with ulcerative colitis. J Gastroenterol. 2007;42:456-460. [PMID: 17671760 DOI: 10.1007/s00535-007-2026-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
530 Robinson RJ, al-Azzawi F, Iqbal SJ, Kryswcki T, Almond L, Abrams K, Mayberry JF. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 1998;43:2500-6. [PMID: 9824142 DOI: 10.1023/a:1026650719552] [Cited by in Crossref: 85] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
531 Hirano A, Yamazaki K, Umeno J, Ashikawa K, Aoki M, Matsumoto T, Nakamura S, Ninomiya T, Matsui T, Hirai F, Kawaguchi T, Takazoe M, Tanaka H, Motoya S, Kiyohara Y, Kitazono T, Nakamura Y, Kamatani N, Kubo M. Association study of 71 European Crohn's disease susceptibility loci in a Japanese population. Inflamm Bowel Dis. 2013;19:526-533. [PMID: 23388546 DOI: 10.1097/mib.0b013e31828075e7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
532 Koutroubakis IE, Petinaki E, Mouzas IA, Vlachonikolis IG, Anagnostopoulou E, Castanas E, Maniatis AN, Kouroumalis EA. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:449-54. [PMID: 11232689 DOI: 10.1111/j.1572-0241.2001.03524.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 36] [Article Influence: 0.4] [Reference Citation Analysis]
533 Kazemi-Shirazi L, Gasche CH, Natter S, Gangl A, Smolen J, Spitzauer S, Valent P, Kraft D, Valenta R. IgA autoreactivity: a feature common to inflammatory bowel and connective tissue diseases. Clin Exp Immunol 2002;128:102-9. [PMID: 11982597 DOI: 10.1046/j.1365-2249.2002.01804.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
534 Carstens A, Dicksved J, Nelson R, Lindqvist M, Andreasson A, Bohr J, Tysk C, Talley NJ, Agréus L, Engstrand L, Halfvarson J. The Gut Microbiota in Collagenous Colitis Shares Characteristics With Inflammatory Bowel Disease-Associated Dysbiosis. Clin Transl Gastroenterol 2019;10:e00065. [PMID: 31343467 DOI: 10.14309/ctg.0000000000000065] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
535 Lees CW, Heys D, Ho GT, Noble CL, Shand AG, Mowat C, Boulton-Jones R, Williams A, Church N, Satsangi J. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26:411-419. [PMID: 17635376 DOI: 10.1111/j.1365-2036.2007.03383.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 6.3] [Reference Citation Analysis]
536 Romberg-Camps MJ, Dagnelie PC, Kester AD, Hesselink-van de Kruijs MA, Cilissen M, Engels LG, Van Deursen C, Hameeteman WH, Wolters FL, Russel MG, Stockbrügger RW. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009;104:371-83. [PMID: 19174787 DOI: 10.1038/ajg.2008.38] [Cited by in Crossref: 190] [Cited by in F6Publishing: 175] [Article Influence: 14.6] [Reference Citation Analysis]
537 Bergeron V, Grondin V, Rajca S, Maubert MA, Pigneur B, Thomas G, Trugnan G, Beaugerie L, Cosnes J, Masliah J, Sokol H, Seksik P, Bachelet M. Current smoking differentially affects blood mononuclear cells from patients with Crohn's disease and ulcerative colitis: relevance to its adverse role in the disease. Inflamm Bowel Dis 2012;18:1101-11. [PMID: 21987436 DOI: 10.1002/ibd.21889] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
538 Koutroubakis IE, Dilaveraki E, Vlachonikolis IG, Vardas E, Vrentzos G, Ganotakis E, Mouzas IA, Gravanis A, Emmanouel D, Kouroumalis EA. Hyperhomocysteinemia in Greek patients with inflammatory bowel disease. Dig Dis Sci. 2000;45:2347-2351. [PMID: 11258554 DOI: 10.1023/a:1005583606647] [Cited by in Crossref: 35] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
539 Lawrance IC, Welman CJ, Shipman P, Murray K. Correlation of MRI-determined small bowel Crohn’s disease categories with medical response and surgical pathology. World J Gastroenterol 2009; 15(27): 3367-3375 [PMID: 19610137 DOI: 10.3748/wjg.15.3367] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 57] [Article Influence: 4.6] [Reference Citation Analysis]
540 Sipeki N, Davida L, Palyu E, Altorjay I, Harsfalvi J, Antal Szalmas P, Szabo Z, Veres G, Shums Z, Norman GL, Lakatos PL, Papp M. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn’s disease. World J Gastroenterol 2015; 21(22): 6952-6964 [PMID: 26078573 DOI: 10.3748/wjg.v21.i22.6952] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
541 Shrestha UK, Karimi O, Crusius JB, Zhou F, Wang Z, Chen Z, van Bodegraven AA, Xiao J, Morré SA, Wang H, Li J, Xia B. Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease. Inflamm Bowel Dis 2010;16:312-9. [PMID: 19714744 DOI: 10.1002/ibd.21059] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
542 Jung YS, Park DI, Hong SN, Kim ER, Kim YH, Cheon JH, Eun CS, Han DS, Lee CK, Kim JH, Huh KC, Yoon SM, Song HJ, Shin JE, Jeon SR. Predictors of Urgent Findings on Abdominopelvic CT in Patients with Crohn’s Disease Presenting to the Emergency Department. Dig Dis Sci 2015;60:929-35. [DOI: 10.1007/s10620-014-3298-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
543 Vermeulen N, Vermeire S, Arijs I, Michiels G, Ballet V, Derua R, Waelkens E, Van Lommel L, Schuit F, Rutgeerts P, Bossuyt X. Seroreactivity against glycolytic enzymes in inflammatory bowel disease. Inflamm Bowel Dis 2011;17:557-64. [PMID: 20629101 DOI: 10.1002/ibd.21388] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
544 Scarpa M, Mescoli C, Rugge M, D'Incà R, Ruffolo C, Polese L, D'Amico DF, Sturniolo GC, Angriman I. Restorative proctocolectomy for inflammatory bowel disease: the Padova prognostic score for colitis in predicting long-term outcome and quality of life. Int J Colorectal Dis 2009;24:1049-57. [PMID: 19415309 DOI: 10.1007/s00384-009-0700-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
545 Al-Meghaiseeb ES, Al-Robayan AA, Al-Otaibi MM, Arfin M, Al-Asmari AK. Association of tumor necrosis factor-α and -β gene polymorphisms in inflammatory bowel disease. J Inflamm Res 2016;9:133-40. [PMID: 27382325 DOI: 10.2147/JIR.S101225] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
546 Ben Alaya W, Sfar I, Aouadi H, Jendoubi S, Najjar T, Filali A, Gorgi Y, Ben Abdallah T, Mouelhi L, Matri S. Association between CTLA-4 gene promoter (49 A/G) in exon 1 polymorphisms and inflammatory bowel disease in the Tunisian population. Saudi J Gastroenterol. 2009;15:29-34. [PMID: 19568552 DOI: 10.4103/1319-3767.43285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
547 Andreu-Ballester JC, Amigó-García V, Catalán-Serra I, Gil-Borrás R, Ballester F, Almela-Quilis A, Millan-Scheiding M, Peñarroja-Otero C. Deficit of gammadelta T lymphocytes in the peripheral blood of patients with Crohn's disease. Dig Dis Sci 2011;56:2613-22. [PMID: 21374064 DOI: 10.1007/s10620-011-1636-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
548 Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Cattan S, Gendre J. Effects of current and former cigarette smoking on the clinical course of Crohn's disease. Aliment Pharmacol Ther 1999;13:1403-11. [PMID: 10571595 DOI: 10.1046/j.1365-2036.1999.00630.x] [Cited by in Crossref: 130] [Cited by in F6Publishing: 126] [Article Influence: 5.7] [Reference Citation Analysis]
549 Li D, Wang Y, Xu N, Wei Q, Wu M, Li X, Zheng P, Sun S, Jin Y, Zhang G, Liao R, Zhang P. Follistatin-like protein 1 is elevated in systemic autoimmune diseases and correlated with disease activity in patients with rheumatoid arthritis. Arthritis Res Ther 2011;13:R17. [PMID: 21303509 DOI: 10.1186/ar3241] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
550 Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp J. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol. 2009;15:3504-3510. [PMID: 19630105 DOI: 10.3748/wjg.15.3504.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
551 Oostenbrug LE, van Dullemen HM, te Meerman GJ, Jansen PL, Kleibeuker JH. Clinical outcome of Crohn’s disease according to the Vienna classification: disease location is a useful predictor of disease course. Eur J Gastroenterol Hepatol. 2006;18:255-261. [PMID: 16462538 DOI: 10.1097/00042737-200603000-00005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
552 Basu D, Lopez I, Kulkarni A, Sellin JH. Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol. 2005;100:2254-2261. [PMID: 16181378 DOI: 10.1111/j.1572-0241.2005.00233.x] [Cited by in Crossref: 107] [Cited by in F6Publishing: 100] [Article Influence: 6.3] [Reference Citation Analysis]
553 Kyle J. Crohn's disease in the northeastern and northern Isles of Scotland: An epidemiological review. Gastroenterology 1992;103:392-9. [DOI: 10.1016/0016-5085(92)90826-k] [Cited by in Crossref: 92] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
554 Kim DS, Yoon J, Kim YJ, Lee JW, Hong SW, Hwang HW, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK. Risk factors for rebleeding in Crohn's disease patients with acute severe lower gastrointestinal bleeding: With special reference to the role of anti-tumor necrosis factor therapy. J Gastroenterol Hepatol 2021. [PMID: 33734479 DOI: 10.1111/jgh.15495] [Reference Citation Analysis]
555 Hov JR, Keitel V, Laerdahl JK, Spomer L, Ellinghaus E, ElSharawy A, Melum E, Boberg KM, Manke T, Balschun T, Schramm C, Bergquist A, Weismüller T, Gotthardt D, Rust C, Henckaerts L, Onnie CM, Weersma RK, Sterneck M, Teufel A, Runz H, Stiehl A, Ponsioen CY, Wijmenga C, Vatn MH, Stokkers PC, Vermeire S, Mathew CG, Lie BA, Beuers U, Manns MP, Schreiber S, Schrumpf E, Häussinger D, Franke A, Karlsen TH; IBSEN Study Group. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One 2010;5:e12403. [PMID: 20811628 DOI: 10.1371/journal.pone.0012403] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 7.1] [Reference Citation Analysis]
556 Cougard PA, Desjeux A, Vitton V, Baumstarck-Barrau K, Lesavre N, Grimaud JC. The usefulness of factor XIII levels in Crohn’s disease. J Crohns Colitis. 2012;6:660-664. [PMID: 22398040 DOI: 10.1016/j.crohns.2011.11.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
557 Freeman HJ. Granuloma-positive Crohn's disease. Can J Gastroenterol 2007;21:583-7. [PMID: 17853953 DOI: 10.1155/2007/917649] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
558 Sokol H, Cosnes J, Chazouilleres O, Beaugerie L, Tiret E, Poupon R, Seksik P. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 2008; 14(22): 3497-3503 [PMID: 18567077 DOI: 10.3748/wjg.14.3497] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]
559 Kim JY, Park DI, Han DS, Huh KC, Lee CK, Shin JE, Kim JH, Kim YS, Jung Y, Jung SA, Song HJ, Jang HJ, Kim YH, Hong SN. Comparing the clinical outcomes of young-onset and adult-onset ulcerative colitis: a multi-center Korean Association for the Study for Intestinal Diseases study. Korean J Intern Med 2017;32:69-78. [PMID: 27338135 DOI: 10.3904/kjim.2014.262] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
560 Romberg-Camps MJ, Hesselink-van de Kruijs MA, Schouten LJ, Dagnelie PC, Limonard CB, Kester AD, Bos LP, Goedhard J, Hameeteman WH, Wolters FL, Russel MG, Stockbrügger RW. Inflammatory Bowel Disease in South Limburg (the Netherlands) 1991-2002: Incidence, diagnostic delay, and seasonal variations in onset of symptoms. J Crohns Colitis 2009;3:115-24. [PMID: 21172254 DOI: 10.1016/j.crohns.2008.12.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
561 Duricova D, Pedersen N, Elkjaer M, Gamborg M, Munkholm P, Jess T. Overall and cause-specific mortality in Crohn’s disease: a meta-analysis of population-based studies. Inflamm Bowel Dis. 2010;16:347-353. [PMID: 19572377 DOI: 10.1002/ibd.21007] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 7.8] [Reference Citation Analysis]
562 Thomas JP, Modos D, Korcsmaros T, Brooks-Warburton J. Network Biology Approaches to Achieve Precision Medicine in Inflammatory Bowel Disease. Front Genet 2021;12:760501. [PMID: 34745229 DOI: 10.3389/fgene.2021.760501] [Reference Citation Analysis]
563 Sicilia B, Vicente R, Arroyo M, Arribas F, Gomollón F. Cirugía de una cohorte incidente de pacientes con enfermedad de Crohn en Aragón: indicaciones, tipo de cirugía y factores de riesgo asociados. Gastroenterología y Hepatología 2005;28:105-9. [DOI: 10.1157/13072008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
564 Somma V, Ababneh H, Ababneh A, Gatti S, Romagnoli V, Bendia E, Conrad K, Bogdanos DP, Roggenbuck D, Ciarrocchi G. The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease. Gastroenterol Res Pract 2013;2013:683824. [PMID: 23762038 DOI: 10.1155/2013/683824] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
565 Croucher PJ, Mascheretti S, Hampe J, Huse K, Frenzel H, Stoll M, Lu T, Nikolaus S, Yang SK, Krawczak M. Haplotype structure and association to Crohn’s disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet. 2003;11:6-16. [PMID: 12529700 DOI: 10.1038/sj.ejhg.5200897] [Cited by in Crossref: 175] [Cited by in F6Publishing: 163] [Article Influence: 9.2] [Reference Citation Analysis]
566 Oostlander AE, Bravenboer N, van Essen HW, Klein-Nulend J, Lems WF, Schulten BA, Dijkstra G, van der Woude CJ, van Bodegraven AA, Lips P; Dutch Initiative on Crohn and Colitis (ICC). Bone cells from patients with quiescent Crohn's disease show a reduced growth potential and an impeded maturation. J Cell Biochem 2012;113:2424-31. [PMID: 22535626 DOI: 10.1002/jcb.24119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
567 Frigstad SO, Høivik ML, Jahnsen J, Cvancarova M, Grimstad T, Berset IP, Huppertz-Hauss G, Hovde Ø, Bernklev T, Moum B, Jelsness-Jørgensen LP. Pain Severity and Vitamin D Deficiency in IBD Patients. Nutrients 2019;12:E26. [PMID: 31877637 DOI: 10.3390/nu12010026] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
568 Cañas-Ventura A, Márquez L, Ricart E, Domènech E, Gisbert JP, García-Sanchez V, Marín-Jiménez I, Rodriguez-Moranta F, Gomollón F, Calvet X, Merino O, Garcia-Planella E, Vázquez-Romero N, Esteve M, Iborra M, Gutiérrez A, Vera M, Andreu M; Spanish GETECCU group (ENEIDA project). Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. J Crohns Colitis 2014;8:1287-93. [PMID: 24726696 DOI: 10.1016/j.crohns.2014.03.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
569 Laube R, Liu K, Schifter M, Yang JL, Suen MK, Leong RW. Oral and upper gastrointestinal Crohn's disease. J Gastroenterol Hepatol. 2018;33:355-364. [PMID: 28708248 DOI: 10.1111/jgh.13866] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
570 Smyth CM, Akasheh N, Woods S, Kay E, Morgan RK, Thornton MA, O'Grady A, Cummins R, Sheils O, Smyth P, Gleich GJ, Murray FM, Costello RW. Activated eosinophils in association with enteric nerves in inflammatory bowel disease. PLoS One 2013;8:e64216. [PMID: 23717571 DOI: 10.1371/journal.pone.0064216] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
571 Sharif F, McDermott M, Dillon M, Drumm B, Rowland M, Imrie C, Kelleher S, Harty S, Bourke B. Focally enhanced gastritis in children with Crohn's disease and ulcerative colitis. Am J Gastroenterol. 2002;97:1415-1420. [PMID: 12094859 DOI: 10.1111/j.1572-0241.2002.05785.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 4.4] [Reference Citation Analysis]
572 Cabriada JL, Ibargoyen N, Hernández A, Bernal A, Castiella A. Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1 year. Dig Liver Dis. 2010;42:432-435. [PMID: 19833566 DOI: 10.1016/j.dld.2009.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
573 Molnár T, Papós M, Gyulai C, Ambrus E, Kardos L, Nagy F, Palkó A, Pávics L, Lonovics J. Clinical Value of Technetium-99m-HMPAO-Labeled Leukocyte Scintigraphy and Spiral Computed Tomography in Active Crohn's Disease. American Journal of Gastroenterology 2001;96:1517-21. [DOI: 10.1111/j.1572-0241.2001.03749.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
574 Cross RK, Langenberg P, Regueiro M, Schwartz DA, Tracy JK, Collins JF, Katz J, Ghazi L, Patil SA, Quezada SM, Beaulieu D, Horst SN, Russman K, Riaz M, Jambaulikar G, Sivasailam B, Quinn CC. A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD). Am J Gastroenterol 2019;114:472-82. [PMID: 30410041 DOI: 10.1038/s41395-018-0272-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 17.7] [Reference Citation Analysis]
575 Wills ES, Jonkers DM, Savelkoul PH, Masclee AA, Pierik MJ, Penders J. Fecal microbial composition of ulcerative colitis and Crohn’s disease patients in remission and subsequent exacerbation. PLoS One. 2014;9:e90981. [PMID: 24608638 DOI: 10.1371/journal.pone.0090981] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 8.9] [Reference Citation Analysis]
576 Zhang S, Luo J, Wu Z, Roggenbuck D, Schierack P, Reinhold D, Li J, Zeng X, Zhang F, Qian J, Li Y. Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease. Clin Transl Gastroenterol 2018;9:e133. [PMID: 29446764 DOI: 10.1038/ctg.2018.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
577 Hoie O, Wolters FL, Riis L, Bernklev T, Aamodt G, Clofent J, Tsianos E, Beltrami M, Odes S, Munkholm P. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507-515. [PMID: 17258717 DOI: 10.1053/j.gastro.2006.11.015] [Cited by in Crossref: 177] [Cited by in F6Publishing: 161] [Article Influence: 11.1] [Reference Citation Analysis]
578 Haapamäki J, Roine RP, Sintonen H, Kolho KL. Health-related quality of life in paediatric patients with inflammatory bowel disease related to disease activity. J Paediatr Child Health. 2011;47:832-837. [PMID: 21435075 DOI: 10.1111/j.1440-1754.2011.02034.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
579 Gismera CS, Fernández GA, Navascues C, López R, González A, Álvarez G, Galán A, Bernal A, Martínez A, Lacort Fernández M, Antón Magarzo J, Altadill Arregui A, Vizoso F. Epidemiología de la enfermedad inflamatoria intestinal crónica en Gijón. Asturias. Gastroenterología y Hepatología 2001;24:228-35. [DOI: 10.1016/s0210-5705(01)70160-4] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
580 Ma P, Feng YC. Decreased serum fetuin-A levels and active inflammatory bowel disease. Am J Med Sci. 2014;348:47-51. [PMID: 24487480 DOI: 10.1097/maj.0000000000000195] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
581 Pernat Drobež C, Repnik K, Gorenjak M, Ferkolj I, Weersma RK, Potočnik U. DNA polymorphisms predict time to progression from uncomplicated to complicated Crohn's disease. Eur J Gastroenterol Hepatol 2018;30:447-55. [PMID: 29293112 DOI: 10.1097/MEG.0000000000001055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
582 Lee HS, Choe J, Lee HJ, Hwang SW, Park SH, Yang DH, Kim KJ, Ye BD, Byeon JS, Myung SJ. Change in the diagnosis of inflammatory bowel disease: a hospital-based cohort study from Korea. Intest Res. 2016;14:258-263. [PMID: 27433148 DOI: 10.5217/ir.2016.14.3.258] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
583 Renda MC, Orlando A, Civitavecchia G, Criscuoli V, Maggio A, Mocciaro F, Rossi F, Scimeca D, Modesto I, Oliva L, Cottone M. The role of CARD15 mutations and smoking in the course of Crohn's disease in a Mediterranean area. Am J Gastroenterol 2008;103:649-55. [PMID: 18341489 DOI: 10.1111/j.1572-0241.2007.01589.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
584 Farrokhyar F, Swarbrick ET, Irvine EJ. A critical review of epidemiological studies in inflammatory bowel disease. Scand J Gastroenterol 2001;36:2-15. [PMID: 11218235 DOI: 10.1080/00365520150218002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
585 Jelsness-jørgensen L, Bernklev T, Hovde Ø, Prytz Berset I, Huppertz-hauss G, Moum B, Lie Høivik M. Patients’ perceptions of quality of care and follow-up in inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2015;51:434-41. [DOI: 10.3109/00365521.2015.1102319] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
586 Vermeulen N, de Béeck KO, Vermeire S, Van Steen K, Michiels G, Ballet V, Rutgeerts P, Bossuyt X. Identification of a novel autoantigen in inflammatory bowel disease by protein microarray. Inflamm Bowel Dis 2011;17:1291-300. [PMID: 21560193 DOI: 10.1002/ibd.21508] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
587 Wilson TJ, Jobim M, Jobim LF, Portela P, Salim PH, Rosito MA, Damin DC, Flores C, Peres A, Machado MB, Chies JAB, Schwartsmann G, Roesler R. Study of killer immunoglobulin-like receptor genes and human leukocyte antigens class I ligands in a Caucasian Brazilian population with Crohn's disease and ulcerative colitis. Human Immunology 2010;71:293-7. [DOI: 10.1016/j.humimm.2009.12.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
588 Roggenbuck D, Reinhold D, Baumgart D, Schierack P, Conrad K, Laass M. Autoimmunity in Crohn's Disease—A Putative Stratification Factor of the Clinical Phenotype. Elsevier; 2016. pp. 77-101. [DOI: 10.1016/bs.acc.2016.06.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
589 Chinen H, Matsuoka K, Sato T, Kamada N, Okamoto S, Hisamatsu T, Kobayashi T, Hasegawa H, Sugita A, Kinjo F, Fujita J, Hibi T. Lamina Propria c-kit+ Immune Precursors Reside in Human Adult Intestine and Differentiate Into Natural Killer Cells. Gastroenterology 2007;133:559-73. [DOI: 10.1053/j.gastro.2007.05.017] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 4.4] [Reference Citation Analysis]
590 Lucaciu LA, Ilieș M, Vesa ȘC, Seicean R, Din S, Iuga CA, Seicean A. Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease. J Pers Med 2021;11:1130. [PMID: 34834482 DOI: 10.3390/jpm11111130] [Reference Citation Analysis]
591 Ahmad T, Marshall SE, Mulcahy-Hawes K, Orchard T, Crawshaw J, Armuzzi A, Neville M, van Heel D, Barnardo M, Welsh KI. High resolution MIC genotyping: design and application to the investigation of inflammatory bowel disease susceptibility. Tissue Antigens. 2002;60:164-179. [PMID: 12392511 DOI: 10.1034/j.1399-0039.2002.600207.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
592 Esters N, Pierik M, van Steen K, Vermeire S, Claessens G, Joossens S, Vlietinck R, Rutgeerts P. Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease. Am J Gastroenterol. 2004;99:299-305. [PMID: 15046221 DOI: 10.1111/j.1572-0241.2004.04040.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 2.3] [Reference Citation Analysis]
593 Sciarretta G, Furno A, Mazzoni M, Basile C, Malaguti P. Technetium-99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: diagnostic and clinical relevance. Gut 1993;34:1364-9. [PMID: 8244102 DOI: 10.1136/gut.34.10.1364] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 2.0] [Reference Citation Analysis]
594 Kim JS, Jang HY, Park SH, Kim KJ, Han K, Yang SK, Ye BD, Park SH, Lee JS, Kim HJ. MR Enterography Assessment of Bowel Inflammation Severity in Crohn Disease Using the MR Index of Activity Score: Modifying Roles of DWI and Effects of Contrast Phases. AJR Am J Roentgenol. 2017;208:1022-1029. [PMID: 28225669 DOI: 10.2214/ajr.16.17324] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 5.4] [Reference Citation Analysis]
595 Gong W, Lv N, Wang B, Chen Y, Huang Y, Pan W, Jiang B. Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study. Dig Dis Sci. 2012;57:503-507. [PMID: 21938485 DOI: 10.1007/s10620-011-1890-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
596 Eglinton T, Reilly M, Chang C, Barclay M, Frizelle F, Gearry R. Ileal disease is associated with surgery for perianal disease in a population-based Crohn's disease cohort. Br J Surg 2010;97:1103-9. [PMID: 20632279 DOI: 10.1002/bjs.7031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
597 Tanaka M, Riddell RH, Saito H, Soma Y, Hidaka H, Kudo H. Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn’s disease from ulcerative colitis. Scand J Gastroenterol. 1999;34:55-67. [PMID: 10048734 DOI: 10.1080/00365529950172844] [Cited by in Crossref: 114] [Cited by in F6Publishing: 86] [Article Influence: 5.0] [Reference Citation Analysis]
598 Correa I, Veny M, Esteller M, Piqué JM, Yagüe J, Panés J, Salas A. Defective IL-10 production in severe phenotypes of Crohn’s disease. J Leukoc Biol. 2009;85:896-903. [PMID: 19237638 DOI: 10.1189/jlb.1108698] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
599 Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, El Yafi F, Colombel JF, Belaiche J. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut. 2003;52:552-557. [PMID: 12631668 DOI: 10.1136/gut.52.4.552] [Cited by in Crossref: 181] [Cited by in F6Publishing: 174] [Article Influence: 9.5] [Reference Citation Analysis]
600 Gearry RB, Kamm MA, Hart AL, Bassett P, Gabe SM, Nightingale JM. Predictors for developing intestinal failure in patients with Crohn’s disease. J Gastroenterol Hepatol. 2013;28:801-807. [PMID: 23301990 DOI: 10.1111/jgh.12115] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
601 Cravo M, Guerreiro CS, dos Santos PM, Brito M, Ferreira P, Fidalgo C, Tavares L, Pereira AD. Risk factors for metabolic bone disease in Crohn's disease patients. Inflamm Bowel Dis. 2010;16:2117-2124. [PMID: 20848459 DOI: 10.1002/ibd.21297] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
602 Sicilia B, Arribas F, Nerín J, López Miguel C, Vicente R, Gomollón F. Risk factors for ulcerative colitis: A population-based, case-control study in Spain. J Crohns Colitis 2008;2:158-61. [PMID: 21172206 DOI: 10.1016/j.crohns.2008.01.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
603 Zouali H, Lesage S, Merlin F, Cézard JP, Colombel JF, Belaiche J, Almer S, Tysk C, O'Morain C, Gassull M, Christensen S, Finkel Y, Modigliani R, Gower-Rousseau C, Macry J, Chamaillard M, Thomas G, Hugot JP; EPWG group., EPIMAD group. CARD4/NOD1 is not involved in inflammatory bowel disease. Gut 2003;52:71-4. [PMID: 12477763 DOI: 10.1136/gut.52.1.71] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 2.4] [Reference Citation Analysis]
604 Arnott ID, Drummond HE, Ghosh S. Gut mucosal secretion of interleukin 1beta and interleukin-8 predicts relapse in clinically inactive Crohn's disease. Dig Dis Sci 2001;46:402-9. [PMID: 11281191 DOI: 10.1023/a:1005617302718] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
605 Bruna-Barranco I, Lué A, Gargallo-Puyuelo CJ, Arroyo MT, Alfambra E, Montero J, Gomollón F. Young age and tobacco use are predictors of lower medication adherence in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2019;31:948-53. [PMID: 31107739 DOI: 10.1097/MEG.0000000000001436] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
606 Titz B, Gadaleta RM, Lo Sasso G, Elamin A, Ekroos K, Ivanov NV, Peitsch MC, Hoeng J. Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification.Int J Mol Sci. 2018;19. [PMID: 30223557 DOI: 10.3390/ijms19092775] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
607 Jung C, Colombel JF, Lemann M, Beaugerie L, Allez M, Cosnes J, Vernier-Massouille G, Gornet JM, Gendre JP, Cezard JP. Genotype/phenotype analyses for 53 Crohn’s disease associated genetic polymorphisms. PLoS One. 2012;7:e52223. [PMID: 23300620 DOI: 10.1371/journal.pone.0052223] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
608 Lee HS, Yang SK, Hong M, Jung S, Kim BM, Moon JW, Park SH, Ye BD, Oh SH, Kim KM, Yoon YS, Yu CS, Baek J, Lee CH, Han B, Liu J, Haritunians T, McGovern DPB, Song K. An Intergenic Variant rs9268877 Between HLA-DRA and HLA-DRB Contributes to the Clinical Course and Long-term Outcome of Ulcerative Colitis. J Crohns Colitis 2018;12:1113-21. [PMID: 29905830 DOI: 10.1093/ecco-jcc/jjy080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
609 Arnott ID, Williams N, Drummond HE, Ghosh S. Whole gut lavage fluid interleukin-1beta and interleukin-8 in smokers and non-smokers with Crohn's disease in clinical remission. Dig Liver Dis 2002;34:424-9. [PMID: 12132790 DOI: 10.1016/s1590-8658(02)80040-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
610 D'Souza S, Levy E, Mack D, Israel D, Lambrette P, Ghadirian P, Deslandres C, Morgan K, Seidman EG, Amre DK. Dietary patterns and risk for Crohn's disease in children. Inflamm Bowel Dis 2008;14:367-73. [PMID: 18092347 DOI: 10.1002/ibd.20333] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 5.9] [Reference Citation Analysis]
611 Cornélio RDCAC, Pinto ALT, Pace FHDL, Moraes JP, Chebli JMF. Não-adesão ao tratamento em pacientes com doença de Crohn: prevalência e fatores de risco. Arq Gastroenterol 2009;46:183-9. [DOI: 10.1590/s0004-28032009000300008] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
612 Buisson A, Hordonneau C, Goutorbe F, Allimant C, Goutte M, Reymond M, Pereira B, Bommelaer G. Bowel wall healing assessed using magnetic resonance imaging predicts sustained clinical remission and decreased risk of surgery in Crohn’s disease. J Gastroenterol 2019;54:312-20. [DOI: 10.1007/s00535-018-1505-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
613 Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Theodoropoulou A, Livadiotaki A, Paspatis G, Kouroumalis EA. Genetic risk factors in patients with inflammatory bowel disease and vascular complications: case-control study. Inflamm Bowel Dis. 2007;13:410-415. [PMID: 17206678 DOI: 10.1002/ibd.20076] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
614 Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Gendre JP. Oral contraceptive use and the clinical course of Crohn’s disease: a prospective cohort study. Gut. 1999;45:218-222. [PMID: 10403733 DOI: 10.1136/gut.45.2.218] [Cited by in Crossref: 66] [Cited by in F6Publishing: 51] [Article Influence: 2.9] [Reference Citation Analysis]
615 Horváth G, Farkas K, Hollósi R, Nagy F, Szepes Z, Papp M, Palatka K, Miheller P, Lakatos L, Szamosi T, Nyári T, Wittmann T, Molnár T. Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease? Scand J Gastroenterol 2012;47:1298-303. [PMID: 22935014 DOI: 10.3109/00365521.2012.703233] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
616 De Toni L, Di Nisio A, Magagna S, Michielan A, Martinato M, Sturniolo GC, D'Incà R, Foresta C, Garolla A. Altered chemokine signalling in endothelial progenitor cells from acute ulcerative colitis patients. Gastroenterol Res Pract 2015;2015:843980. [PMID: 25737719 DOI: 10.1155/2015/843980] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
617 Tavares M, de Lima C, Fernandes W, Martinelli V, de Lucena M, Lima F, Telles A, Brandão L, de Melo Júnior M. Tumour necrosis factor-alpha (-308G/A) promoter polymorphism is associated with ulcerative colitis in Brazilian patients. Int J Immunogenet 2016;43:376-82. [DOI: 10.1111/iji.12289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
618 Esteve M, Mallolas J, Klaassen J, Abad-lacruz A, Gonzàlez-huix F, Cabré E, Fernández-bañares F, Menacho M, Condom E, Martí-ragué J, Gassull MA. Factors Related to the Presence of IgA Class Antineutrophil Cytoplasmic Antibodies in Ulcerative Colitis. American Journal of Gastroenterology 1998;93:615-8. [DOI: 10.1111/j.1572-0241.1998.175_b.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
619 Orlic ZC, Turk T, Sincic BM, Stimac D, Cvijanovic O, Maric I, Tomas MI, Jurisic-Erzen D, Licul V, Bobinac D. How activity of inflammatory bowel disease influences bone loss. J Clin Densitom 2010;13:36-42. [PMID: 20171567 DOI: 10.1016/j.jocd.2009.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
620 Zankel E, Rogler G, Andus T, Reng CM, Schölmerich J, Timmer A. Crohn's disease patient characteristics in a tertiary referral center: comparison with patients from a population-based cohort. Eur J Gastroenterol Hepatol. 2005;17:395-401. [PMID: 15756091 DOI: 10.1097/00042737-200504000-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
621 Oliver J, Gómez-García M, Paco L, López-Nevot MA, Piñero A, Correro F, Martín L, Brieva JA, Nieto A, Martín J. A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population. Inflamm Bowel Dis 2005;11:576-9. [PMID: 15905705 DOI: 10.1097/01.mib.0000161916.20007.76] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
622 Pearce CB, Lawrance IC. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J Gastroenterol Hepatol. 2007;22:1671-1677. [PMID: 17845695 DOI: 10.1111/j.1440-1746.2006.04739.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
623 Heresbach D, Alexandre JL, Branger B, Bretagne JF, Cruchant E, Dabadie A, Dartois-Hoguin M, Girardot PM, Jouanolle H, Kerneis J. Frequency and significance of granulomas in a cohort of incident cases of Crohn's disease. Gut. 2005;54:215-222. [PMID: 15647184 DOI: 10.1136/gut.2004.041715] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 4.4] [Reference Citation Analysis]
624 Moum B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I, Schulz T, Stray N, Fausa O. Clinical Course during the 1st Year after Diagnosis in Ulcerative Colitis and Crohn's Disease: Results of a Large, Prospective Population-based Study in Southeastern Norway, 1990-93. Scandinavian Journal of Gastroenterology 2009;32:1005-12. [DOI: 10.3109/00365529709011217] [Cited by in Crossref: 112] [Cited by in F6Publishing: 104] [Article Influence: 8.6] [Reference Citation Analysis]
625 Christian KE, Jambaulikar GD, Hagan MN, Syed AM, Briscoe JA, Brown SA, Campbell EV, Gadani AB, Cross RK. Predictors of Early Readmission in Hospitalized Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1891-1897. [PMID: 28837523 DOI: 10.1097/mib.0000000000001213] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
626 Pichler J, Memaran N, Huber WD, Aufricht C, Bidmon-Fliegenschnee B. Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody. Acta Paediatr 2021;110:661-7. [PMID: 32781480 DOI: 10.1111/apa.15522] [Reference Citation Analysis]
627 Oliver J, Gómez-Garcia M, Vilchez JR, López-Nevot MA, Piñero A, Correro F, Nieto A, Martín J. Inducible and endothelial nitric oxide synthase genes polymorphism in inflammatory bowel disease. Tissue Antigens 2006;67:326-30. [PMID: 16634870 DOI: 10.1111/j.1399-0039.2006.00578.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
628 Meijer B, Seinen ML, van Egmond R, Bouma G, Mulder CJJ, van Bodegraven AA, de Boer NKH. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication? Inflamm Bowel Dis 2017;23:2011-7. [PMID: 28617756 DOI: 10.1097/MIB.0000000000001168] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
629 Aguas M, Garrigues V, Bastida G, Nos P, Ortiz V, Fernandez A, Ponce J. Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD). J Crohns Colitis. 2011;5:227-233. [PMID: 21575886 DOI: 10.1016/j.crohns.2011.01.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
630 Ahmad T, Armuzzi A, Neville M, Bunce M, Ling KL, Welsh KI, Marshall SE, Jewell DP. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens. 2003;62:527-535. [PMID: 14617036 DOI: 10.1046/j.1399-0039.2003.00129.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
631 Park JB, Yang SK, Byeon JS, Park ER, Moon G, Myung SJ, Park WK, Yoon SG, Kim HS, Lee JG. Familial occurrence of inflammatory bowel disease in Korea. Inflamm Bowel Dis. 2006;12:1146-1151. [PMID: 17119389 DOI: 10.1097/01.mib.0000235094.01608.59] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
632 Hugot JP. Genetic origin of IBD. Inflamm Bowel Dis 2004;10 Suppl 1:S11-5. [PMID: 15168824 DOI: 10.1097/00054725-200402001-00003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
633 Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. Inflammatory bowel disease in Iran: a review of 457 cases. J Gastroenterol Hepatol. 2005;20:1691-1695. [PMID: 16246187 DOI: 10.1111/j.1440-1746.2005.03905.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 4.2] [Reference Citation Analysis]
634 Castro-Santos P, Mozo L, Gutiérrez C, Suárez A. TNFalpha genotype influences development of IgA-ASCA antibodies in Crohn's disease patients with CARD15 wild type. Clin Immunol 2006;121:305-13. [PMID: 16952484 DOI: 10.1016/j.clim.2006.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
635 Ferguson L, Browning B, Huebner C, Petermann I, Shelling A, Demmers P, Mcculloch A, Gearry R, Barclay M, Philpott M. Single nucleotide polymorphisms in human Paneth cell defensin A5 may confer susceptibility to inflammatory bowel disease in a New Zealand Caucasian population. Digestive and Liver Disease 2008;40:723-30. [DOI: 10.1016/j.dld.2008.02.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
636 Buisson A, Hordonneau C, Goutte M, Scanzi J, Goutorbe F, Klotz T, Boyer L, Pereira B, Bommelaer G. Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn's disease. Digestive and Liver Disease 2016;48:260-6. [DOI: 10.1016/j.dld.2015.10.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
637 Juillerat P, Pittet V, Bulliard J, Guessous I, Antonino AT, Mottet C, Felley C, Vader J, Michetti P. Prevalence of Inflammatory Bowel Disease in the Canton of Vaud (Switzerland): A population-based cohort study. Journal of Crohn's and Colitis 2008;2:131-41. [DOI: 10.1016/j.crohns.2007.10.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
638 Defendenti C, Sarzi-Puttini P, Saibeni S, Bollani S, Bruno S, Almasio PL, Declich P, Atzeni F. Significance of serum Il-9 levels in inflammatory bowel disease. Int J Immunopathol Pharmacol. 2015;28:569-575. [PMID: 26377844 DOI: 10.1177/0394632015600535] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
639 Cottone M, Pietrosi G, Martorana G, Casà A, Pecoraro G, Oliva L, Orlando A, Rosselli M, Rizzo A, Pagliaro L. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s colitis. Am J Gastroenterol. 2001;96:773-775. [PMID: 11280549 DOI: 10.1111/j.1572-0241.2001.03620.x] [Cited by in Crossref: 203] [Cited by in F6Publishing: 196] [Article Influence: 9.7] [Reference Citation Analysis]
640 Torres J, Bao X, Goel A, Colombel JF, Pekow J, Jabri B, Williams KM, Castillo A, Odin JA, Meckel K, Fasihuddin F, Peter I, Itzkowitz S, Hu J. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther 2016;43:790-801. [PMID: 26857969 DOI: 10.1111/apt.13552] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 12.0] [Reference Citation Analysis]
641 Tavano F, di Mola FF, Latiano A, Palmieri O, Bossa F, Valvano MR, Latiano T, Annese V, Andriulli A, di Sebastiano P. Neuroimmune interactions in patients with inflammatory bowel diseases: disease activity and clinical behavior based on Substance P serum levels. J Crohns Colitis 2012;6:563-70. [PMID: 22398048 DOI: 10.1016/j.crohns.2011.11.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
642 Algaba A, Linares PM, Fernández-Contreras ME, Ordoñez A, Trápaga J, Guerra I, Chaparro M, de la Poza G, Gisbert JP, Bermejo F. Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease. J Crohns Colitis 2013;7:e569-79. [PMID: 23642997 DOI: 10.1016/j.crohns.2013.04.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
643 Geerling BJ, v Houwelingen AC, Badart-Smook A, Stockbrügger RW, Brummer RJ. Fat intake and fatty acid profile in plasma phospholipids and adipose tissue in patients with Crohn's disease, compared with controls. Am J Gastroenterol. 1999;94:410-417. [PMID: 10022638 DOI: 10.1111/j.1572-0241.1999.869_a.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.0] [Reference Citation Analysis]
644 King K</